quetiapine fumarate profile

Quetiapine Fumarate: A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	25058200
MeSH ID	M0398083

Synonym
seroquel
quetiapine fumarate
2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol fumarate (2:1) (salt)
bis{2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol} (2e)-but-2-enedioate

Excerpt	Reference	Relevance
" Thus, clinicians should address patients' concerns about adverse effects and attempt to choose medications that will improve their patients' quality of life as well as overall health."	( Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. , 1998)	0.3
" Nevertheless, clinical trials currently available suggest that quetiapine has a beneficial side effect profile, particularly with regard,to extrapyramidal symptoms."	( Review of quetiapine side effects. Garver, DL, 2000)	0.31
" Their adverse effects, which include extrapyramidal side effects, tardive dyskinesia, weight gain, sedation, and sexual dysfunction, often lead to non-compliance; their use may have a negative impact on the overall course of illness; and they may not be as effective as lithium in treating the core manic symptoms over the long term."	( Antipsychotic drug side effect issues in bipolar manic patients. Zarate, CA, 2000)	0.31
" Quetiapine is associated with high levels of patient acceptability and satisfaction, which may result from its combination of efficacy and relatively benign adverse effect profile."	( Quetiapine: a review of its safety in the management of schizophrenia. Dev, V; Raniwalla, J, 2000)	0.31
" Doses were adjusted to maximize efficacy and to minimize adverse events."	( A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Jibson, MD; Mullen, J; Sweitzer, D, 2001)	0.31
" The most common adverse events in the quetiapine and risperidone groups were somnolence (31."	( A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Jibson, MD; Mullen, J; Sweitzer, D, 2001)	0.31
"Psychopharmacology research aims to expand the therapeutic ratio between efficacy, on the one hand, and adverse events and safety, on the other."	( Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. McIntyre, RS, 2002)	0.31
"The effects of haloperidol, risperidone, and thioridazine on the pharmacokinetics and side-effect profile of quetiapine were investigated in 36 patients with schizophrenia, schizoaffective disorder, or bipolar disorder in a single-center, two-period, multiple-dose, open-label, randomized trial."	( The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. Alva, G; Arvanitis, LA; Bera, R; Potkin, SG; Thyrum, PT; Yeh, C, 2002)	0.31
" The new generation of atypical antipsychotics introduced over the past decade have comparable or greater efficacy than traditional antipsychotics in treating the psychotic symptoms of schizophrenia and a much improved neurologic side effect profile."	( Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. Nasrallah, HA; Tandon, R, 2002)	0.31
" This is because of their efficacy in the treatment of several psychiatric disorders, ease of administration, and absence of the well-known extrapyramidal adverse effects long-attributed to the standard dopamine blocking anti-psychotic medications."	( Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician. Bailey, RK, 2003)	0.32
"Quetiapine is a novel, atypical antipsychotic agent that has been shown to provide long-term efficacy without serious adverse effects in adults."	( Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. Browne, K; Carrero, L; Chaney, R; Foster, K; Friedman, L; McConville, B; Potter, L; Sorter, M; Sweitzer, D, 2003)	0.32
" The aim of this paper is to review literature about newer antipsychotics, focusing on their advantages in terms of efficacy and side effect profiles when compared to classical and older atypical antipsychotics, and to evaluate the efficacy of the different new antipsychotics when compared to one another."	( New antipsychotics and schizophrenia: a review on efficacy and side effects. Berardi, D; De Ronchi, D; Lorenzi, C; Serretti, A, 2004)	0.32
" While typical antipsychotics are often switched to atypical agents when adverse effects become limiting, there is little preclinical information to support this strategy, both in terms of efficacy and side effects."	( Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M, 2004)	0.32
" Furthermore, quetiapine was well tolerated throughout the study period, with a low incidence of extrapyramidal symptom-related adverse events."	( Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. Brecher, M; Fitton, L; Jones, AM; Kasper, S, 2004)	0.32
"Five new antipsychotic drugs introduced in the United States in the last decade offer physicians the ability to treat patients with schizophrenia and bipolar mania without the adverse effects of the first-generation antipsychotics."	( The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. Citrome, L; Volavka, J, 2004)	0.32
" The most common adverse events for quetiapine were dry mouth, somnolence, and weight gain, while lithium was associated with tremor and insomnia."	( A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. Bowden, CL; Brecher, M; Grunze, H; Jones, M; Mullen, J; Paulsson, B; Svensson, K; Vågerö, M, 2005)	0.33
" However, there are still significant adverse effects and toxicities with this class of medications."	( Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Dubois, D, 2005)	0.33
"Continued research to evaluate adverse effects and tolerability of atypical antipsychotics compared with first-generation antipsychotics and each other is reviewed."	( Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Dubois, D, 2005)	0.33
"While new atypical antipsychotic medications may have a safer therapeutic and overdose profile than first-generation antipsychotic medications, many adverse and toxic effects still need to be considered in therapeutic monitoring and overdose management."	( Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Dubois, D, 2005)	0.33
"Quetiapine, an atypical antipsychotic, is effective for psychosis in younger patients, with limited adverse effects reported."	( The efficacy and safety of quetiapine for treatment of geriatric psychosis. Hwang, JP; Tsai, SJ; Yang, CH, 2005)	0.33
"These data agree with recent clinical reports concerning the direct or mediated toxic effects of olanzapine on progenitor and committed cells (GM-CFU) and suggest that the correlation between its plasma levels and clinical effects warrants further investigation."	( In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU). Bareggi, S; Bonomi, A; Cavicchini, L; Croera, C; Guizzardi, F; Pessina, A; Turlizzi, E, 2006)	0.33
" Several clinical trials have not shown efficacy, and there have been concerns about adverse events."	( Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Dagerman, K; Insel, PS; Schneider, LS, 2006)	0.33
" Clinical and trials characteristics, outcomes, and adverse events were extracted."	( Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Dagerman, K; Insel, PS; Schneider, LS, 2006)	0.33
" Adverse events were mainly somnolence and urinary tract infection or incontinence across drugs, and extrapyramidal symptoms or abnormal gait with risperidone or olanzapine."	( Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Dagerman, K; Insel, PS; Schneider, LS, 2006)	0.33
" Dropouts and adverse events further limit effectiveness."	( Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Dagerman, K; Insel, PS; Schneider, LS, 2006)	0.33
" There are also continued efforts to understand, predict and manage the side-effect risk with quetiapine."	( Quetiapine: efficacy, tolerability and safety in schizophrenia. Lerner, V; Miodownik, C, 2006)	0.33
" Endocrine and metabolic adverse effects are among the most concerning adverse effects of commonly used psychotropic medications."	( Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Carlson, HE; Correll, CU, 2006)	0.33
"Clinicians and caregivers need to be aware of potential endocrine and metabolic adverse effects of psychiatric medications."	( Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Carlson, HE; Correll, CU, 2006)	0.33
" No patients discontinued because of an adverse event."	( Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. Demeter, CA; Findling, RL; McNamara, NK; O'Riordan, MA; Reed, MD; Stansbrey, RJ, 2006)	0.33
" Adverse event reporting, Simpson Angus Scale (SAS), and Barnes Akathisia Rating Scale (BARS) scores were recorded."	( Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder. Adler, CM; Brecher, M; Fleck, DE; Strakowski, SM, 2007)	0.34
"Most adverse events were mild to moderate."	( Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder. Adler, CM; Brecher, M; Fleck, DE; Strakowski, SM, 2007)	0.34
" Safety evaluations included the incidence of extrapyramidal symptoms (EPS) and adverse events (AEs)."	( Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. Haushofer, M; Pfolz, H; Rainer, M; Struhal, C; Wick, W, 2007)	0.34
" Safety outcome measures were all new clinical adverse events between the start of treatment (which could be before April 2003) and 30 November 2004."	( Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Ashton, J; Garcia-Quiroga, J; Harrison-Woolrych, M; Herbison, P, 2007)	0.34
" A total of 131 (31%) children experienced an adverse event."	( Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Ashton, J; Garcia-Quiroga, J; Harrison-Woolrych, M; Herbison, P, 2007)	0.34
" This was also the most frequently reported specified adverse drug reaction (ADR) to quetiapine (7; 11% of 65 reported ADRs) and the highest reported clinical reason for stopping quetiapine (51; 6% of the 734 reported reasons for stopping)."	( The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England. Shakir, SA; Twaites, BR; Wilton, LV, 2007)	0.34
" Adverse events, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests were evaluated throughout the studies."	( Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. Davis, PC; Earley, WR; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2008)	0.35
" Quetiapine was well tolerated, with no serious adverse events and no unexpected events reported."	( Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. Davis, PC; Earley, WR; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2008)	0.35
" In addition, adverse events were also evaluated."	( [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO]. Agoston, T; István, S; Tamás, T; Zoltán, J, 2007)	0.34
" During the randomization phase, the most common adverse events occurring in > or =5% in the quetiapine group were somnolence, nasopharyngitis, and headache."	( Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). Brecher, M; Eggens, I; Paulsson, B; Persson, I; Suppes, T; Vieta, E, 2008)	0.35
" Based on recent criteria for pediatric populations, patients were considered "at risk for adverse health outcome" if they met at least 1 of the following criteria: (1) > or = 85th BMI percentile plus presence of 1 or more negative weight-related clinical outcomes, or (2) > or = 95th BMI percentile."	( Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. Arango, C; Cifuentes, A; Fraguas, D; Giráldez, M; Laita, P; Merchán-Naranjo, J; Moreno, D; Parellada, M; Ruiz-Sancho, A, 2008)	0.35
" The number of patients at risk for adverse health outcome increased from 11 (16."	( Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. Arango, C; Cifuentes, A; Fraguas, D; Giráldez, M; Laita, P; Merchán-Naranjo, J; Moreno, D; Parellada, M; Ruiz-Sancho, A, 2008)	0.35
" The 2 cases direct our attention to at least 3 important points regarding safe administration of ECT shortly after the occurrence of PE, that is, careful evaluation of cardiac function and residual deep vein thrombosis before the start of an ECT course, adjustment of anticoagulants, and prevention of recurrent deep vein thrombosis and PE by methods in addition to anticoagulant therapy (fluid infusion, use of support hose, and timely ECT)."	( Safety of electroconvulsive therapy in psychiatric patients shortly after the occurrence of pulmonary embolism. Fujiyama, K; Matsuoka, H; Suzuki, K; Takamatsu, K; Takano, T; Tanabe, Y, 2008)	0.35
"Our study in acutely ill drug-naive first-episode psychosis patients suggests that quetiapine is a safe and well-tolerated antipsychotic medication."	( Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years. Amminger, PG; Berger, GE; Kerr, M; Lubman, D; Markulev, C; McConchie, M; McGorry, PD; O'Donnell, C; Polari, A; Proffitt, TM; Wood, S; Yuen, HP, 2008)	0.35
" The most common adverse events were sedation (54%), dry mouth (38%) and dizziness (29%)."	( Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: an open-label, pilot study. Anderson, IM; Haddad, PM; Sarsfield, A, 2009)	0.35
"Second-generation antipsychotics (SGAs) are far more commonly used in the United States compared to first-generation antipsychotics (FGAs), but the relative safety of SGAs compared to FGAs following acute toxic ingestions has not been studied."	( Comparing acute toxicity of first- and second-generation antipsychotic drugs: a 10-year, retrospective cohort study. Ciranni, MA; Kearney, TE; Olson, KR, 2009)	0.35
" Cases were coded for overall severity of adverse outcome as defined by the American Association of Poison Control Centers criteria and for presence of specific symptoms and treatments."	( Comparing acute toxicity of first- and second-generation antipsychotic drugs: a 10-year, retrospective cohort study. Ciranni, MA; Kearney, TE; Olson, KR, 2009)	0.35
" During the treatment with quetiapine the patient presented complains about adverse effects like weight gain and somnolence."	( [Psychodynamic psychopharmacology in clinical practice--interpretations of adverse events of pharmacotherapy. Case report]. Murawiec, S, )	0.13
"In some cases adverse events of medication have not only biological but also emotional roots."	( [Psychodynamic psychopharmacology in clinical practice--interpretations of adverse events of pharmacotherapy. Case report]. Murawiec, S, )	0.13
" The most common adverse events were sedation, somnolence, and dry mouth."	( Safety and efficacy of quetiapine in bipolar depression. Bogart, GT; Chavez, B, 2009)	0.35
"Based on the literature reviewed here, quetiapine appears to be a safe and efficacious short-term treatment option for bipolar depression."	( Safety and efficacy of quetiapine in bipolar depression. Bogart, GT; Chavez, B, 2009)	0.35
" We describe two patients who experienced serious quetiapine adverse effects potentially mediated through an interaction with ritonavir-boosted atazanavir."	( Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. McCoy, C; Pollack, TM; Stead, W, 2009)	0.35
"The overall incidence of adverse events (AEs) was similar for quetiapine XR (69."	( Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies. Brecher, M; Huizar, K; Meulien, D, 2010)	0.36
" Safety was assessed by comparing incidence of adverse drug effects causing discontinuation of either study drug."	( Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. Allison, KM; Byers, MG; Lee, JK; Wendel, CS, 2010)	0.36
"To compare the efficacy and adverse effect profiles of 2 widely used atypical antipsychotics in the short-term phase of first-episode schizophrenia in patients who were treatment-naive."	( Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. Craig, TK; Elanjithara, T; Gafoor, R; Landau, S; McGuire, P; Power, P, 2010)	0.36
" Psychopathologic diagnoses and adverse effects were assessed by blinded raters at 4 weekly intervals."	( Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. Craig, TK; Elanjithara, T; Gafoor, R; Landau, S; McGuire, P; Power, P, 2010)	0.36
"Both quetiapine and risperidone were associated with a reduction in immediate symptoms and relatively few adverse effects other than weight gain."	( Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. Craig, TK; Elanjithara, T; Gafoor, R; Landau, S; McGuire, P; Power, P, 2010)	0.36
"Quetiapine and risperidone are both effective treatments in first-episode schizophrenia at doses lower than those used in patients with long-term schizophrenia and are similar in efficacy and the incidence of adverse effects."	( Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. Craig, TK; Elanjithara, T; Gafoor, R; Landau, S; McGuire, P; Power, P, 2010)	0.36
" Safety measures included adverse event (AE) reporting and administration of the Abnormal Involuntary Movement Scale (AIMS)."	( Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. Bachinsky, M; Cavus, I; Chappell, P; Glue, P; Karayal, ON; Kolluri, S; Stewart, M, 2011)	0.37
" Secondary outcomes were adverse events, metabolic side effects, and symptom severity."	( A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. Eriksson, H; Gendron, A; Honer, WG; Labelle, A; MacEwan, GW; Stip, E; Williams, R, 2012)	0.38
" Both doses of quetiapine were safe and well tolerated."	( A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. Eriksson, H; Gendron, A; Honer, WG; Labelle, A; MacEwan, GW; Stip, E; Williams, R, 2012)	0.38
" Based on adverse drug reaction (ADR) reports of QT prolongation and torsades de pointes, regulatory agencies recommended the use of continuous telemetry or advising against the intravenous administration in general."	( Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. Guglielmo, BJ; Meier, CR; Meyer-Massetti, C; Rätz Bravo, AE; Vaerini, S, 2011)	0.37
"While regulatory agencies advise against the use of intravenous haloperidol, review of VigiBase does not reveal that the intravenous route is any more likely to be associated with cardiac adverse events."	( Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. Guglielmo, BJ; Meier, CR; Meyer-Massetti, C; Rätz Bravo, AE; Vaerini, S, 2011)	0.37
" Several case reports on adverse effects with low doses of the drug were also included."	( Safety of low doses of quetiapine when used for insomnia. Coe, HV; Hong, IS, 2012)	0.38
" At recommended doses, atypical antipsychotics such as quetiapine are associated with metabolic adverse events (diabetes, obesity, hyperlipidemia)."	( Safety of low doses of quetiapine when used for insomnia. Coe, HV; Hong, IS, 2012)	0.38
" The most common treatment-related adverse events in the group receiving quetiapine XR were sedation (10."	( Safety of quetiapine fumarate extended release in the treatment of Korean patients with acute schizophrenia. Kim, CE; Kim, CY; Kim, YH; Kim, YT; Lee, JG; Lee, JI; Yoo, SY; Yoon, JS, 2012)	0.38
"Atypical antipsychotic agents have been associated with cerebrovascular adverse events, particularly in elderly dementia patients."	( Comparative risk of cerebrovascular adverse events in community-dwelling older adults using risperidone, olanzapine and quetiapine: a multiple propensity score-adjusted retrospective cohort study. Aparasu, RR; Chatterjee, S; Chen, H; Johnson, ML, 2012)	0.38
"16) was associated with a decrease in the risk of cerebrovascular adverse events compared with olanzapine."	( Comparative risk of cerebrovascular adverse events in community-dwelling older adults using risperidone, olanzapine and quetiapine: a multiple propensity score-adjusted retrospective cohort study. Aparasu, RR; Chatterjee, S; Chen, H; Johnson, ML, 2012)	0.38
" Prescribers should closely monitor the patients treated with atypical agents for the incidence of cerebrovascular adverse events."	( Comparative risk of cerebrovascular adverse events in community-dwelling older adults using risperidone, olanzapine and quetiapine: a multiple propensity score-adjusted retrospective cohort study. Aparasu, RR; Chatterjee, S; Chen, H; Johnson, ML, 2012)	0.38
" Safety endpoints included adverse events and assessments of clinical chemistry values, suicidality, and extrapyramidal symptoms."	( Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. Earley, WR; Findling, RL; McKenna, K; Pathak, S; Stankowski, J, 2012)	0.38
" Adverse events associated with quetiapine were mostly mild to moderate in intensity and were consistent with its known profile in adults with schizophrenia."	( Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. Earley, WR; Findling, RL; McKenna, K; Pathak, S; Stankowski, J, 2012)	0.38
"Primary metabolic markers (body mass index, blood pressure, fasting blood glucose, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides), percentage of patients who stay on the randomly assigned atypical antipsychotic for at least 6 months, psychopathology, percentage of patients who develop metabolic syndrome, and percentage of patients who develop serious and nonserious adverse events."	( Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA, 2013)	0.39
"Because of a high incidence of serious adverse events, quetiapine was discontinued midway through the trial."	( Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA, 2013)	0.39
"Lurasidone 80 mg and 160 mg doses administered once-daily in the evening, were safe and effective treatments for subjects with acute schizophrenia, with increased response rates observed at the higher dose."	( Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Cucchiaro, J; Hsu, C; Kalali, AH; Loebel, A; Pikalov, A; Potkin, SG; Sarma, K; Xu, L, 2013)	0.39
" Adverse events associated with quetiapine were mostly mild to moderate in intensity."	( Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. Acevedo, LD; Delbello, MP; Earley, WR; Findling, RL; Pathak, S; Stankowski, J, 2013)	0.39
" Treatment was generally well tolerated and adverse events were broadly consistent with the known profile of quetiapine in adults with bipolar disorder."	( Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. Acevedo, LD; Delbello, MP; Earley, WR; Findling, RL; Pathak, S; Stankowski, J, 2013)	0.39
" Safety and tolerability outcomes assessed from open-label baseline to week 26 included adverse events (AEs), metabolic/laboratory parameters, extrapyramidal symptoms, suicidality, and vital signs."	( Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study. DelBello, M; Earley, WR; Findling, RL; Liu, S; Pathak, S, 2013)	0.39
"In this 26-week study, quetiapine flexibly dosed at 400-800 mg/day, with options to reduce dosing based on tolerability, was generally safe and well tolerated in youth."	( Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study. DelBello, M; Earley, WR; Findling, RL; Liu, S; Pathak, S, 2013)	0.39
" The safety was evaluated by the Udvalg Kliniske Undersogelser side effect rating scale."	( Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. Choi, SH; Choi, WJ; Kim, JJ; Park, JY; Park, KM; Seok, JH; Yoon, HJ, 2013)	0.39
" Fifteen subjects experienced a few adverse events, but there were no significant differences in adverse event profiles among the four groups."	( Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. Choi, SH; Choi, WJ; Kim, JJ; Park, JY; Park, KM; Seok, JH; Yoon, HJ, 2013)	0.39
"Haloperidol, risperidone, olanzapine, and quetiapine were equally efficacious and safe in the treatment of delirium."	( Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. Choi, SH; Choi, WJ; Kim, JJ; Park, JY; Park, KM; Seok, JH; Yoon, HJ, 2013)	0.39
" Quetiapine XR was generally safe and well tolerated."	( Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial. DelBello, MP; Earley, WR; Findling, RL; Liu, S; Pathak, S, 2014)	0.4
" The aim of this study was to identify genetic markers related to the pharmacokinetics, pharmacodynamics, and adverse effects of quetiapine."	( Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects. Abad-Santos, F; Borobia, A; Cabaleiro, T; Carcas, A; López-Rodríguez, R; Novalbos, J; Ochoa, D; Román, M, 2015)	0.42
"The reports submitted to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from 1997 to 2011 were reviewed to assess serious adverse events induced by the administration of antipsychotics to children."	( Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T, 2015)	0.42
" Signals in the data that signified a drug-associated adverse event were detected via quantitative data mining algorithms."	( Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T, 2015)	0.42
" Significant signals of the QT prolongation adverse event were detected only for ziprasidone and risperidone."	( Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T, 2015)	0.42
"It was suggested that there is a level of diversity in the strength of the association between various first- and second-generation antipsychotics with associated serious adverse events, which possibly lead to fatal outcomes."	( Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T, 2015)	0.42
"7%) experienced adverse events including headache, exacerbation of psychosis and dysuria."	( The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population. Lee, MS; Pan, PY; Yeh, CB, 2015)	0.42
" Safety measures included body mass index, serum prolactin, extrapyramidal adverse effects, and electrocardiogram."	( Efficacy and Safety of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder Comorbid With Conduct Disorder. Masi, G; Milone, A; Pisano, S; Stawinoga, A; Veltri, S, 2015)	0.42
" EPS were assessed at baseline and 4, 8, and 12 weeks after naturalistic SGA initiation for schizophrenia, mood, disruptive behavior, and autism spectrum disorders using the Simpson-Angus Scale (SAS), Barnes Akathisia Scale, Abnormal Involuntary Movement Scale (AIMS), and Treatment Emergent Side Effect Scale."	( Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. Al-Jadiri, A; Azzo, S; Carbon, M; Correll, CU; Kane, JM; Kapoor, S; Saito, E; Sarkaria, T; Sheridan, E, 2015)	0.42
"In this population of critically ill youth, short-term use of quetiapine as treatment for delirium appears to be safe, without serious adverse events."	( Evaluation of the Safety of Quetiapine in Treating Delirium in Critically Ill Children: A Retrospective Review. Greenwald, BM; Herrup, E; Joyce, C; Kaur, S; Mendez-Rico, E; Silver, G; Traube, C; Witcher, R, 2015)	0.42
"The aim of this study was to evaluate demographic, clinical, and treatment factors that may impact on neurological adverse effects in naive and quasi-naive children and adolescents treated with antipsychotics."	( Neurological Adverse Effects of Antipsychotics in Children and Adolescents. Alda, JA; Andrés Nestares, P; Arango, C; Baeza, I; Cantarero, CM; Castro-Fornieles, J; de la Serna, E; Garcia-Amador, M; Merchán-Naranjo, J; Moreno, C; Muñoz, D; Tapia, C, 2015)	0.42
" Total dyskinesia score (DyskinesiaS) and total Parkinson score (ParkinsonS) were calculated from the Maryland Psychiatric Research Center Involuntary Movement Scale, total UKU-Cognition score was calculated from the UKU Side Effect Rating Scale."	( Neurological Adverse Effects of Antipsychotics in Children and Adolescents. Alda, JA; Andrés Nestares, P; Arango, C; Baeza, I; Cantarero, CM; Castro-Fornieles, J; de la Serna, E; Garcia-Amador, M; Merchán-Naranjo, J; Moreno, C; Muñoz, D; Tapia, C, 2015)	0.42
"Antipsychotics increased neurological adverse effects in a naive and quasi-naive pediatric population and should be carefully monitored."	( Neurological Adverse Effects of Antipsychotics in Children and Adolescents. Alda, JA; Andrés Nestares, P; Arango, C; Baeza, I; Cantarero, CM; Castro-Fornieles, J; de la Serna, E; Garcia-Amador, M; Merchán-Naranjo, J; Moreno, C; Muñoz, D; Tapia, C, 2015)	0.42
" The aim of this paper was to review and describe adverse drug events associated with quetiapine use in older adults."	( Quetiapine safety in older adults: a systematic literature review. El-Saifi, N; Jones, C; Moyle, W; Tuffaha, H, 2016)	0.43
" The most commonly reported adverse events were somnolence (25-39%), dizziness (15-27%), headache (10-23%), postural hypotension (6-18%) and weight gain (11-30%)."	( Quetiapine safety in older adults: a systematic literature review. El-Saifi, N; Jones, C; Moyle, W; Tuffaha, H, 2016)	0.43
" Adverse events occurred in 96 patients (65."	( Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial. Gao, C; Gu, N; Li, H; Li, K; Li, L; Lu, Z; Ning, Y; Shi, J; Tan, Q; Tian, H; Wang, G; Wang, X; Xie, S; Xu, X; Xu, Y; Yang, F; Yu, X; Zhang, H; Zhang, K, 2016)	0.43
" Quetiapine XR was generally safe and well tolerated (ClinicalTrials."	( Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial. Gao, C; Gu, N; Li, H; Li, K; Li, L; Lu, Z; Ning, Y; Shi, J; Tan, Q; Tian, H; Wang, G; Wang, X; Xie, S; Xu, X; Xu, Y; Yang, F; Yu, X; Zhang, H; Zhang, K, 2016)	0.43
" Although knowledge of adverse drug reactions in children and adolescents is scarce, quetiapine is increasingly being used for youth in Denmark."	( Adverse events in children and adolescents treated with quetiapine: an analysis of adverse drug reaction reports from the Danish Medicines Agency database. Bruhn, CH; Fink-Jensen, A; Hashemi, N; Jakobsen, KD; Nielsen, J; Pagsberg, AK; Wallach-Kildemoes, H, 2017)	0.46
" Safety objectives included adverse event (AE) monitoring, laboratory test results, and electrocardiograms."	( A 6-week, multicenter, double-blind, double-dummy, chlorpromazine-controlled non-inferiorityrandomized phase iiitrial to evaluate the efficacy and safety of quetiapine fumarate (SEROQUEL) extended-release (XR) in the treatment of patients with schizophren Gu, N; Li, H; Li, K; Ma, C; Shen, Y; Shi, J; Wang, G; Wang, X; Xie, S; Xu, X; Zhang, H, 2018)	0.48
" The most frequent treatment-emergent adverse events in patients receiving brexpiprazole were akathisia (6."	( Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study. Augustine, C; Brewer, C; Hefting, N; Hobart, M; Josiassen, MK; McQuade, RD; Sanchez, R; Skuban, A; Zhang, P, 2018)	0.48
" The use of antipsychotics is associated with a number of adverse effects for which routine monitoring is recommended."	( Antipsychotic Prescribing and Safety Monitoring Practices in Children and Youth: A Population-Based Study in Alberta, Canada. Cepoiu-Martin, M; Chen, W; Cooke, L; Duncan, D; Pringsheim, T; Stang, A; Symonds, C, 2018)	0.48
"We examined systematic adverse events (AEs) in Part 1 (of 2) of a study describing the assessment and reporting of AEs in clinical trials."	( Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events. Canner, JK; Dickersin, K; Fusco, N; Hong, H; Li, T; Mayo-Wilson, E, 2019)	0.51
"We examined nonsystematic adverse events (AEs) in Part 2 (of 2) of a study describing the assessment and reporting AEs in clinical trials."	( Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events. Canner, JK; Dickersin, K; Fusco, N; Hong, H; Li, T; Mayo-Wilson, E, 2019)	0.51
" Different methods for reporting adverse events across trials or across sources for a single trial may produce inconsistent information about the adverse events associated with interventions."	( Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events. Canner, JK; Dickersin, K; Fusco, N; Hong, H; Li, T; Mayo-Wilson, E, 2019)	0.51
" The effect size, remission/response rate, and risk for discontinuation due to adverse events (AEs), weight gain (WG), nervous systems and gastrointestinal AEs were assessed and compared between two regions with Cohen's d or number needed to treat/harm."	( Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? Bai, Y; Chen, G; Gao, K; Yang, H, 2020)	0.56
" Adverse events over 7 days were evaluated."	( Safety and effectiveness of antipsychotic medication for delirium in patients with advanced cancer: A large-scale multicenter prospective observational study in real-world palliative care settings. Akechi, T; Imai, K; Iwase, S; Maeda, I; Matsumoto, Y; Morita, T; Nakahara, R; Ogawa, A; Oyamada, S; Sakashita, A; Uemura, K; Yamaguchi, T; Yoshiuchi, K, )	0.13
"5%) were the most prevalent adverse events."	( Safety and effectiveness of antipsychotic medication for delirium in patients with advanced cancer: A large-scale multicenter prospective observational study in real-world palliative care settings. Akechi, T; Imai, K; Iwase, S; Maeda, I; Matsumoto, Y; Morita, T; Nakahara, R; Ogawa, A; Oyamada, S; Sakashita, A; Uemura, K; Yamaguchi, T; Yoshiuchi, K, )	0.13
"The use of antipsychotics as part of comprehensive delirium management was safe and may provide some symptomatic benefits for patients with terminal illness and delirium."	( Safety and effectiveness of antipsychotic medication for delirium in patients with advanced cancer: A large-scale multicenter prospective observational study in real-world palliative care settings. Akechi, T; Imai, K; Iwase, S; Maeda, I; Matsumoto, Y; Morita, T; Nakahara, R; Ogawa, A; Oyamada, S; Sakashita, A; Uemura, K; Yamaguchi, T; Yoshiuchi, K, )	0.13
" Neonatal providers should be aware of maternal medications and prepare for possible adverse effects, particularly from common psychotropic exposures."	( Why the Maternal Medication List Matters: Neonatal Toxicity From Combined Serotonergic Exposures. Brajcich, MR; Marks, J; Messer, RD; Murphy, ME; Palau, MA, 2021)	0.62
" Available safety outcomes included discontinuations (all-cause, lack of efficacy, adverse events), metabolic parameters (weight change, cholesterol, triglycerides, glucose), changes in prolactin, and somnolence."	( Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression. DelBello, MP; Hagi, K; Heller, V; Kadakia, A; Loebel, A; Nosaka, T; Singh, R, 2022)	0.72
" SGAs used for approved indications are associated with significant metabolic adverse effects, including weight gain."	( Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. Agarwal, SM; Asgariroozbehani, R; Bowden, S; Hahn, MK; McIntyre, WB; Remington, G; Siskind, D; Smith, E; Stogios, N; Tran, V, 2022)	0.72
" Patients treated with these agents may be at higher risk for adverse events such as QTc prolongation and arrhythmias."	( Atypical Antipsychotic Safety in the CICU. Abdul-Aziz, AA; Adie, SK; Deshmukh, A; Gondi, K; Hanna, MP; Ketcham, SW; Konerman, MC; Prescott, HC; Thomas, MP, 2022)	0.72
" Finally, there was no significant difference in the frequency of adverse events."	( Levetiracetam adjunct to quetiapine for the acute manic phase of bipolar disorder: a randomized, double-blind and placebo-controlled clinical trial of efficacy, safety and tolerability. Akhondzadeh, S; Arbabi, M; Hasanzadeh, A; Naderi, S; Ostadpour, M; Samsami, FS; Shamabadi, A; Zarezadeh, F, 2022)	0.72
" Secondary outcomes included psychopathology, remission, all-cause-discontinuation, inefficacy-related discontinuation, and adverse events."	( Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. Correll, CU; Hagi, K; Kane, JM; Kishimoto, T; Kurokawa, S, 2023)	0.91
"Retrospective studies using spontaneous reporting system databases have provided a great understanding of adverse drug reactions (ADRs) in the real world, complementing the data obtained from randomized controlled trials."	( Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019. Byeon, SJ; Chung, SJ; Oh, S, 2022)	0.72
"Data were collected from the Korea Adverse Event Reporting System database between 2010 and 2019."	( Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019. Byeon, SJ; Chung, SJ; Oh, S, 2022)	0.72
"In total, 5067 adverse events associated with antipsychotic drugs were reported."	( Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019. Byeon, SJ; Chung, SJ; Oh, S, 2022)	0.72
"5 mg/day) treatment during the first hospitalization did not cause any side effects, but treatment with mirtazapine (15 mg/day) and venlafaxine (150 mg/day) during the second hospitalization caused clonus and disturbance of consciousness, and these adverse effects resulted in a prolonged period of hospitalization."	( A case of mood disorder with severe side effects of antidepressants in association with resistance to thyroid hormone beta with a THRB mutation. Hasegawa, C; Komahashi-Sasaki, H; Maehara, R; Shimoda, K; Yasui-Furukori, N, 2022)	0.72
" The changes in the depressive rating scale, remission/response rates, nervous system adverse events (NSAEs), gastrointestinal adverse events (GIAEs), metabolic parameters, and prolactin were compared between medication and placebo or among medications with the Cohen's d or number needed to treat/harm."	( Efficacy and safety profiles of mood stabilizers and antipsychotics for bipolar depression: a systematic review. Bai, Y; Cai, L; Chen, G; Yang, H, 2023)	0.91
" Due to the limitations of clinical trials, the association between quetiapine and rare cardiac adverse events (AEs) is still unclear."	( Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system. Ding, Y; Liu, L; Shu, Y; Zhang, Q, 2023)	0.91
" However, it can cause mild or severe hepatic adverse events and rarely fatal liver damage."	( Investigation of hepatic adverse events due to quetiapine by using the common data model. Chang, DJ; Chang, SH; Choi, IY; Chung, YW; Kang, DY; Kim, K; Ko, S; Seo, YG, 2023)	0.91
" We analyzed the status of quetiapine use, adverse events, and hepatic impairment."	( Investigation of hepatic adverse events due to quetiapine by using the common data model. Chang, DJ; Chang, SH; Choi, IY; Chung, YW; Kang, DY; Kim, K; Ko, S; Seo, YG, 2023)	0.91
"The numbers of patients with non-serious and severe hepatic adverse reactions were 2566 (5."	( Investigation of hepatic adverse events due to quetiapine by using the common data model. Chang, DJ; Chang, SH; Choi, IY; Chung, YW; Kang, DY; Kim, K; Ko, S; Seo, YG, 2023)	0.91
"Our findings suggest that quetiapine should be cautiously used, and hepatic function should be monitored in patients using quetiapine because it can cause mild or severe hepatic adverse events, complications, and in rare cases, fatal liver damage."	( Investigation of hepatic adverse events due to quetiapine by using the common data model. Chang, DJ; Chang, SH; Choi, IY; Chung, YW; Kang, DY; Kim, K; Ko, S; Seo, YG, 2023)	0.91
"To compare the risk for in-hospital adverse events associated with oral haloperidol, olanzapine, quetiapine, and risperidone in older patients after major surgery."	( Comparative Safety Analysis of Oral Antipsychotics for In-Hospital Adverse Clinical Events in Older Adults After Major Surgery : A Nationwide Cohort Study. Bateman, BT; Ely, EW; Inouye, SK; Jones, RN; Kim, DH; Lee, SB; Levin, R; Marcantonio, ER; Metzger, E; Pandharipande, PP; Park, CM; Pisani, MA, 2023)	0.91
"These results suggest that atypical antipsychotics and haloperidol have similar rates of in-hospital adverse clinical events in older patients with postoperative delirium who receive an oral low-to-moderate dose antipsychotic drug."	( Comparative Safety Analysis of Oral Antipsychotics for In-Hospital Adverse Clinical Events in Older Adults After Major Surgery : A Nationwide Cohort Study. Bateman, BT; Ely, EW; Inouye, SK; Jones, RN; Kim, DH; Lee, SB; Levin, R; Marcantonio, ER; Metzger, E; Pandharipande, PP; Park, CM; Pisani, MA, 2023)	0.91

Excerpt	Reference	Relevance
" The present assay method was used to support a study comparing the pharmacokinetic profile of quetiapine with the time course of dopamine D2 and serotonin 5-HT2 receptor occupancy in the brain using positron emission tomography (PET)."	( Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection. Davis, PC; Gefvert, O; Wong, J, 1999)	0.3
" Key assessments were pharmacokinetic analysis of plasma quetiapine concentrations and neurologic, safety, and efficacy evaluations."	( Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. Arvanitis, LA; Brown, KL; Chaney, RO; Foster, KD; Friedman, LM; Heubi, JE; McConville, BJ; Sorter, MT; Thyrum, PT; Wilkinson, LA; Yeh, C, 2000)	0.31
" Decline in serum quetiapine concentration followed a biexponential pattern with a terminal elimination half-life of 22 hours."	( Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. Pollak, PT; Zbuk, K, 2000)	0.31
" Elevated serum concentrations associated with this overdose remained above the limit of detection long enough to document a terminal elimination half-life of 22 hours in this patient."	( Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. Pollak, PT; Zbuk, K, 2000)	0.31
" No clinically significant differences were found when the pharmacokinetic parameters for subjects with renal or hepatic impairment were compared with those for healthy control subjects."	( Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Thyrum, PT; Wong, YW; Yeh, C, 2000)	0.31
" The time course of quetiapine concentrations was described by use of a one-compartment open linear pharmacokinetic model with first-order absorption and elimination."	( Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Holford, NH; Kimko, HC; Peck, CC; Reele, SS, 2000)	0.31
" In pharmacokinetic studies in humans, quetiapine was rapidly absorbed after oral administration, with median time to reach maximum observed plasma concentration ranging from 1 to 2 hours."	( Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. DeVane, CL; Nemeroff, CB, 2001)	0.31
" Key assessments included pharmacokinetic analysis of quetiapine, the Udvalg for kliniske undersøgelser (UKU) Side Effect Rating Scale, and safety evaluations (e."	( Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. Alva, G; Arvanitis, LA; Carreon, D; Kalali, A; Potkin, SG; Thyrum, PT; Yeh, C, 2002)	0.31
" Quetiapine plasma concentrations were measured before and after cimetidine coadministration, and quetiapine pharmacokinetic parameters were calculated."	( The effect of multiple doses of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders. Keck, PE; Strakowski, SM; Thyrum, PT; Wong, YW; Yeh, C, 2002)	0.31
" In humans, quetiapine exhibits linear pharmacokinetics with a mean terminal half-life of 7 hours."	( Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. Goldstein, J; Kinkead, B; Nemeroff, CB, 2002)	0.31
" Descriptive statistics summarised plasma quetiapine concentrations and pharmacokinetic parameters by trial day."	( Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders. Arvanitis, LA; Fuller, MA; Jaskiw, GE; Thyrum, PT; Yeh, C, 2004)	0.32
" The apparent oral clearance, volume of distribution and half-life did not change as a function of dose."	( Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders. Arvanitis, LA; Fuller, MA; Jaskiw, GE; Thyrum, PT; Yeh, C, 2004)	0.32
" Individual pharmacokinetic parameter values were calculated using a one-compartment open model and a Bayesian fitting procedure."	( Quetiapine in overdosage: a clinical and pharmacokinetic analysis of 14 cases. Boswijk, DJ; de Haas, JA; Hunfeld, NG; Touw, DJ; van Putten, MJ; Westerman, EM, 2006)	0.33
" A fully Bayesian methodology for population pharmacokinetic analysis was used and data were modelled using WinBUGS."	( Pharmacokinetics of quetiapine in overdose and the effect of activated charcoal. Duffull, SB; Friberg, LE; Hackett, LP; Isbister, GK, 2007)	0.34
"To determine whether there is a pharmacokinetic drug interaction between quetiapine fumarate and divalproex sodium."	( Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Davis, PC; DeVane, CL; Ennis, DJ; Figueroa, C; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2007)	0.34
"Combination therapy with quetiapine (150 mg bid) and divalproex (500 mg bid) resulted in small and statistically non-significant pharmacokinetic changes."	( Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Davis, PC; DeVane, CL; Ennis, DJ; Figueroa, C; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2007)	0.34
"This 10-day, single-center, open-label, randomized, crossover study compared pharmacokinetic profiles and tolerability of extended release quetiapine fumarate (quetiapine XR) with quetiapine immediate release (quetiapine IR) in patients with schizophrenia, schizoaffective disorder or bipolar disorder."	( Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Brecher, M; Figueroa, C; Hamer-Maansson, JE; Winter, H, 2009)	0.35
" The antidepressive response is considered to be mediated by the metabolite N-desalkylquetiapine, and the aim of this study was to assess the interindividual pharmacokinetic variability of quetiapine and N-desalkylquetiapine in psychiatric patients based on therapeutic drug monitoring samples."	( Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Bakken, GV; Hermann, M; Molden, E; Refsum, H; Rudberg, I, 2011)	0.37
" Pharmacokinetic variability was expressed as the 5-95 percentile range in dose-adjusted serum concentrations (C/D ratios)."	( Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Bakken, GV; Hermann, M; Molden, E; Refsum, H; Rudberg, I, 2011)	0.37
"The pharmacokinetic variability was greater for quetiapine compared with N-desalkylquetiapine."	( Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Bakken, GV; Hermann, M; Molden, E; Refsum, H; Rudberg, I, 2011)	0.37
" The method is proved to be accurate and specific, and was applied to the pharmacokinetic study in healthy Chinese volunteers."	( Validated LC-MS-MS method for the determination of quetiapine in human plasma: application to a pharmacokinetic study. Kuo, BP; Pan, RN; Pao, LH, 2012)	0.38
" Compared with fasting, a high-fat meal increased the AUC and Cmax for quetiapine XR, whereas a light meal had no significant effect on these parameters."	( Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications. Bui, K; Earley, W; Nyberg, S, 2013)	0.39
"At steady state, quetiapine XR provided a similar AUC and Cmin and a slightly lower Cmax relative to an equivalent dose of quetiapine IR administered twice daily."	( Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications. Bui, K; Earley, W; Nyberg, S, 2013)	0.39
" A linear mixed model was performed to compare pharmacokinetic parameters."	( MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers. Dorado, P; Estévez-Carrizo, FE; Fariñas, H; González-Vacarezza, N; Llerena, A; Peñas-Lledó, EM, 2013)	0.39
" The present study aims to improve our understanding of antipsychotic-related adverse reactions (ARs) and their possible association with common genetic variants of pharmacodynamic proteins such as neurotransmitter receptors/transporters."	( Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. Abad-Santos, F; Ayuso, C; Borobia, AM; Cabaleiro, T; Carcas, AJ; López-Rodríguez, R; Novalbos, J; Ochoa, D; Román, M, 2013)	0.39
"Genetic variants in pharmacodynamic genes could represent valuable markers of AR risk and antipsychotic safety."	( Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. Abad-Santos, F; Ayuso, C; Borobia, AM; Cabaleiro, T; Carcas, AJ; López-Rodríguez, R; Novalbos, J; Ochoa, D; Román, M, 2013)	0.39
" After a single dose of 100 mg quetiapine was administered, plasma concentrations of quetiapine were measured for 24 h and pharmacokinetic analysis was carried out."	( Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. Joo, HJ; Kim, KA; Lee, HM; Park, JY, 2014)	0.4
"3435C>>T did not affect plasma levels of quetiapine, and its pharmacokinetic parameters did not differ among ABCB1 genotype groups."	( Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. Joo, HJ; Kim, KA; Lee, HM; Park, JY, 2014)	0.4
" Pharmacokinetic parameters for both quetiapine and N-desalkyl quetiapine (norquetiapine) were determined."	( Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. Chen, JX; Li, Q; Liu, Y; Si, TM; Su, YA; Tan, YL; Yang, FD, 2014)	0.4
" The geometric mean elimination half-life (t ½) of both quetiapine and N-desalkyl quetiapine was consistent for the three dosing groups (approximately 7 h for quetiapine and approximately 18 h for N-desalkyl quetiapine)."	( Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. Chen, JX; Li, Q; Liu, Y; Si, TM; Su, YA; Tan, YL; Yang, FD, 2014)	0.4
"Quetiapine fumarate XR has a dose-proportional pharmacokinetic profile at doses ranging from 300 to 800 mg once daily, and a slower time to reach C max and steady state after 3 days of sequential dosing."	( Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. Chen, JX; Li, Q; Liu, Y; Si, TM; Su, YA; Tan, YL; Yang, FD, 2014)	0.4
" The purpose of the current study was to use physiologically based pharmacokinetic modeling (PBPK) quantitatively to predict the PK of the XR formulation in children and adolescents."	( Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents. Bui, KH; Johnson, TN; Zhou, D, 2014)	0.4
" Increasing half-life was observed for QLNC in relation to free-QTP due to o significant decrease in total clearance."	( Pre-clinical investigation of the modulation of quetiapine plasma pharmacokinetics and tissues biodistribution by lipid-core nanocapsules. Carreño, F; Dalla Costa, T; Guterres, SS; Paese, K; Silva, CM, 2016)	0.43
"We conducted a single-dose open-label crossover pharmacokinetic study in 10 healthy adults to determine whether quetiapine compounded as a rectal suppository or a topical cream achieved absorption similar to that achieved by a commercially available oral formulation."	( A Single-Dose Crossover Pharmacokinetic Comparison Study of Oral, Rectal and Topical Quetiapine in Healthy Adults. Bobo, WV; Cunningham, JL; Dierkhising, RA; Kung, S; Lapid, MI; Leung, JG; Nelson, S; Plevak, MF; Thompson, VH, 2016)	0.43
" The aim of this work was to develop a physiologically based pharmacokinetic (PBPK)/pharmacodynamic (PD) model to predict changes in the PK parameters associated with genetic polymorphisms and the impact of these changes on drugs' PD effect."	( Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs. Alqahtani, S; Kaddoumi, A, 2016)	0.43
" Pharmacokinetic data from a randomized crossover study evaluating 2 quetiapine 25 mg immediate-release tablets after single oral dose were used to develop a population pharmacokinetic model."	( Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment. Derendorf, H; Melhem, M; Shilbayeh, SA; Sy, SK; Zmeili, R, 2015)	0.42
"The objectives of this study were to evaluate the bioequivalence of Quesero extended release (Quesero XR) tablets and Seroquel extended release (Seroquel XR) tablets under fasting and fed conditions and to determine the effect of food on the pharmacokinetic (PK) properties of Quesero XR or Seroquel XR in Chinese healthy volunteers."	( Bioequivalence of two quetiapine extended release tablets in Chinese healthy volunteers under fasting and fed conditions and effects of food on pharmacokinetic profiles. He, C; Huang, X; Liu, L; Ma, Y; Mei, H; Tian, R; Yang, H; Zhang, B; Zhang, S, 2019)	0.51
" This study applied pharmacokinetic modelling principles to investigate the mechanism of these changes and to propose new dosing strategies to counteract these changes."	( Quetiapine dose optimisation during gestation: a pharmacokinetic modelling study. Badhan, RKS; Macfarlane, H, 2020)	0.56
"A pharmacokinetic modelling approach was implemented using virtual population groups."	( Quetiapine dose optimisation during gestation: a pharmacokinetic modelling study. Badhan, RKS; Macfarlane, H, 2020)	0.56
" Models were verified by assessing goodness-of-fit plots and ratios of predicted-to-observed pharmacokinetic parameters."	( Dose Adjustment of Quetiapine and Aripiprazole for Pregnant Women Using Physiologically Based Pharmacokinetic Modeling and Simulation. Jiang, X; Tang, R; Tang, S; Wang, L; Xu, M; Zheng, L, 2021)	0.62
" As such, kratom may precipitate pharmacokinetic drug interactions when co-consumed with certain medications."	( A Case of Potential Pharmacokinetic Kratom-drug Interactions Resulting in Toxicity and Subsequent Treatment of Kratom Use Disorder With Buprenorphine/Naloxone. Brogdon, HD; Burns, AG; Cox, EJ; McPhee, MM; Paine, MF, )	0.13

Excerpt	Reference	Relevance
"Quetiapine (QTP) combined with lithium (Li) or divalproex (DVP) for the treatment of mania was evaluated in 2 double-blind, placebo-controlled studies."	( Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. Mullen, J; Paulsson, B; Vågerö, AM; Yatham, LN, 2004)	0.32
"This 6-week, open-label, multicenter study evaluated the efficacy and safety of quetiapine in combination with citalopram in adult patients (n=25) with ICD-10/DSM-IV unipolar psychotic depression."	( Quetiapine in combination with citalopram in patients with unipolar psychotic depression. Aschauer, H; Hrubos, W; Kasper, S; Konstantinidis, A; Lehofer, M; Nirnberger, G; Windhager, E, 2007)	0.34
"The aim of this analysis was to compare the rates of remission/euthymia in patients with bipolar mania receiving quetiapine in combination with lithium/divalproex (QTP+Li/DVP) versus placebo (PBO) in combination with Li/DVP (PBO+Li/DVP)."	( Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania. Mullen, J; Paulsson, B; Sussman, N; Vågerö, M, 2007)	0.34
"At Days 21 and 42, quetiapine combined with Li/DVP compared to Li/DVP monotherapy yielded significant, sustained improvements in the rate of clinical remission/euthymia in patients with bipolar mania."	( Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania. Mullen, J; Paulsson, B; Sussman, N; Vågerö, M, 2007)	0.34
" Variables included in the analysis were age, gender, and concomitant treatment with a total of 41 drugs most often used in combination with quetiapine."	( Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. Castberg, I; Skogvoll, E; Spigset, O, 2007)	0.34
" On the basis of our data and pharmacokinetic considerations, the majority of drugs commonly used in psychiatry can safely be given in combination with quetiapine."	( Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. Castberg, I; Skogvoll, E; Spigset, O, 2007)	0.34
"This study examined the efficacy and safety of quetiapine in combination with lithium or divalproex compared with placebo with lithium or divalproex in the prevention of recurrent mood events in bipolar I patients, most recent episode mania, depression, or mixed."	( Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). Brecher, M; Eggens, I; Paulsson, B; Persson, I; Suppes, T; Vieta, E, 2008)	0.35
"Treatment with quetiapine in combination with lithium/divalproex significantly increased the time to recurrence of any mood event compared with placebo plus lithium/divalproex."	( Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). Brecher, M; Eggens, I; Paulsson, B; Persson, I; Suppes, T; Vieta, E, 2008)	0.35
"Maintenance treatment with quetiapine in combination with lithium/divalproex significantly increased time to recurrence of any event (mania, depression, or mixed) irrespective of the polarity of the index episode compared with placebo with lithium/divalproex."	( Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). Brecher, M; Eggens, I; Paulsson, B; Persson, I; Suppes, T; Vieta, E, 2008)	0.35
" After at least 12 weeks of clinical stability, 628 patients were randomly assigned to double-blind treatment with quetiapine or placebo, in combination with lithium or divalproex, for up to 104 weeks."	( Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Brecher, M; Liu, S; Paulsson, B; Suppes, T; Vieta, E, 2009)	0.35
" The need to provide effective therapeutic interventions to patients who do not have an optimal response to clozapine is the most common reason for simultaneously prescribing a second antipsychotic drug in combination with clozapine."	( Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Barbui, C; Boso, M; Cipriani, A, 2009)	0.35
"Clinicians caring for patients infected with the human immunodeficiency virus (HIV) and diagnosed with psychiatric comorbidities must be aware of potential drug-drug interactions, particularly with protease inhibitor-based antiretroviral therapy."	( Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. McCoy, C; Pollack, TM; Stead, W, 2009)	0.35
"Quetiapine is now used in the treatment of unipolar and bipolar disorders, both alone and in combination with other medications."	( Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission. Blier, P; Chernoloz, O; El Mansari, M, 2012)	0.38
" We reexamined all his possible medical conditions and found that the patient had an abnormally enlarged cavus septum pellucidum (CSP) combined with cavum vergae (CV) (maximum length >30 mm)."	( A case report on the relationship between treatment-resistant childhood-onset schizophrenia and an abnormally enlarged cavum septum pellucidum combined with cavum vergae. Hu, SH; Liao, ZL; Xu, Y, 2012)	0.38
"To determine the efficacy and safety of quetiapine combined with lithium or divalproex for preventing mood events in patients with bipolar I disorder."	( Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials. Ekholm, B; Gustafsson, U; Suppes, T; Vieta, E, 2013)	0.39
"In patients with bipolar I disorder previously stabilized on quetiapine and lithium or divalproex, maintenance therapy with quetiapine significantly increased the time to recurrence of a mood event (mania or depression) versus placebo, regardless of whether it was combined with lithium or divalproex."	( Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials. Ekholm, B; Gustafsson, U; Suppes, T; Vieta, E, 2013)	0.39
" The goal of this study was to investigate the reinforcing effects of quetiapine alone and in combination with intravenous cocaine in monkeys."	( Evaluation of the Reinforcing Effect of Quetiapine, Alone and in Combination with Cocaine, in Rhesus Monkeys. Brutcher, RE; Nader, MA; Nader, SH, 2016)	0.43
" For these people, a number of treatment strategies have emerged, including the prescription of a second anti-psychotic drug in combination with clozapine."	( Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017)	0.46
" Available data indicate to us that all HIV protease inhibitors combined with ritonavir are likely to be strong CYP3A inhibitors."	( Dosing Recommendations for Quetiapine When Coadministered With HIV Protease Inhibitors. Cao, KY; Gish, PL; Hyon, K; Mishra, P; Sampson, MR; Tauber, W; Younis, IR; Zhao, P; Zhou, EH, 2019)	0.51
" We systematically searched for studies of acute toxicity of quetiapine or other antipsychotics combined with morphine or methadone."	( Quetiapine and other antipsychotics combined with opioids in legal autopsy cases: A random finding or cause of fatal outcome? Andersen, CU; Andersen, FD; Simonsen, U, 2021)	0.62
"Quetiapine combined with sodium valproate is an effective and more suitable drug treatment for Alzheimer's disease."	( Quetiapine Combined with Sodium Valproate in Patients with Alzheimer's Disease with Mental and Behavioral Symptoms Efficacy Observation. Fu, K; He, X; Liu, W; Xu, J; Xu, P; Zhang, Z, 2022)	0.72
"Methadone and buprenorphine have pharmacologic properties that are concerning for a high risk of drug-drug interactions (DDIs)."	( Identifying Clinically Relevant Drug-Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection. Acton, EK; Bilker, WB; Brensinger, CM; Dawwas, GK; Hennessy, S; Leonard, CE; Li, L; Miano, TA; Neuman, M; Nguyen, TPP; Soprano, SE; Wang, L; Woody, G; Yu, E, 2022)	0.72
"Polypharmacy increases the risk of potential drug-drug interactions (pDDIs)."	( Clinical significance of potential drug-drug interactions in older adults with psychiatric disorders: a retrospective study. Cui, Y; Ding, Y; Ji, M; Liu, Y; Wang, D; Wang, H; Yang, M; Zhang, H; Zhuang, T, 2022)	0.72
"In this preliminary study involving healthy participants, paroxetine combined with oxycodone, compared with oxycodone alone, significantly decreased the ventilatory response to hypercapnia on days 1 and 5, whereas quetiapine combined with oxycodone did not cause such an effect."	( Effect of Paroxetine or Quetiapine Combined With Oxycodone vs Oxycodone Alone on Ventilation During Hypercapnia: A Randomized Clinical Trial. Boughner, R; Burkhart, K; Dahan, A; Davis, MC; Florian, J; Ford, K; Gershuny, V; Han, X; Ismaiel, OA; Matta, M; Patel, V; Prentice, K; Racz, R; Rouse, R; Sanabria, C; Shah, A; Stone, M; Strauss, DG; van der Schrier, R; Wang, C; Weaver, J, 2022)	0.72

Excerpt	Reference	Relevance
" The absolute bioavailability is unknown, but the relative bioavailability from orally administered tablets compared with a solution was nearly complete."	( Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. DeVane, CL; Nemeroff, CB, 2001)	0.31
"The goal of the present study was to assess the relative bioavailability of a new XR formulation of quetiapine 300 mg versus the XR reference product after the administration of a high-fat breakfast as required to assume bioequivalence according to the Uruguayan regulatory authority."	( Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers. Ercoli, MC; Estevez-Carrizo, FE; Estevez-Parrillo, FT; Parrillo, S, 2011)	0.37
" This analytical method was applied in a relative bioavailability study in order to compare a test mirtazapine 30 mg single-dose formulation vs a reference formulation in 31 volunteers of both sexes."	( A fast, sensitive and simple method for mirtazapine quantification in human plasma by HPLC-ESI-MS/MS. Application to a comparative bioavailability study. Barrientos-Astigarraga, RE; Borges, NC; Donato, JL; Felix, L; Galvinas, PA; Moreno, P; Moreno, RA; Sverdloff, CE, 2012)	0.38
" Those CNS drugs which have limited oral bioavailability due to pharmacokinetic consequences and brain barrier repulsion are getting onto this direction."	( Comparative study between simple and optimized liposomal dispersion of quetiapine fumarate for diffusion through nasal route. Pundarikakshudu, K; Sheth, N; Trivedi, J; Upadhyay, P, 2016)	0.43
" For this, both the formulations were checked and compared for their diffusion profile, as it is an essential property for bioavailability through nasal route."	( Comparative study between simple and optimized liposomal dispersion of quetiapine fumarate for diffusion through nasal route. Pundarikakshudu, K; Sheth, N; Trivedi, J; Upadhyay, P, 2016)	0.43
" The development of an in vitro-in vivo correlation (IVIVC) and the use of in vitro data to predict in vivo bioavailability parameters has been of great interest for the rational development and evaluation process for extended release dosage forms."	( Development of a level A in vitro-in vivo correlation for extended release dosage forms of quetiapine fumarate. Gonçalves de Lima, L; Rossi de Campos, D, 2016)	0.43
" Significantly higher brain/blood ratio and 2 folds higher nasal bioavailability in brain with QF-NP in comparison to drug solution following intranasal administration revealed preferential nose to brain transport bypassing blood-brain barrier and prolonged retention of QF at site of action suggesting superiority of chitosan as permeability enhancer."	( "Application of Box-Behnken design for optimization and development of quetiapine fumarate loaded chitosan nanoparticles for brain delivery via intranasal route* ". Khunt, D; Misra, M; Padh, H; Shah, B, 2016)	0.43
" The aim of this study was to develop QF based microemulsion (ME) with and without chitosan (CH) to investigate its potential use in improving the bioavailability and brain targeting efficiency following non-invasive intranasal administration."	( Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: Formulation, physicochemical and pharmacokinetic consideration. Khunt, D; Misra, M; Padh, H; Shah, B, 2016)	0.43
"Quetiapine fumarate (QF), an anti-schizophrenic drug, suffers from rapid elimination and poor bioavailability due to extensive first-pass effect."	( Bio-shielding In Situ Forming Gels (BSIFG) Loaded With Lipospheres for Depot Injection of Quetiapine Fumarate: In Vitro and In Vivo Evaluation. Abo Elela, MM; Basalious, EB; ElKasabgy, NA, 2017)	0.46
"Lymphatic route is one of the prominent routes for improving the poor bioavailability of the drugs which undergo extensive hepatic first pass metabolism."	( Solid Lipid Nanoparticles Approach for Lymphatic Targeting Through Intraduodenal Delivery of Quetiapine Fumarate. Gaur, PK; Kumar, SS; Puri, D; Shehkar, P; Yasir, M, 2018)	0.48
" It exhibited better bioavailability as compared to drug suspension."	( Solid Lipid Nanoparticles Approach for Lymphatic Targeting Through Intraduodenal Delivery of Quetiapine Fumarate. Gaur, PK; Kumar, SS; Puri, D; Shehkar, P; Yasir, M, 2018)	0.48
"This study was conducted in order to compare the bioavailability of two film-coated tablets containing 25 mg of quetiapine."	( A bioequivalence study of quetiapine 25 mg film-coated tablets in healthy Indonesian subjects . Harahap, Y; Lusthom, W; Prasaja, B; Sinandang, T; Yusvita, LY, 2018)	0.48
"Quetiapine fumarate, a 2nd generation anti-psychotic drug has oral bioavailability of 9% because of hepatic first pass metabolism."	( Quality by Design Approach for Development and Characterisation of Solid Lipid Nanoparticles of Quetiapine Fumarate. Agarwal, S; Garg, R; Harikumar, SL; Murthy, RSR, 2020)	0.56
"QF, an anti-psychotic drug, has an oral bioavailability of 9% due to hepatic first- pass metabolism necessitating the use of high doses."	( Quetiapine Fumarate Loaded Nanostructured Lipid Carrier for Enhancing Oral Bioavailability: Design, Development and Pharmacokinetic Assessment. Agarwal, S; Garg, R; HariKumar, SL; Negi, P; Upadhyay, N, 2021)	0.62
"The objective of the study was the enhancement of bioavailability of the NLC of QF by preferential lymphatic uptake."	( Quetiapine Fumarate Loaded Nanostructured Lipid Carrier for Enhancing Oral Bioavailability: Design, Development and Pharmacokinetic Assessment. Agarwal, S; Garg, R; HariKumar, SL; Negi, P; Upadhyay, N, 2021)	0.62
"The results validated DoE as an appropriate tool for developing QF loaded NLC and proved NLC to be a promising delivery system for the enhancement of oral bioavailability of QF."	( Quetiapine Fumarate Loaded Nanostructured Lipid Carrier for Enhancing Oral Bioavailability: Design, Development and Pharmacokinetic Assessment. Agarwal, S; Garg, R; HariKumar, SL; Negi, P; Upadhyay, N, 2021)	0.62
"Quetiapine (QTP) is a first-line antipsychotic drug, but its therapeutic druggability and patient adherence were limited due to high oral dose strength, low bioavailability and physicochemical/biopharmaceutical issues."	( Roles of Fatty Acid Chain Length and Enzyme-Oriented Drug Controlled Release from pH-Triggering Self-Assembled Fatty Acid Conjugated Quetiapine Nanosuspensions. Gil, MC; Lee, BJ; Ngo, HV; Nguyen, HD; Nguyen, VH, 2023)	0.91

Excerpt	Relevance	Reference
" In the present study, 12 patients suffering from schizophrenia or schizophreniform disorder with predominantly positive symptomatology were treated in an open clinical trial for 4 weeks with seroquel at a maximum dosage of 750 mg/day."	( Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Benkert, O; Hain, C; Schlegel, S; Szegedi, A; Wetzel, H; Wiesner, J, 1995)	0.29
" Seroquel's restoration of PPI in apomorphine-treated rats follows simple monotonic ascending dose-response properties, and is not accompanied by consistent changes in startle reflex amplitude."	( Seroquel (ICI 204,636) restores prepulse inhibition of acoustic startle in apomorphine-treated rats: Similarities to clozapine. Swerdlow, NR; Taaid, N; Zisook, D, 1994)	0.29
" However, risperidone induced a U-shaped dose-response curve."	( Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Skarsfeldt, T, 1995)	0.29
"Five fixed doses of the atypical antipsychotic "Seroquel" (quetiapine) were evaluated to delineate a dose-response relationship, as measured by changes from baseline in Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), and Modified Scale for the Assessment of Negative Symptoms (SANS) summary scores, and to compare efficacy and tolerability opposite placebo and haloperidol."	( Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Arvanitis, LA; Miller, BG, 1997)	0.3
" However, since dopamine D2 receptor occupancies correlate poorly with plasma concentrations of antipsychotics, plasma elimination half-life may not predict either duration of clinical effect or dosing frequency."	( A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. King, DJ; Kowalcyk, B; Link, CG, 1998)	0.3
" Quetiapine interacts with phenytoin, carbamazepine, barbiturates, rifampin and glucocorticoids; and coadministration with these drugs may require dosage adjustment."	( Quetiapine: a new atypical antipsychotic. Erpenbach, JE; Fuller, WC; Hamlyn, H; Misra, LK, 1998)	0.3
" A steady-state treatment condition was ensured by dosing the patients with 750 mg quetiapine daily during 3 weeks followed by a period of tapering off the dose."	( N-[11C]methylspiperone PET, in contrast to [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic. Bergström, M; Gefvert, O; Hagberg, G; Långström, B; Lindström, L; Wiesel, FA; Wieselgren, IM, 1998)	0.3
" Dosing requirements for elderly patients tend to be much lower than those for younger adults."	( Conventional vs. newer antipsychotics in elderly patients. Harris, MJ; Jeste, DV; Lacro, J; Lohr, JB; Rockwell, E, 1999)	0.3
" The atypical properties of first-line atypical antipsychotics as well as clozapine are reviewed here, with clinical pearls and dosing tips for each based upon a consensus of information from both clinical trials and clinical practice."	( Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. Stahl, SM, 1999)	0.3
" Published studies have drawn criticism in terms of inappropriate titration schedules, nonequivalent dosing between treatment groups, short treatment duration, and inadequate sample sizes."	( Clozapine: a comparison with other novel antipsychotics. Fleischhacker, WW, 1999)	0.3
" The effective dosage range is usually 300-450 mg/day split into two doses."	( Focus on quetiapine. Green, B, 1999)	0.3
" Surprisingly, there has been little relationship between the pivotal trials designed for FDA approval and current dosing strategies in broader clinical settings."	( New antipsychotic medications: more than old wine and new bottles. Schulz, SC, 2000)	0.31
"Quetiapine shows a transiently high D2 occupancy, which decreases to very low levels by the end of the dosing interval."	( A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Jones, C; Kapur, S; Remington, G; Seeman, P; Shammi, CS; Zipursky, R, 2000)	0.31
" The results indicate that dosage adjustment of quetiapine may be unnecessary in psychotic patients with decreased renal function."	( Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Thyrum, PT; Wong, YW; Yeh, C, 2000)	0.31
" We also provide evidence of deficient NT neurotransmission as well as a left-shifted antipsychotic drug dose-response curve in isolation-reared rats."	( Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. Binder, EB; Kilts, CD; Kinkead, B; Nemeroff, CB; Owens, MJ, 2001)	0.31
" These results indicate that dosage adjustment of quetiapine may be necessary when the two drugs are given concurrently and that caution may be required when administering other drugs that inhibit or induce cytochromes, particularly P450 3A4."	( The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. Thyrum, PT; Wong, YW; Yeh, C, 2001)	0.31
" Quetiapine has a wide clinical dosing range (150-750 mg/day), although doses of 400 mg or above should be used in patients who do not fully respond to lower doses of the drug."	( Review of quetiapine and its clinical applications in schizophrenia. Kasper, S; Müller-Spahn, F, 2000)	0.31
" Quetiapine dosage adjustment, therefore, may be necessary when coadministered with phenytoin, thioridazine or other potent CYP3A4 inducers or inhibitors."	( Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. DeVane, CL; Nemeroff, CB, 2001)	0.31
" Risk factors are a high dosage of antipsychotics, akathisia in a previous treatment, and diabetes mellitus."	( [Drug-induced akathisia]. van Harten, PN, 2002)	0.31
"A 27-year-old white woman was observed to have a seizure while receiving a stable dosage of olanzapine 15 mg/d, with the addition of quetiapine 100 mg in the evening 1 day before the occurrence of the seizure."	( New-onset seizure associated with quetiapine and olanzapine. Hedges, DW; Jeppson, KG, 2002)	0.31
" Key assessments included the pharmacokinetics of quetiapine at steady state (area under the curve within a dosing interval [AUCtSS], maximum [CmaxSS], and minimum [CminSS] observed plasma concentrations, and oral clearance [Cl/f]), as well as the UKU Side Effect Rating Scale scores and safety evaluations."	( The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. Alva, G; Arvanitis, LA; Bera, R; Potkin, SG; Thyrum, PT; Yeh, C, 2002)	0.31
" Fluoxetine increased the quetiapine area under the plasma concentration time curve during a 12-hour interval (+12%), maximum plasma concentration during the dosing interval (C(ss)(max); +26%), and minimum plasma concentration at the end of the dosing interval (+8%), although it decreased oral clearance (-11%)."	( Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. Alva, G; Arvanitis, LA; Carreon, D; Kalali, A; Potkin, SG; Thyrum, PT; Yeh, C, 2002)	0.31
" Quetiapine dosage was adjusted according to therapeutic effects."	( Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. Beauclair, L; Bélanger, MC; Chouinard, G; Margolese, HC, 2002)	0.31
" He was started on paroxetine, with increases in dosage and no significant improvement."	( Quetiapine therapy for posttraumatic stress disorder. Bhatia, SC; Grant, K; Petty, F; Sattar, SP; Ucci, B, 2002)	0.31
" Although not affected by smoking, alterations in quetiapine disposition due to age or hepatic impairment are manageable by appropriate dosage reduction."	( Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. Goldstein, J; Kinkead, B; Nemeroff, CB, 2002)	0.31
"Utilizing a double-blind design, 21 hospitalized adult men or women with DSM-IV schizophrenia or schizoaffective disorder, who had received unchanged doses (for 2 weeks) of either 400 or 600 mg daily of quetiapine administered in 2 doses, were randomly assigned to once- or twice-daily administration for 4 weeks and then crossed over to the opposite dosing regimen for an additional 4 weeks."	( A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study. Brar, JS; Chengappa, KN; Goldstein, JM; Mullen, J; Parepally, H; Shilling, A, 2003)	0.32
"These pilot data suggest that it is clinically feasible to switch most quetiapine-treated subjects receiving a therapeutic twice-daily dosing schedule to a once-daily regimen."	( A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study. Brar, JS; Chengappa, KN; Goldstein, JM; Mullen, J; Parepally, H; Shilling, A, 2003)	0.32
" Subjects had completed a pharmacokinetic study over 23 days, during which the dosage of quetiapine was increased sequentially from 25 mg bid to a maximum of 400 mg bid (800 mg/day) (McConville et al."	( Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. Browne, K; Carrero, L; Chaney, R; Foster, K; Friedman, L; McConville, B; Potter, L; Sorter, M; Sweitzer, D, 2003)	0.32
" However, no correlation between prolactin levels and dosage could be found."	( [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics]. Fric, M; Laux, G, 2003)	0.32
" Typical dosage was 600 to 800 mg per day."	( Treating impulsivity, irritability, and aggression of antisocial personality disorder with quetiapine. Allen, TS; Thomas, J; Walker, C, 2003)	0.32
"Twelve patients with DSM-IV delirium were treated with flexible doses of open-label quetiapine (mean +/- SD dosage = 44."	( A prospective, open-label, flexible-dose study of quetiapine in the treatment of delirium. Denda, K; Inoue, S; Inoue, T; Koyama, T; Matsuyama, T; Sasaki, Y; Sunami, T, 2003)	0.32
" Unfortunately, this type of drugs cannot block the D2 receptors only in the mesolimbic dopaminergic pathway (which mediates their therapeutic effects), because of their non-selective D2 receptor blockage in both the mesolimbic and striatal regions, and the consequent appearance of side effects related to striatal interaction in the same dosage range as is needed for the therapeutical effects."	( New antipsychotics and schizophrenia: a review on efficacy and side effects. Berardi, D; De Ronchi, D; Lorenzi, C; Serretti, A, 2004)	0.32
" The clinical dosage regime caused no drug accumulation."	( Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. Cheng, ZN; Li, HD; Li, KY; Li, X; Peng, WX; Zhang, BK, 2004)	0.32
" Patients receiving a stable dosage of an SSRI for at least 6 weeks who also had persistent anxiety symptoms (Hamilton Anxiety scale [HAM-A] > or =16), were enrolled in a 9-week, open-label, variable dose study."	( Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Adson, DE; Eiben, KM; Kushner, MG; Schulz, SC, 2004)	0.32
") Furthermore, while current prescribing information recommends that quetiapine be administered at doses up to 750 mg/day (800 mg/day in the USA and Canada), there is growing evidence that dosing up to 1600 mg/day of quetiapine has been well tolerated in some patients."	( Managing acute exacerbations of schizophrenia: focus on quetiapine. Arango, C; Bobes, J, 2004)	0.32
" A mean therapeutic dosage for Seroquel was 316."	( [Influence of long-term quetiapine (Seroquel) and haloperidol therapy on cognitive deficit in patients with paranoid schizophrenia]. Kabanov, SO; Mosolov, SN, 2004)	0.32
" However, should future studies be performed, it seems reasonable that they be conducted with more rigor, less treatment-resistant cohorts, and, possibly, a different dosing strategy."	( Quetiapine in nine youths with autistic disorder. Blumer, JL; Demeter, C; Findling, RL; Gracious, BL; McNamara, NK; O'Riordan, MA; Reed, MD, 2004)	0.32
" However, the results suggest that quetiapine, when given within the recommended dosage range, has a benign EPS profile, with potentially greater tolerability and comparable efficacy to risperidone in older outpatients with psychotic disorders."	( A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone. Mintzer, JE; Mullen, JA; Sweitzer, DE, 2004)	0.32
"7 years; range, 5-28 years) received a quetiapine trial (mean +/- SD dosage = 248."	( A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. Barkenbus, JE; Corson, AH; McDougle, CJ; Posey, DJ; Stigler, KA, 2004)	0.32
"A significant positive correlation of the serum concentration and the daily dosage was found."	( [Determining serum concentrations of the modern antipsychotic quetiapin: clinical relevance in therapeutic drug monitoring]. Köhnlein, O; Lutz, R; Messer, T; Schmauss, M, 2004)	0.32
"While a correlation of dosage and effect could be shown with Quetiapin, inter- and intraindividual differences could be observed."	( [Determining serum concentrations of the modern antipsychotic quetiapin: clinical relevance in therapeutic drug monitoring]. Köhnlein, O; Lutz, R; Messer, T; Schmauss, M, 2004)	0.32
" When quetiapine is co-administered with CYP3A inhibitors such as erythromycin, the dosing regimen should be modified according to quetiapine TDM."	( Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia. Cheng, ZN; Li, HD; Li, KY; Li, X; Peng, WX; Zhang, BK, 2005)	0.33
"In an international, multicenter, double-blind, parallel-group, 12-week study, patients with a DSM-IV diagnosis of bipolar I disorder (manic episode) were randomly assigned to treatment with quetiapine (flexibly dosed up to 800 mg/day), placebo, or lithium."	( A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. Bowden, CL; Brecher, M; Grunze, H; Jones, M; Mullen, J; Paulsson, B; Svensson, K; Vågerö, M, 2005)	0.33
" Mice were acclimated to individual housing, given ad libitum access to chow and water, dosed with placebo peanut butter pills for 1 week, and then dosed daily with AAPD-laced peanut butter pills for 4 weeks."	( Antipsychotic drug-induced weight gain: development of an animal model. Allison, DB; Casey, DE; Cope, MB; Fernández, JR; Geary, N; Nagy, TR, 2005)	0.33
" CYP3A4 is the primary enzyme responsible for CYP-mediated metabolism of QTP in clinical therapy dosage in vivo."	( Metabolic mechanism of quetiapine in vivo with clinical therapeutic dose. Cheng, ZN; Li, HD; Li, KY; Li, X, 2005)	0.33
" Dosage alterations of olanzapine and clozapine, dependent on cytochrome P450 1A2 (CYP1A2) for clearance, and quetiapine, dependent on cytochrome P450 3A (CYP3A), may be necessary when used with other drugs that inhibit or induce their metabolic enzymes."	( The dosing of atypical antipsychotics. Armstrong, SC; Cozza, KL; de Leon, J, )	0.13
" Clinicians were instructed to target dosing at 500 mg/day of quetiapine or 200 mg of haloperidol decanoate every 4 weeks."	( Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. Glick, ID; Marder, SR, 2005)	0.33
" Among the classes of medications that are H1 antagonists we point out that atypical antipsychotic medications such as olanzapine and quetiapine are among the most potent H1 antagonists, and can have simple daily dosing schedules and thus may be particularly useful in ACD."	( Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Altschuler, EL; Kast, RE, 2005)	0.33
"The original dosing recommendations for quetiapine in the treatment of schizophrenia suggested escalation to 400 mg/d using the following schedule, administered twice daily in divided doses: Day 1, 50 mg; Day 2, 100 mg; Day 3, 200 mg; Day 4, 300 mg; Day 5, 400 mg."	( Rapid dose escalation with quetiapine: a pilot study. Brecher, M; Hamer-Maansson, J; McCoy, R; Smith, MA, 2005)	0.33
" Olanzapine might be useful for delusion of PD in patients not responded to quetiapine, although it should be started at a very low dosage to ameliorate worsening parkinsonism."	( [The efficacy of olanzapine for delusion in patients with Parkinson's disease]. Atsuta, N; Hirayama, M; Ito, M; Sobue, G; Watanabe, H, 2005)	0.33
"Patients (n=302) with bipolar I disorder (manic episode) were randomised to 12 weeks' double-blind treatment with quetiapine (flexibly dosed up to 800 mg/day), placebo, or haloperidol (up to 8 mg/day)."	( Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Brecher, M; Huizar, K; McIntyre, RS; Mullen, J; Paulsson, B, 2005)	0.33
" Patients were initiated with quetiapine to 400 mg/day over 7 days, and then flexibly dosed (300-750 mg/day) for 11 weeks."	( Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. Altman, C; de Nayer, A; Jones, AM; Larmo, I; Lindenbauer, B; Platz, T; Rittmannsberger, H; Windhager, E, 2005)	0.33
" Forty patients with delirium were randomly assigned to either AMSP or QTP groups, with a flexible dosing schedule."	( Amisulpride versus quetiapine for the treatment of delirium: a randomized, open prospective study. Bahk, WM; Kweon, YS; Lee, CT; Lee, HK; Lee, KU; Pae, CU; Won, WY, 2005)	0.33
" To our knowledge, this represents the second published report associating quetiapine with priapism, and the first to associate priapism with routine dosing of the drug."	( Priapism associated with routine use of quetiapine: case report and review of the literature. Davol, P; Rukstalis, D, 2005)	0.33
" Based on the results of this study, it appears that quetiapine is an efficacious and safe treatment for geriatric inpatients with psychosis, however, there is a wide dosing range and optimal dosage is diagnosis-dependent."	( The efficacy and safety of quetiapine for treatment of geriatric psychosis. Hwang, JP; Tsai, SJ; Yang, CH, 2005)	0.33
" The purpose of this article is to review the past and present dosing patterns of quetiapine for the treatment of schizophrenia."	( Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. Citrome, L; Jaffe, A; Levine, J; Lindenmayer, JP, 2005)	0.33
" Trends in dosing of quetiapine in a large, state-operated psychiatric hospital system and the anecdotal evidence describing the use of quetiapine in excess of 800 mg/day were also reviewed."	( Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. Citrome, L; Jaffe, A; Levine, J; Lindenmayer, JP, 2005)	0.33
" The symptoms reduced remarkably when fluoxetine was added to her treatment regimen while keeping the quetiapine dosage unchanged."	( Obsessive compulsive symptoms associated with quetiapine treatment in a schizophrenic patient: a case report. Arsava, M; Demir, B; Ertuğrul, A; Ozer, S, 2006)	0.33
" TDM and pharmacogenetic tests are useful tools to improve pharmacotherapy by preventing dose-dependent adverse drug events, optimizing dosage during long-term treatment and identifying ultrarapid metabolizers and malcompliance."	( [Therapeutic drug monitoring: A pharmacotherapeutic tool in psychiatry]. Etzensberger, M; Jaquenoud Sirot, E; Stephan, PL, 2006)	0.33
" Atypical antipsychotics are an alternative treatment, and this 12-week, randomised, flexibly dosed study compared the efficacy, safety and tolerability of quetiapine and olanzapine in this regard."	( Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Koren, A; Pannet, I; Sirota, P; Tchernichovsky, E, 2006)	0.33
" The PK of quetiapine supports twice-daily dosing in children with CD."	( Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. Demeter, CA; Findling, RL; McNamara, NK; O'Riordan, MA; Reed, MD; Stansbrey, RJ, 2006)	0.33
"Quetiapine demonstrated some efficacy as a sedative agent in the emergency setting, although no clear dose-response pattern emerged over the narrow dose range tested."	( A pilot, open-label safety study of quetiapine for treatment of moderate psychotic agitation in the emergency setting. Currier, GW; Trenton, AJ; van Wijngaarden, E; Walsh, PG, 2006)	0.33
" Adverse effects were evaluated using the Dosage Record and Treatment Emergent Symptom Scale."	( Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. Bellino, S; Bogetto, F; Paradiso, E, 2006)	0.33
" Quetiapine, flexibly dosed (25-100 mg/day), was added to their original treatment regimen for 12 weeks."	( An open-label study of quetiapine in the treatment of fibromyalgia. Calandre, EP; Hidalgo, J; Rico-Villademoros, F, 2007)	0.34
"The authors conducted a multicenter, double-blind, placebo-controlled, randomized trial of flexibly dosed quetiapine and haloperidol."	( Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Copenhaver, M; Katz, IR; Mintzer, JE; Schneider, L; Street, J; Tariot, PN; Williams-Hughes, C, 2006)	0.33
" We added quetiapine to patients' medication and attempted to increase the dosage to at least 400 mg daily."	( Add-on quetiapine for bipolar depression: a 12-month open-label trial. Abraham, G; Milev, R; Zaheer, J, 2006)	0.33
"29 BPD outpatients entered, and 23 completed, a 12 week, open-label, regime of quetiapine at an average daily dosage of 540 mg (range: 400-800 mg)."	( Quetiapine for the treatment of borderline personality disorder; an open-label study. Carrus, D; Costa, E; Perrella, C; Schifano, F, 2007)	0.34
", dosage adjustments, behavioral or psychosocial interventions) before switching medications."	( Effectiveness of switching antipsychotic medications. Covell, NH; Davis, SM; Essock, SM; Lieberman, JA; Rosenheck, RA; Stroup, TS, 2006)	0.33
" Patients were randomised to either lithium or quetiapine in addition to the maximally dosed antidepressant and any other concurrent medications."	( Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Des Rosiers, J; Dorée, JP; Elie, R; Gendron, A; Lew, V; Stip, E; Tourjman, SV, 2007)	0.34
" The aim of the present study was to evaluate the effectiveness, tolerability and clinical reasons associated to the use of high dosage of quetiapine (>800 mg), when used under routine clinical conditions, in a sample of bipolar disorder and schizoaffective bipolar inpatients."	( Quetiapine dosage in bipolar disorder episodes and mixed states. Chatton, A; Khazaal, Y; Preisig, M; Rothen, S; Tapparel, S; Zullino, D, 2007)	0.34
"5 microg/mL) (Li/DVP) (for 3-6 weeks) in four double-blind, placebo-controlled studies according to a predetermined dosing schedule."	( Quetiapine in the treatment of acute mania: target dose for efficacious treatment. Goldberg, JF; Mullen, J; Paulsson, B; Vågerö, M; Vieta, E, 2007)	0.34
" Dose escalation was rapid, with 92% of patients treated with monotherapy and 80% of patients treated with combination therapy reaching doses of 400 mg/day by Day 4, in accordance with protocol-defined dosing guidance."	( Quetiapine in the treatment of acute mania: target dose for efficacious treatment. Goldberg, JF; Mullen, J; Paulsson, B; Vågerö, M; Vieta, E, 2007)	0.34
"Thirty-eight outpatients on long-term treatment with clozapine (250-500 mg/d, n = 10), olanzapine (10-20 mg/d, n = 12), risperidone (3-6 mg/d, n = 9), or quetiapine (200-600 mg/d, n = 7) received adjunctive topiramate, gradually titrated up to a final dosage of 200 mg/d for 6 weeks."	( Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. Bruno, A; Cacciola, M; Campolo, D; Cortese, L; D'Arrigo, C; Migliardi, G; Santoro, V; Spina, E, )	0.13
" An unexpectedly large placebo effect, inadequate dosage (mean 120 mg/day), and inadequate power may have contributed to lack of demonstrable benefit."	( Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Cummings, J; Kurlan, R; Raman, R; Thal, L, 2007)	0.34
" Inpatients (n = 269) diagnosed with schizophrenia or schizoaffective disorder received rapid (n = 139) or conventional (n = 130) initiation of quetiapine, followed by flexible dosing (maximum 800 mg/day)."	( Rapid dose initiation of quetiapine for the treatment of acute schizophrenia and schizoaffective disorder: a randomised, multicentre, parallel-group, open study. Boidi, G; Ferro, M, 2007)	0.34
"Steady-state plasma concentrations of (R)- (ie, the active form), (S)-, and (R,S)-methadone were measured in 14 addict patients in methadone maintenance treatment, before and after introduction of quetiapine, administered at a mean dosage of 138 mg/d (SD, 87 mg/d; median, 125 mg/d; range, 50-300 mg/d) during a mean period of 30 days (SD, 8 days; median, 30 days; range, 20-48 days)."	( Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. Brawand-Amey, M; Brocard, M; Chassot, P; Crettol, S; Eap, CB; Koeb, L; Uehlinger, C, 2007)	0.34
"An open-label, nonrandomized trial was conducted in 41 patients with rapid-cycling bipolar disorder (type I=33, type II=7, NOS=1) who received flexibly dosed quetiapine monotherapy (n=19) or add-on therapy (n=22) for up to one year."	( Effectiveness of quetiapine in rapid cycling bipolar disorder: a preliminary study. Filkowski, MM; Goldberg, JF; Hsu, DJ; Kelley, ME; Nassir Ghaemi, S; Rosenquist, KJ, 2008)	0.35
" Quetiapine and valproic acid plasma concentration-time data over a 12-h steady-state dosing interval were used to determine C(max), T(max), C(min), area under the plasma concentration-time curve (AUC(tau)), and oral clearance (CL/F)."	( Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Davis, PC; DeVane, CL; Ennis, DJ; Figueroa, C; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2007)	0.34
"The trial was a prospective, open-label, single-center one with a flexible dosing of SGAs."	( Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Cejpková, A; Rodáková, I; Svestka, J; Synek, O; Tomanová, J, 2007)	0.34
" A 'high-dose' theory of quetiapine activity has developed, leading many prescribers to disregard the formal upper limit of the quetiapine dosage range (750 or 800 mg/day, depending on local labelling)."	( Quetiapine: dose-response relationship in schizophrenia. Jones, S; Sparshatt, A; Taylor, D, 2008)	0.35
" Phase 1 consisted of 10 weeks of open-label paroxetine CR flexibly dosed to a maximum of 62."	( Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Connor, KM; Davidson, JR; Hoge, EA; LeBeau, RT; Pollack, MH; Simon, NM; Worthington, JJ; Zhang, W, 2008)	0.35
" The predictability in quetiapine concentration profiles for children aged 10 years to adults suggests that no dosage adjustment may be required when treating patients of these ages."	( Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. Davis, PC; Earley, WR; Hamer-Maansson, JE; Smith, MA; Winter, HR, 2008)	0.35
" For patients receiving standing dose regimens, diagnosis, total daily dose, and dosing adequacy were ascertained."	( Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Carpenter, LL; Mello, K; Philip, NS; Price, LH; Tyrka, AR, )	0.13
" Patients receiving prn dosing had a similar distribution of diagnoses."	( Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Carpenter, LL; Mello, K; Philip, NS; Price, LH; Tyrka, AR, )	0.13
" An extended-release (XR) formulation of quetiapine is currently being developed to achieve similar efficacy using a once-daily dosing regimen."	( Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. Barsoum, P; Gendron, A; Goldstein, J; Kapur, S; Mamo, DC; Uchida, H; Vitcu, I, 2008)	0.35
"Once-daily dosing of the XR formulation gives peak and trough plasma levels and central D(2) receptor occupancy comparable to twice-daily dosing of the IR formulation."	( Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. Barsoum, P; Gendron, A; Goldstein, J; Kapur, S; Mamo, DC; Uchida, H; Vitcu, I, 2008)	0.35
" Quetiapine XR has been developed to reduce the frequency of quetiapine dosing by introducing once-daily administration and to simplify the treatment initiation schedule."	( [Administration of once-daily extended release quetiapine in schizophrenic disorders]. Bartkó, G, 2007)	0.34
" Quetiapine was flexibly dosed starting at 25 mg to a maximum of 100 mg daily."	( A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Fava, M; Garakani, A; Hirschowitz, J; Marcus, S; Martinez, JM; Rickels, K; Weaver, J, 2008)	0.35
" Treatment was at the psychiatrist's discretion, including flexible dosing and use of concomitant therapies and medications, with assessments at 0, 3, 6, 12, 18, 24, 30, and 36 months."	( Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. Anders, M; Dossenbach, M; Irimia, V; Kotler, M; Logozar-Perkovic, D; Lowry, AJ; Pecenak, J; Peciukaitiene, D; Smulevich, AB; Szulc, A; Treuer, T; West, TM, 2008)	0.35
"Quetiapine was assessed in patients diagnosed with borderline personality disorder (BPD) to examine its potential effect on symptoms and explore a tolerated dosing pattern."	( Quetiapine in patients with borderline personality disorder: an open-label trial. Brown, E; Lee, S; Romine, A; Schulz, SC; Thuras, P, )	0.13
" The dosing strategy in the study was well tolerated."	( Quetiapine in patients with borderline personality disorder: an open-label trial. Brown, E; Lee, S; Romine, A; Schulz, SC; Thuras, P, )	0.13
" In contrast to multiepisode patients, dosing should be more conservative in untreated new-onset cases."	( Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years. Amminger, PG; Berger, GE; Kerr, M; Lubman, D; Markulev, C; McConchie, M; McGorry, PD; O'Donnell, C; Polari, A; Proffitt, TM; Wood, S; Yuen, HP, 2008)	0.35
" Logistic regressions were carried-out to assess links between quetiapine discharge dosage (> or =800 mg/day vs."	( Quetiapine dosage across diagnostic categories. Chatton, A; Khan, R; Khazaal, Y; Zullino, D, 2009)	0.35
"Quetiapine seems to be used in a variety of clinical situations, with a wide range of doses and a lower dosage in patients treated for personality disorders."	( Quetiapine dosage across diagnostic categories. Chatton, A; Khan, R; Khazaal, Y; Zullino, D, 2009)	0.35
" Patient characteristics, prescribing provider characteristics, length of therapy, and dosing were examined."	( Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. Hamer, AM; Hartung, DM; Haxby, DG; McFarland, BH; Middleton, L; Pollack, DA; Wisdom, JP, 2008)	0.35
"Among 830 individuals in our sample who began treatment with an atypical antipsychotic, only 15% had a documented diagnosis of schizophrenia, subtherapeutic dosing was common (up to 86% of patients taking quetiapine), and 40% continued less than 30 days with the index prescription."	( Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. Hamer, AM; Hartung, DM; Haxby, DG; McFarland, BH; Middleton, L; Pollack, DA; Wisdom, JP, 2008)	0.35
" Articles providing support for appropriate dosing of quetiapine were distributed to physicians, and peer discussions about prescribing practices were held."	( Best practices: an intervention to promote evidence-based prescribing at a large psychiatric hospital. Fabian, TJ; Ghinassi, FA; Haskett, RF; Nash, KC; Stowell, KR, 2009)	0.35
" Unique characteristics in this case included length of therapy without dosage change or titration and no known history of drug-related EPS."	( Neuroleptic malignant syndrome secondary to quetiapine. Fagan, A; Gortney, JS; Kissack, JC, 2009)	0.35
" Clinicians should be aware that NMS with EPS can occur with quetiapine at steady state doses without recent dosage adjustments or titration."	( Neuroleptic malignant syndrome secondary to quetiapine. Fagan, A; Gortney, JS; Kissack, JC, 2009)	0.35
" The primary end point was the level of sedation 1 hour after dosing on day 1, as rated by subjects using a visual analog scale (VAS) ranging from 0 = alert to 100 = drowsy."	( Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Berggren, L; Datto, C; Eriksson, H; Patel, JB, 2009)	0.35
" One hour after dosing on day 1, sedation was significantly greater with quetiapine IR than with quetiapine XR (mean VAS score, 33."	( Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Berggren, L; Datto, C; Eriksson, H; Patel, JB, 2009)	0.35
"Although clozapine has been shown to be the treatment of choice in people with schizophrenia that are resistant to treatment, one third to two thirds of people still have persistent positive symptoms despite clozapine monotherapy of adequate dosage and duration."	( Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Barbui, C; Boso, M; Cipriani, A, 2009)	0.35
"The purpose of this article is to review the utilization and dosing of ziprasidone in a state hospital system and to compare the dosing to dosing recommendations contained in product labeling that suggest a starting dose of 40 mg/day and a target dose range of 40 to 160 mg/day for schizophrenia."	( How dosing of ziprasidone in a state hospital system differs from product labeling. Citrome, L; Jaffe, A; Levine, J, 2009)	0.35
" If the patient is currently taking other mood stabilizers, their dosage should be optimized, and the clinician should consider adding or switching to lithium, quetiapine, or lamotrigine."	( The psychopharmacology algorithm project at the Harvard South Shore Program: an update on bipolar depression. Ansari, A; Osser, DN, )	0.13
"Extended release quetiapine fumarate (quetiapine XR) is a new formulation that allows once-daily dosing and a titration regimen that is simpler than that of immediate release quetiapine (quetiapine IR) and may potentially increase patients' adherence to their prescribed medication."	( Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies. Brecher, M; Huizar, K; Meulien, D, 2010)	0.36
" Additional information about gender, age, co-medication and dosage was obtained."	( Individual clearance and therapeutic drug monitoring of quetiapine in clinical practice. Haen, E; Hajak, G; Hausner, H; Köstlbacher, A; Wittmann, M, 2010)	0.36
" Further investigations are warranted to identify patient characteristics and antipsychotic dosage regimens that are not associated with a greater risk of mortality in elderly patients with dementia."	( Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? Dysken, MW; Lederle, FA; Rector, TS; Rossom, RC, 2010)	0.36
" Patients [n = 493; Young Mania Rating Scale (YMRS) score >or= 20] were randomized (2:2:1) to flexibly dosed paliperidone ER (3-12 mg/day), quetiapine (400-800 mg/day), or placebo for the acute treatment phase."	( A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Berwaerts, J; Hough, DW; Lim, P; Nuamah, IF; Palumbo, JM; Vieta, E; Yuen, EC, 2010)	0.36
" Patients treated with lithium or divalproex (ongoing or assigned at screening) were randomized to receive quetiapine (dosed up to 400 mg/d over 7 days, followed by 300 to 800 mg/d flexible dosing until study end) or placebo."	( A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. Brown, ES; Calabrese, JR; Kotz, M; Pettinati, HM; Raines, S; Stedman, M, 2010)	0.36
"We recommend a quick reduction of the quetiapine dosage and a change to an alternative antipsychotic for patients treated with quetiapine, who report such respiratory symptoms without a somatic cause for the symptoms."	( Quetiapine-induced hyperventilation and dyspnea. Grosshans, M; Mutschler, J; Obermann, C, 2010)	0.36
" Medication was administered by a specialized clinical team following dosing guidelines."	( Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. Craig, TK; Elanjithara, T; Gafoor, R; Landau, S; McGuire, P; Power, P, 2010)	0.36
"We report on 6 cases with partial response of psychotic positive symptoms to QTP despite sufficient dosage (mean, 783 mg/d) and serum levels (mean, 405 μg/L)."	( Quetiapine combined with amisulpride in schizophrenic patients with insufficient responses to quetiapine monotherapy. Englisch, S; Enning, F; Grosshans, M; Marquardt, L; Waltereit, R; Zink, M, )	0.13
" Then, the medication was shifted to quetiapine at a dosage of 25 mg/d."	( Effectiveness of quetiapine for poststroke pathological laughing: case report and review of the literature. Chen, YR; Huang, YP; Kuan, TH; Lin, CH; Lin, SJ, )	0.13
"025 mg/kg of risperidone daily for 4 months, then the dosage was doubled for another 4 months."	( Post-drug consequences of chronic atypical antipsychotic drug administration on the ability to adjust behavior based on feedback in young monkeys. Mandell, DJ; Sackett, GP; Unis, A, 2011)	0.37
"The dose-response relationship for (immediate-release) quetiapine is established."	( Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. Kapur, S; Patel, MX; Sparshatt, A; Taylor, D, 2011)	0.37
" In order to be eligible for randomization, subjects were required to prospectively fail to demonstrate an initial therapeutic response during a 4-week run-in phase with quetiapine at 600 mg/d (immediate release and dosed twice a day)."	( A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder. Citrome, L; Kaushik, S; Khan, A; Lindenmayer, JP, 2011)	0.37
" This study attempts to elucidate the dose-response and comparative efficacy and tolerability (metabolic data) of quetiapine across psychiatric disorders."	( Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Dubreucq, S; Moteshafi, H; Potvin, S; Rompré, PP; Stip, E; Zhornitsky, S, 2011)	0.37
"Quetiapine XR dosed up to 300 mg/day was generally well tolerated, with a similar profile to that of quetiapine IR."	( Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study. De Deyn, PP; Eriksson, H; Svensson, H, 2012)	0.38
"Patients with schizophrenia or schizoaffective disorder with a body mass index ≥ 27 and non-high-density lipoprotein (non-HDL) cholesterol ≥ 130 mg/dl who were on a stable treatment dosage of olanzapine, quetiapine, or risperidone were randomly assigned to switch to ari-piprazole (N=109) for 24 weeks or stay on their current medication (N=106)."	( A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Hamer, RH; LaVange, LM; Lieberman, JA; McEvoy, JP; Nussbaum, AM; Perkins, DO; Ring, KD; Rosenheck, RA; Stroup, TS; Swartz, MS, 2011)	0.37
" The numbers needed to treat to achieve an additional response over antidepressant plus placebo were 11-18 and 8-9 in the quetiapine XR 150 and 300 mg/day dosage groups, respectively."	( Quetiapine extended release: adjunctive treatment in major depressive disorder. Sanford, M, 2011)	0.37
" Quetiapine treatment was initiated at an initial dosage of 300 mg/day."	( Report of a case of steroid-induced psychosis and inappropriate sexual behaviour in an adolescent. Demir, T; Dogangun, B; Karacetin, G; Kocabasoglu, N, 2012)	0.38
" Propensity-stratified and propensity-weighted models as well as analyses controlling for site of care and medication dosage revealed similar patterns."	( Risk of mortality among individual antipsychotics in patients with dementia. Blow, FC; Chiang, C; Cunningham, F; Kales, HC; Kim, HM; Schneider, LS; Seyfried, LS; Valenstein, M; Zivin, K, 2012)	0.38
" There was a dose-response relation for all drugs except quetiapine."	( Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. Avorn, J; Crystal, S; Gerhard, T; Huybrechts, KF; Levin, R; Lucas, JA; Olfson, M; Schneeweiss, S, 2012)	0.38
"Unmedicated individuals (n = 25) meeting DSM-IV criteria for BP-II disorder, currently depressed, were randomly assigned to weekly sessions of IPSRT (n = 14) or quetiapine (n = 11), flexibly dosed from 25-300 mg."	( A randomized pilot study of psychotherapy and quetiapine for the acute treatment of bipolar II depression. Cheng, Y; Frank, E; Swartz, HA, 2012)	0.38
" When used for sleep, doses typically seen are less than the Food and Drug Administration-recommended dosage of 150-800 mg/day; those evaluated in the studies reviewed here were 25-200 mg/day)."	( Safety of low doses of quetiapine when used for insomnia. Coe, HV; Hong, IS, 2012)	0.38
" There were no differences in treatment outcomes between quetiapine 300 mg/day and 600 mg/day dosage groups."	( Quetiapine: a review of its use in the management of bipolar depression. Keating, GM; Sanford, M, 2012)	0.38
" Fifty-one female FM patients were randomized, and a flexible dosage of 50 to 300 mg/d was used."	( Add-on treatment of quetiapine for fibromyalgia: a pilot, randomized, double-blind, placebo-controlled 12-week trial. Bissonnette, A; Cloutier, C; Gendron, A; Marchand, S; Morin, M; Potvin, S, 2012)	0.38
"Available literature points toward an early induction of hypomania or mania with low dosage of quetiapine treatment (between 100 and 400 mg/day never exceeding 600 mg/day)."	( Quetiapine induced hypomania: a case report and a review of the literature. Baddoura, C; Khalil, RB, 2012)	0.38
" No study addressed the issue of pre-existing/concurrent psychosocial interventions, and comorbid stimulant medication and its dosage was only partially addressed."	( Atypical antipsychotics for disruptive behaviour disorders in children and youths. Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K, 2012)	0.38
" A dosage ≥400 mg/day was defined as antipsychotic."	( A retrospective study of clinical usage of quetiapine XR and quetiapine IR in outpatients with schizophrenia in Denmark. Carlborg, A; Emborg, C; Hallerbäck, T; Jörgensen, L, 2012)	0.38
" Use in antipsychotic dosage was seen for 89% XR versus 63% IR patients (mean daily dose ≥400 mg/day; p < 0."	( A retrospective study of clinical usage of quetiapine XR and quetiapine IR in outpatients with schizophrenia in Denmark. Carlborg, A; Emborg, C; Hallerbäck, T; Jörgensen, L, 2012)	0.38
" Further study is needed with a larger sample size, randomized controlled design and control of the dosage prescribed."	( Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study. Chen, CK; Chen, YC; Wang, LJ, 2012)	0.38
"All trials were industry supported, with some variability in dosage of haloperidol."	( Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. Capapey, J; Colom, F; Goikolea, JM; Grande, I; Sanchez-Moreno, J; Torres, I; Undurraga, J; Valentí, M; Vieta, E, 2013)	0.39
" The results support and expand previous findings that lithium should be dosed high enough to achieve plasma levels ≥0."	( The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144) Nolen, WA; Weisler, RH, 2013)	0.39
"The use of quetiapine for treatment of bipolar disorders at a higher dosage than the licensed range is not unusual in clinical practice."	( Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. Bilancioni, R; Chatton, A; Eap, CB; Kaufmann, N; Khazaal, Y; Preisig, M, 2013)	0.39
"The aim of this study was to investigate the dosing patterns of adjunctive quetiapine or adjunctive aripiprazole in the treatment of major depressive disorder from 2006 to 2010, and to evaluate the impact of Food and Drug Administration (FDA) approval on these dosing patterns."	( Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010). Forbes, RA; Guo, Z; Hebden, T; Jing, Y; Kalsekar, I; Thase, ME, 2013)	0.39
"Participants, who were recently admitted inpatients with schizophrenia with an acute exacerbation of psychotic symptoms, were randomly assigned to 6 weeks of fixed-dose, double-blind treatment with lurasidone 80 mg (n=125), lurasidone 160 mg (n=121), quetiapine XR 600 mg (QXR-600 mg; n=119; active control included to test for assay sensitivity), or placebo (n=121), all dosed once daily in the evening."	( Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Cucchiaro, J; Hsu, C; Kalali, AH; Loebel, A; Pikalov, A; Potkin, SG; Sarma, K; Xu, L, 2013)	0.39
"To examine the effectiveness of switching patients to lurasidone using 3 different dosing strategies."	( Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. Citrome, L; Cucchiaro, J; Hernandez, D; Hsu, J; Loebel, A; McEvoy, JP; Pikalov, A, 2013)	0.39
"Adults with DSM-IV-defined schizophrenia or schizoaffective disorder in a nonacute phase of illness were randomized to 1 of 3 lurasidone dosing regimens for the initial 2 weeks of the study: (1) 40 mg/d for 2 weeks; (2) 40 mg/d for 1 week, increased to 80 mg/d on day 8 for week 2 (up-titration group); and (3) 80 mg/d for 2 weeks."	( Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. Citrome, L; Cucchiaro, J; Hernandez, D; Hsu, J; Loebel, A; McEvoy, JP; Pikalov, A, 2013)	0.39
" Once-daily dosing and simpler dose titration makes using quetiapine XR convenient for clinicians and patients."	( Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications. Bui, K; Earley, W; Nyberg, S, 2013)	0.39
" Elderly patients (≥66 years; DSM-IV MDD; Hamilton Rating Scale for Depression [HAM-D] total score ≥22, HAM-D Item 1 score ≥2) were randomized to quetiapine XR (flexible dosing 50-300 mg/day) or placebo."	( Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder. Datto, C; Endicott, J; Locklear, JC; Svedsäter, H, 2013)	0.39
" More data are needed to establish specific dosing regimens for off-label uses and to examine the dose relationship to metabolic side effects and extrapyramidal side effects to determine whether various off-label uses justify the risk incurred with using this powerful drug."	( Efficacy of quetiapine off-label uses: data synthesis. Carney, AC, 2013)	0.39
" One-third of children and adolescents had abnormal serum triglycerides and cholesterol; however, a dose-response was not demonstrated."	( Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics. Amminger, GP; Becker, J; O'Donoghue, B; Papageorgiou, K; Schäfer, MR, 2014)	0.4
" During the open-label study, quetiapine was flexibly dosed at 400-800 mg/day, with options to reduce dosing to 200 mg/day based on tolerability."	( Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study. DelBello, M; Earley, WR; Findling, RL; Liu, S; Pathak, S, 2013)	0.39
"In this 26-week study, quetiapine flexibly dosed at 400-800 mg/day, with options to reduce dosing based on tolerability, was generally safe and well tolerated in youth."	( Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study. DelBello, M; Earley, WR; Findling, RL; Liu, S; Pathak, S, 2013)	0.39
"Treatment patterns and dosing differ in patients with bipolar disorder treated with quetiapine XR compared with those treated with quetiapine IR."	( Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data. Alemayehu, B; Brody, RS; Chavoshi, S; Earley, WR; Kern, D; Locklear, JC; Tunceli, O, 2013)	0.39
"Patients who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) criteria for schizophrenia were randomized to 6 weeks of double-blind treatment with fixed doses of lurasidone 80 mg/d (n = 125), lurasidone 160 mg/d (n = 121), quetiapine XR 600 mg/d (n = 119), or placebo (n = 121), all dosed once daily in the evening, with food."	( Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. Cucchiaro, JB; Harvey, PD; Loebel, AD; Pikalov, AA; Siu, CO, 2014)	0.4
" Other important study considerations included limited exclusion criteria to maximize generalizability, flexible dosing of APT medications to mimic real-world treatment, and an intent-to-treat analysis plan."	( Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): a pragmatic trial of complex treatment for a complex disorder. Bobo, WV; Bowden, CL; Calabrese, JR; Deckersbach, T; Friedman, ES; Ketter, TA; Kocsis, JH; Leon, AC; McElroy, SL; McInnis, MG; Nierenberg, AA; Reilly-Harrington, NA; Schoenfeld, D; Shelton, RC; Shesler, LW; Singh, V; Sylvia, LG; Thase, ME; Tohen, M, 2014)	0.4
" The geometric mean elimination half-life (t ½) of both quetiapine and N-desalkyl quetiapine was consistent for the three dosing groups (approximately 7 h for quetiapine and approximately 18 h for N-desalkyl quetiapine)."	( Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. Chen, JX; Li, Q; Liu, Y; Si, TM; Su, YA; Tan, YL; Yang, FD, 2014)	0.4
" In this study, a case of schizophrenia in which manic symptoms developed after increasing the dosage of quetiapine to 300 mg/day, and subsequently disappeared after cessation of treatment is presented."	( [Mania associated with quetiapine treatment]. Cam, B; Gülseren, S, 2014)	0.4
" Assessment was performed with Hamilton Depression Rating Scale (also considering clusters "core," "somatic anxiety," "psychic anxiety," "activity," and "delusion"), Hamilton Anxiety Rating Scale, Dosage Record and Treatment Emergent Symptom Scale."	( Quetiapine extended release: preliminary evidence of a rapid onset of the antidepressant effect in bipolar depression. Balzarro, B; de Ronchi, D; Porcelli, S; Serretti, A, 2014)	0.4
" The results from the study can help inform dosing regimens in pediatrics using the quetiapine XR formulation."	( Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents. Bui, KH; Johnson, TN; Zhou, D, 2014)	0.4
" In addition, a voxel-wise analysis of correlations between the duration of treatment or dosage and volume was also performed."	( Brain differences in first-episode schizophrenia treated with quetiapine: a deformation-based morphometric study. Bai, Y; Gao, H; Lu, W; Wu, S; Yang, C, 2015)	0.42
" A negative correlation was observed between dosage and volume in the hippocampus, while a positive correlation was found in the caudate."	( Brain differences in first-episode schizophrenia treated with quetiapine: a deformation-based morphometric study. Bai, Y; Gao, H; Lu, W; Wu, S; Yang, C, 2015)	0.42
" Such differences may be partially relevant to dosage and treatment duration in clinic."	( Brain differences in first-episode schizophrenia treated with quetiapine: a deformation-based morphometric study. Bai, Y; Gao, H; Lu, W; Wu, S; Yang, C, 2015)	0.42
"This study investigated the dosing patterns of quetiapine augmentation (QA) for major depressive disorder (MDD) in routine practice."	( Quetiapine augmentation for depression: dosing pattern in routine practice. Han, C; Lee, SJ; Masand, PS; Pae, CU; Patkar, AA; Wang, SM, 2015)	0.42
" Data were derived from a 12 week randomized double-blind study comparing flexible dosage of sertindole 12-20mg and quetiapine 400-600mg in patients with schizophrenia."	( Cardiac effects of sertindole and quetiapine: analysis of ECGs from a randomized double-blind study in patients with schizophrenia. Graff, C; Kanters, JK; Matz, J; Mittoux, A; Nielsen, J; Polcwiartek, C; Struijk, JJ; Toft, E, 2015)	0.42
" The risk factors for treatment non-adherence include dosing frequency and complexity."	( The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population. Lee, MS; Pan, PY; Yeh, CB, 2015)	0.42
" Although our study suggests the prescription dosage and duration of antipsychotic treatment decreased significantly after FDA warning in 2005, the duration of treatment was still long."	( Dosage and duration of antipsychotic treatment in demented outpatients with agitation or psychosis. Chiang, HL; Hwang, TJ; Hwu, HG; Lin, YT; Shan, JC; Sheu, YH, 2015)	0.42
" Principal results of the study are as follows: (i) Pharmaceutically equivalent quetiapine fumarate extended release dosage form of Seroquel XR was developed using a quality by design/design of experiment (QbD/DoE) paradigm."	( An understanding of modified release matrix tablets behavior during drug dissolution as the key for prediction of pharmaceutical product performance - case study of multimodal characterization of quetiapine fumarate tablets. Dorożyński, PP; Haznar-Garbacz, D; Kulinowski, P; Rappen, GM; Węglarz, WP; Woyna-Orlewicz, K, 2015)	0.42
" Due to the simple dosing regimen of QUE-XR, conducting therapy with this drug may contribute to the improvement of compliance."	( [The place of quetiapine extended release in the treatment of mental disorders]. Datka, W; Drozdowicz, K; Dudek, D; Jaeschke, R; Siwek, M; Styczeń, K, )	0.13
" The enzyme activity varied according to the dose, brain region, and acute or chronic dosing protocols."	( Acute and Chronic Treatments with Quetiapine Increase Mitochondrial Respiratory Chain Complex Activity in the Rat Brain. Abelaira, HM; Bruchchen, L; Carlessi, AS; Carvalho-Silva, M; da Luz, JR; Gomes, LM; Ignácio, ZM; Matias, BI; Quevedo, J; Rebelo, J; Réus, GZ; Streck, EL; Titus, SE, 2015)	0.42
" There was no support for a dose-response relationship for any drug combination."	( Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia. Joyce, DW; Mateos Fernandez, MJ; Sarkar, SN; Shergill, SS; Tracy, DK, 2015)	0.42
" Treatment with 20% acetylcysteine oral solution was initiated at a dosage of 600 mg twice daily as an adjunct to quetiapine therapy."	( Acetylcysteine for treatment of autism spectrum disorder symptoms. Dopheide, J; Stutzman, D, 2015)	0.42
" Moreover, available tools that guide dosing in neuropsychiatric pediatric patients are scant, leading to the possibility of reduced efficacy and/or increased risks of toxicity."	( Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. Auricchio, F; Baldelli, S; Bernardini, R; Bertella, S; Bravaccio, C; Capuano, A; Carnovale, C; Cattaneo, D; Clementi, E; Ferrajolo, C; Fucile, S; Guastella, G; Mani, E; Molteni, M; Pascotto, A; Pisano, S; Pozzi, M; Radice, S; Rafaniello, C; Riccio, MP; Rizzo, R; Rossi, F; Scuderi, MG; Sperandeo, S; Sportiello, L; Villa, L, 2016)	0.43
" Next, monkeys were treated with quetiapine (25 mg, by mouth, twice a day) for approximately 30 days, and then the quetiapine self-administration dose-response curve was redetermined."	( Evaluation of the Reinforcing Effect of Quetiapine, Alone and in Combination with Cocaine, in Rhesus Monkeys. Brutcher, RE; Nader, MA; Nader, SH, 2016)	0.43
" The development of an in vitro-in vivo correlation (IVIVC) and the use of in vitro data to predict in vivo bioavailability parameters has been of great interest for the rational development and evaluation process for extended release dosage forms."	( Development of a level A in vitro-in vivo correlation for extended release dosage forms of quetiapine fumarate. Gonçalves de Lima, L; Rossi de Campos, D, 2016)	0.43
" Analyses were conducted assuming pooled dosing from randomised clinical trials included in the MTCs."	( Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK. Beillat, M; Robinson, P; Sapin, C; Tempest, M; Treur, M, 2015)	0.42
" There are currently no studies evaluating non-oral compounded dosage forms of quetiapine."	( A Single-Dose Crossover Pharmacokinetic Comparison Study of Oral, Rectal and Topical Quetiapine in Healthy Adults. Bobo, WV; Cunningham, JL; Dierkhising, RA; Kung, S; Lapid, MI; Leung, JG; Nelson, S; Plevak, MF; Thompson, VH, 2016)	0.43
" When detected, serum levels achieved with topical quetiapine were delayed and low in comparison with those produced by the oral and rectal dosage forms."	( A Single-Dose Crossover Pharmacokinetic Comparison Study of Oral, Rectal and Topical Quetiapine in Healthy Adults. Bobo, WV; Cunningham, JL; Dierkhising, RA; Kung, S; Lapid, MI; Leung, JG; Nelson, S; Plevak, MF; Thompson, VH, 2016)	0.43
" bolus dosing of nonencapsulated drug (FQ) and QLNC formulations alone and in association with probenecid to male Wistar rats."	( Pharmacokinetic Investigation of Quetiapine Transport across Blood-Brain Barrier Mediated by Lipid Core Nanocapsules Using Brain Microdialysis in Rats. Carreño, F; Dalla Costa, T; Guterres, SS; Paese, K; Silva, CM, 2016)	0.43
" These results indicate that higher doses of these drugs could lead to greater QT prolongation in a dose-response manner."	( A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. Cho, JY; Chung, H; Chung, JY; Jang, IJ; Kim, A; Lee, H; Lim, KS; Yoon, SH; Yu, KS, 2016)	0.43
" The interpretation based on the simulations does not call for a genotype-based dosing scheme and is consistent with consensus guidelines for quetiapine that therapeutic drug monitoring is considered useful."	( Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment. Derendorf, H; Melhem, M; Shilbayeh, SA; Sy, SK; Zmeili, R, 2015)	0.42
" Quetiapine was used in all studies with a bedtime dosage between 50 and 300 mg/day."	( Antipsychotics for fibromyalgia in adults. Häuser, W; Klose, P; Phillips, T; Üçeyler, N; Walitt, B, 2016)	0.43
" This open-label, parallel-group study was performed to compare finger-stick-based capillary with corresponding venous plasma concentrations for risperidone, paliperidone, quetiapine, olanzapine, and aripiprazole and their major metabolites after repeated dosing in patients with schizophrenia or related illnesses."	( Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole. Ariyawansa, J; De Meulder, M; Remmerie, B; Savitz, A, 2016)	0.43
"After a 1-week placebo run-in, quetiapine was started at a daily dosage of 25 mg and increased to a maximum of 800 mg; the average was 258 mg (range, 50-800 mg)."	( Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. Calais, LA; Cañive, JM; Durklaski, V; Hamner, MB; Qualls, C; Robert, S; Villarreal, G; Zhai, Y, 2016)	0.43
" Despite estimates being robust following sensitivity analyses, limitations include the potential for residual confounding and ascertainment bias and an inability to examine dosage effects."	( Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study. Geddes, JR; Hayes, JF; King, M; Marston, L; Osborn, DP; Walters, K, 2016)	0.43
" This study aims at designing a novel dosage form of sustained release taste-masked QT orally disintegrating tablets (ODTs) based on solid lipid micro-pellets (SLMPs)."	( A dual strategy to improve psychotic patients' compliance using sustained release quetiapine oral disintegrating tablets. Boraei, N; Ismail, F; Refaat, A; Sokar, M, 2016)	0.43
" However, acute hyperglycemic effect was detected only after dosing of the drug at the beginning of an active phase."	( Effect of a dosing-time on quetiapine-induced acute hyperglycemia in mice. Ando, H; Fujimura, A; Fujiwara, Y; Hosohata, K; Kapse, S; Kitamura, H; Kotani, K; Shimba, S; Suzuki, C; Ushijima, K, 2017)	0.46
"4β-Hydroxycholesterol (4βOHC) is sensitive towards induction or inhibition of CYP3A4, but its potential usefulness as a dosing biomarker remains to be demonstrated."	( 4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. Andreassen, OA; Gjestad, C; Haslemo, T; Molden, E, 2017)	0.46
" This supports the potential usefulness of 4βOHC as a phenotype biomarker for individualized dosing of quetiapine and other drugs where systemic exposure is mainly determined by CYP3A4 metabolism."	( 4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. Andreassen, OA; Gjestad, C; Haslemo, T; Molden, E, 2017)	0.46
"The median daily dosage of quetiapine was 300mg (Q1: 300mg, Q3: 600mg, range 200-800mg)."	( Pregnancy exposure to quetiapine - Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood and obstetrical outcomes. Augustin, M; Goecke, TW; Gründer, G; Kuzin, M; Paulzen, M; Schoretsanitis, G, 2018)	0.48
" A significant positive correlation was observed between estimated daily dosage of quetiapine and average concentration in hair for individuals with natural hair colour (p=0."	( Post-mortem quetiapine concentrations in hair segments of psychiatric patients - Correlation between hair concentration, dose and concentration in blood. Banner, J; Günther, KN; Johansen, SS; Linnet, K; Nielsen, MKK; Wicktor, P, 2018)	0.48
" The duration of each adequate antipsychotic treatment at an optimal dosage was 4 weeks or more."	( Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study. Sakamoto, S; Sato, K; Takaki, M; Yamada, N; Yoshimura, B, 2019)	0.51
" There were no differences in first-line antipsychotics, dosage of antipsychotics at time of response and adherence rates to algorithm-based pharmacotherapy between remitters and non-remitters."	( Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study. Sakamoto, S; Sato, K; Takaki, M; Yamada, N; Yoshimura, B, 2019)	0.51
"Although current quetiapine labeling recommends that its dosage should be lowered 6-fold when coadministered with strong cytochrome P450 (CYP)3A inhibitors, a reported case of coma in a patient receiving quetiapine with lopinavir and ritonavir prompted the reevaluation of labeling recommendations for the dosing of quetiapine when coadministered with human immunodeficiency virus (HIV) protease inhibitors."	( Dosing Recommendations for Quetiapine When Coadministered With HIV Protease Inhibitors. Cao, KY; Gish, PL; Hyon, K; Mishra, P; Sampson, MR; Tauber, W; Younis, IR; Zhao, P; Zhou, EH, 2019)	0.51
" Hence, a different dosing strategy is required among smoking and nonsmoking patients."	( Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2. Deckert, J; Hommers, LG; Menke, A; Samanski, L; Scherf-Clavel, M; Unterecker, S, 2019)	0.51
"During a period of inflammation in patients taking quetiapine, according to our results, attention in dosing strategies is required to prevent toxic plasma concentrations."	( Pathological Concentration of C-reactive Protein is Correlated to Increased Concentrations of Quetiapine, But Not of Risperidone, Olanzapine and Aripiprazole in a Naturalistic Setting. Deckert, J; Menke, A; Scherf-Clavel, M; Unterecker, S; Weidner, A, 2020)	0.56
"The aim of this study was to investigate time trends in dosing and prevalence of antipsychotic prescriptions in Scandinavia."	( Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016. Correll, CU; Højlund, M; Johnsen, E; Kroken, RA; Munk-Jørgensen, P; Pottegård, A; Reutfors, J, 2019)	0.51
"Using patient-derived glioblastoma stem cell (GSC) cultures from 15 GBM patients, we described stem cell properties of individual cultures, determined the dose-response relationships of the drugs in the CUSP9, and assessed the efficacy the CUSP9 combination with TMZ in concentrations clinically achievable."	( The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. Grieg, Z; Langmoen, IA; Sandberg, CJ; Skaga, E; Skaga, IØ; Vik-Mo, EO, 2019)	0.51
"8 points), quetiapine dosage (-150 mg), blood pressure (-2."	( An Indoor Therapeutic Garden for Behavioral Symptoms in Alzheimer's Disease: A Randomized Controlled Trial. Brasioli, A; Fonte, C; Muti, E; Pedrinolla, A; Schena, F; Smania, N; Sollima, A; Tamburin, S; Venturelli, M, 2019)	0.51
" Particularly, impact associated with dosage has been barely studied."	( Effects of long-term antipsychotics treatment on body weight: A population-based cohort study. Bazo-Alvarez, JC; Carpenter, JR; Hayes, JF; Morris, TP; Petersen, I, 2020)	0.56
"The dose-response relationships of antipsychotic drugs for schizophrenia are not well defined, but such information would be important for decision making by clinicians."	( Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S, 2020)	0.56
" Dose-response curves were constructed with random-effects dose-response meta-analyses and a spline model."	( Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S, 2020)	0.56
" For some drugs, higher than currently licensed doses might be tested in further trials, because their dose-response curves did not plateau."	( Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S, 2020)	0.56
" This study applied pharmacokinetic modelling principles to investigate the mechanism of these changes and to propose new dosing strategies to counteract these changes."	( Quetiapine dose optimisation during gestation: a pharmacokinetic modelling study. Badhan, RKS; Macfarlane, H, 2020)	0.56
" A dosing optimisation strategy identified that dose increases to 500-700 mg twice daily would result in 32-55% of subjects possessing trough concentration in excess of 50 ng/ml."	( Quetiapine dose optimisation during gestation: a pharmacokinetic modelling study. Badhan, RKS; Macfarlane, H, 2020)	0.56
" We used the Generalized Propensity Score method to evaluate the dose-response risk of Parkinsonism associated with SGAs."	( Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults-a propensity score matched cohort study. Chyou, TY; Nishtala, PS; Nishtala, R, 2020)	0.56
" It is not possible to put a temporal period for each segment, as the hair growth at the age of 32 months is not the same as for an adult (difference in the duration of the anagen period), nor to put any quantitative dosage or frequency of exposure(s) when interpreting the data."	( The Difficult Interpretation of a Hair Test Result from a 32-Month-Old Child: Administration of Propranolol and Quetiapine or Contamination? Ameline, A; Kintz, P; Raul, JS, 2020)	0.56
" Dosing recommendations however are often based on strategies used in patients with normal body habitus."	( Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium. Barletta, JF; Erstad, BL, 2020)	0.56
" Remission from SW/SRE was noted in all cases with measures including antipsychotic dosage reduction, discontinuation of medication, switching to an alternate medication, and use of continuous positive airway pressure (CPAP) for comorbid obstructive sleep apnea (OSA) treatment."	( Sleepwalking and sleep-related eating associated with atypical antipsychotic medications: Case series and systematic review of literature. Baliga, N; Chopra, A; Das, P; Narahari, A; Patel, RS, )	0.13
"To determine if adjunctive use of quetiapine reduces sedative dosage requirements among mechanically ventilated adults without delirium."	( Effectiveness of Quetiapine as a Sedative Adjunct in Mechanically Ventilated Adults Without Delirium. Cox, CE; Gilstrap, DL; Kram, BL; Kram, SJ; Ohman, KL; Schultheis, JM; Yang, Z, 2021)	0.62
" The primary outcome was the change in sedative dosage requirements over 24 hours following quetiapine initiation."	( Effectiveness of Quetiapine as a Sedative Adjunct in Mechanically Ventilated Adults Without Delirium. Cox, CE; Gilstrap, DL; Kram, BL; Kram, SJ; Ohman, KL; Schultheis, JM; Yang, Z, 2021)	0.62
"Adjunctive use of quetiapine was not associated with a significant reduction in sedative dosage requirements 24 or 48 hours following initiation among mechanically ventilated adults without delirium."	( Effectiveness of Quetiapine as a Sedative Adjunct in Mechanically Ventilated Adults Without Delirium. Cox, CE; Gilstrap, DL; Kram, BL; Kram, SJ; Ohman, KL; Schultheis, JM; Yang, Z, 2021)	0.62
" Regression and dose-response models were utilized to identify the threshold dose (maximum daily dose)."	( Discontinuation of antipsychotics treatment for elderly patients within a specialized behavioural unit: a retrospective review. Gao, RL; Lim, KS; Luthra, AS, 2021)	0.62
" An optimized dose-response curve is then presented, introducing (±) amphetamine hydrochloride (0."	( A Molecularly Imprinted Polymer-based Dye Displacement Assay for the Rapid Visual Detection of Amphetamine in Urine. Arreguin-Campos, R; Caldara, M; Cleij, TJ; Diliën, H; Eersels, K; Heidt, B; Jimenez-Monroy, KL; Lowdon, JW; Rogosic, R; van Grinsven, B, 2020)	0.56
" The dose-response association was further analysed by 3 quetiapine doses: low (≤<=0."	( Dose-response association of acute-phase quetiapine treatment with risk of new-onset hypothyroidism in schizophrenia patients. Li, M; Retnakaran, R; Sun, Z; Wen, SW; Yuan, X; Zhai, D; Zhang, R; Zhao, Y, 2021)	0.62
"Acute phase quetiapine treatment for schizophrenia patients was strongly associated with increased risk of developing new-onset hypothyroidism, with a clear dose-response association."	( Dose-response association of acute-phase quetiapine treatment with risk of new-onset hypothyroidism in schizophrenia patients. Li, M; Retnakaran, R; Sun, Z; Wen, SW; Yuan, X; Zhai, D; Zhang, R; Zhao, Y, 2021)	0.62
" For the treatment of pediatric populations or patient populations with trouble swallowing tablets, an oral suspension would be an ideal dosage formulation."	( The stability of quetiapine oral suspension compounded from commercially available tablets. Deville, R; Dong, X; Evans, J; Gervase, MA; Tran, J, 2021)	0.62
" A dose-response association between quetiapine exposure and decline in TSH index and TFQI was observed (P < 0."	( Impaired central set point of thyroid homeostasis during quetiapine treatment in the acute phase of schizophrenia. Guan, Q; Han, J; Hao, W; Huang, X; Retnakaran, R; Shi, J; Sun, J; Wang, Q; Wen, SW; Yang, J; Zhai, D; Zhang, R; Zhang, X; Zhao, Y, 2022)	0.72
"Quetiapine was associated with TSH index and TFQI reduction in a dose-response pattern, suggesting that impaired central set point may be involved in the mechanism by which quetiapine affects hypothalamus-pituitary-thyroid axis in acute phase schizophrenia patients."	( Impaired central set point of thyroid homeostasis during quetiapine treatment in the acute phase of schizophrenia. Guan, Q; Han, J; Hao, W; Huang, X; Retnakaran, R; Shi, J; Sun, J; Wang, Q; Wen, SW; Yang, J; Zhai, D; Zhang, R; Zhang, X; Zhao, Y, 2022)	0.72
" The proportion of patients dosed above the new limit decreased from 8 to 1% in patients ≤ 65 years and from 46 to 23% in patients > 65 years old for citalopram versus 14-5% and 47-31% for escitalopram."	( Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data. Bleich, S; Bridler, R; de Bardeci, M; Greil, W; Grohmann, R; Hasler, G; Kasper, S; Köberle, U; Rüther, E; Seifert, J; Stassen, H; Toto, S; Willms, J, 2023)	0.91
"The effects of antipsychotic drugs are dose-dependent, which is particularly true for their efficacy, each antipsychotic having a specific dose-response curve."	( Comorbidities and the right dose: antipsychotics. Azorin, JM; Simon, N; Torrents, R, )	0.13
"Factors liable to impact antipsychotic dosage are numerous and their subsequent effects often hard to predict, due to multilevel interactions and compensatory phenomena."	( Comorbidities and the right dose: antipsychotics. Azorin, JM; Simon, N; Torrents, R, )	0.13
" No known medication dosage increases had been made, nor had any new serotonergic agents been added to the patient's drug regimen."	( A 70-Year-Old Woman Presenting with Confusion and Muscle Spasms Due to Serotonin Syndrome Associated with Paroxetine and Quetiapine Treatment. Mostel, E; Patel, S; Wiener, BG, 2022)	0.72
"54]) subgroups, at the dosage of 50 mg (SMD: -0."	( Effects of quetiapine on sleep: A systematic review and meta-analysis of clinical trials. Chiang, CH; Lin, CY; Loh, EW; Tam, KW; Tseng, MM, 2023)	0.91
" The present study reviews analytical methods with their validation parameters published during the last 22 years (1999-2021) either as a single entity or combination in dosage form, and determination from biological samples."	( Quetiapine Fumarate: A Review of Analytical Methods. Hamsa, A; Kariyarambath, P; Karumandampalayam Shanmugaramasamy, K; Kathirvel, S, 2023)	0.91
" Potential dosage effects were examined in a 3 × 1 ANOVA."	( Treatment with the second-generation antipsychotic quetiapine is associated with increased subgenual ACC activation during reward processing in major depressive disorder. Bauer, J; Borgers, T; Dannlowski, U; Dohm, K; Enneking, V; Goltermann, J; Grotegerd, D; Klug, M; Kraus, A; Kugel, H; Leehr, EJ; Omlor, N; Opel, N; Redlich, R; Repple, J; Richter, M; Steinmann, LA, 2023)	0.91
" We applied one-stage random-effects dose-response meta-analyses using restricted cubic splines to model the dose-response relationships."	( Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis. Burschinski, A; Davis, JM; Leucht, S; Priller, J; Schneider-Thoma, J; Siafis, S; Wang, D; Wu, H, 2023)	0.91
"We hypothesized that QTP-IR is inferior to QTP-ER at any dose in efficacy for the acute treatment in schizophrenia and tested using a dose-response model-based network meta-analysis (NMA)."	( Comparative efficacy of quetiapine by dose and formulation for psychosis in schizophrenia: A systematic review and dose-response model-based network meta-analysis. Fukushima, H; Terao, I; Yokoi, A, 2023)	0.91
" A random effect Bayesian dose-response model-based NMA was performed to compare the dose-response relationships between QTP-IR and QTP-ER."	( Comparative efficacy of quetiapine by dose and formulation for psychosis in schizophrenia: A systematic review and dose-response model-based network meta-analysis. Fukushima, H; Terao, I; Yokoi, A, 2023)	0.91
" Current research revealed the successful development of intranasal QF-Nanoemulgel as a novel dosage form for the safe and effective delivery of QF in schizophrenia patients."	( A Nanoemulgel for Nose-to-Brain delivery of Quetiapine - QbD-Enabled formulation development & in-vitro characterization. Gadhave, D; Goyal, M; Gupta, V; Quadros, M; Ugale, AR, 2023)	0.91
" By varying fatty acid chain length, the enzyme-oriented QTP controlled release dosage form was challenged to enhance the therapeutic effectiveness of QTP."	( Roles of Fatty Acid Chain Length and Enzyme-Oriented Drug Controlled Release from pH-Triggering Self-Assembled Fatty Acid Conjugated Quetiapine Nanosuspensions. Gil, MC; Lee, BJ; Ngo, HV; Nguyen, HD; Nguyen, VH, 2023)	0.91

Class	Description
fumarate salt	An organic salt derived from fumaric acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	98 (3.35)	18.2507
2000's	1222 (41.78)	29.6817
2010's	1244 (42.53)	24.3611
2020's	361 (12.34)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	619 (19.58%)	5.53%
Reviews	479 (15.15%)	6.00%
Case Studies	826 (26.12%)	4.05%
Observational	29 (0.92%)	0.25%
Other	1,209 (38.24%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (371)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole, Quetiapine and Ziprasidone Over 1 Year [NCT02534363]	Phase 4	136 participants (Actual)	Interventional	2005-10-31	Completed
Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis- An Investigator-initiated, Phase IV, Randomised Double-blind Multi-centre Trial of the Benefits and Harms of Aripiprazole Versus Quetiapine in Children and Adolescents With [NCT01119014]	Phase 4	300 participants (Anticipated)	Interventional	2010-05-31	Active, not recruiting
[NCT01587066]	Phase 4	0 participants (Actual)	Interventional	2010-08-31	Withdrawn
Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up [NCT02526030]	Phase 4	203 participants (Actual)	Interventional	2008-10-31	Completed
A Twelve-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric H [NCT01193166]	Phase 4	0 participants (Actual)	Interventional	2010-08-31	Withdrawn(stopped due to This study was stopped due to an internal reconsideration of priorities of the product portfolio.)
Efficacy of Quetiapine XR vs. Placebo as Concomitant Treatment to Mood Stabilizers in the Control of Subsyndromal Symptoms of Bipolar Disorder [NCT01197846]	Phase 3	28 participants (Actual)	Interventional	2010-09-30	Completed
A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine [NCT04164758]	Phase 2	11 participants (Actual)	Interventional	2019-10-23	Terminated(stopped due to Study enrollment impacted by COVID-19 pandemic and Sponsor terminated for business reasons)
A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adult Subjects With Schizophrenia, Schizoaffective Disorder, or First Episode Psychos [NCT03568500]	Phase 4	44 participants (Actual)	Interventional	2018-05-21	Completed
Functional Reciprocity Between Heightened Stress Reactivity and Emotional Numbing in PTSD: Novel Predictors of Pharmacotherapeutic Outcomes [NCT01066156]		34 participants (Actual)	Interventional	2010-02-28	Completed
Phase IV Study of Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) [NCT01250847]	Phase 4	83 participants (Anticipated)	Interventional	2010-11-30	Recruiting
Chinese Longitudinal and Systematic Study of Bioplar Disorder [NCT05480150]		10,000 participants (Anticipated)	Interventional	2021-11-01	Recruiting
Controlled, Double-blind, Randomized Clinical Trial for Prophylaxis of Postoperative Delirium in High Risk Surgical Patients With Quetiapine [NCT03739476]	Phase 3	50 participants (Actual)	Interventional	2019-02-13	Terminated(stopped due to Due to the crisis SARS-COV-2 pandemic: recruitment of patients for the trial is stopped, healthcare pressure generated, suspend the non-essential scheduled surgical activity and on June 30, 2020 medication expired, funding has been exhausted.)
An Observational Drug Utilization Study of SYCREST^® (Asenapine) in the United Kingdom [NCT01498770]		42 participants (Actual)	Observational	2013-04-01	Completed
Open-Label Study of Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar and Bipolar Spectrum Disorder [NCT00181883]	Phase 4	30 participants (Actual)	Interventional	2005-02-28	Completed
The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope [NCT01357967]	Phase 4	60 participants (Anticipated)	Interventional	2011-05-31	Recruiting
Effectiveness of Antipsychotic Drugs to Treat Psychosis Syndrome: an Open Label, Controlled Study [NCT02137616]		300 participants (Anticipated)	Interventional	2012-06-30	Recruiting
A Phase 1, 2-Part, Open-Label, Randomized, Crossover Pilot Trial to Assess the Relative Bioavailability of Quetiapine Versus Seroquel® 300-mg Oral Tablets in Subjects With Schizophrenia or Bipolar Disorder and 25-mg Oral Tablets in Healthy Subjects [NCT03872596]	Phase 1	58 participants (Actual)	Interventional	2019-03-27	Completed
Effects of Seroquel XR (Quetiapine Fumarate Extended-Release) on Sleep Architecture in Patients With Major Depressive Disorder [NCT01189318]	Phase 2	0 participants (Actual)	Interventional	2012-03-31	Withdrawn
A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) in the Treatment of Elderly Patients With Major Depressive Disorder [NCT00388973]	Phase 3	338 participants (Actual)	Interventional	2006-09-30	Completed
Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea [NCT05303935]	Phase 2	15 participants (Actual)	Interventional	2022-05-25	Completed
Changes of Heart Rate Variability in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine [NCT01047215]	Phase 4	120 participants (Anticipated)	Interventional	2009-08-31	Recruiting
A Randomized Trial Comparing Efficacy and Tolerability of Levomilnacipran Switch Versus Adjunctive Quetiapine in Major Depressive Disorder (MDD) With Inadequate Response to SSRIs [NCT02720198]	Phase 3	60 participants (Actual)	Interventional	2017-01-23	Completed
A Randomized, Multi-site, Parallel-group, Rater-blind Study Comparing Response With Aripiprazole Once Monthly and Standard of Care Oral Antipsychotics in Non-adherent Outpatients With Schizophrenia Identified Using the Brief Adherence Rating Scale [NCT02282085]	Phase 4	200 participants (Anticipated)	Interventional	2014-12-31	Recruiting
Neuroendocrine, Metabolite Substrates, Clinical Symptoms and Cognitive Function in Schizophrenia [NCT02423096]		200 participants (Anticipated)	Observational [Patient Registry]	2013-12-31	Recruiting
[NCT02297763]	Phase 3	194 participants (Anticipated)	Interventional	2015-03-31	Not yet recruiting
Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Quetiapine-Referenced, Fixed-Dose Study of Lu AA39959 in the Treatment of Depression in Patients With Bipolar I or II Disorder [NCT00771134]	Phase 2	105 participants (Actual)	Interventional	2008-12-31	Terminated(stopped due to Study was previously suspended and is now terminated)
Pharmacotherapy of Generalized Anxiety Disorder With Seroquel: Normalization of Brain Stress and Reward Function [NCT01066143]		8 participants (Actual)	Interventional	2010-02-28	Terminated(stopped due to The underwriter stopped the funding)
Serotonin Transporter Genetic Variation and Amygdala Responses to Quetiapine and Selective Serotonin Reuptake Inhibitor Treatment in Major Depression [NCT02132286]	Phase 4	57 participants (Actual)	Interventional	2008-12-31	Completed
A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia [NCT01129674]	Phase 2/Phase 3	1,210 participants (Anticipated)	Interventional	2010-06-30	Terminated(stopped due to The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.)
A Dose-finding, Safety and Tolerability Trial of Extended-release Quetiapine in Relapsing-remitting and Progressive Multiple Sclerosis [NCT02087631]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2014-12-31	Completed
A Single Dose Pharmacokinetic Study of Topical and Rectal Quetiapine Compared to Oral Quetiapine in Healthy Adults [NCT02131545]	Phase 1	10 participants (Actual)	Interventional	2014-06-30	Completed
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics for the Prevention of Relapse in Long-term Stabilized Schizophrenic Patients: a Randomized, Single-blind, Longitudinal Trial [NCT02307396]	Phase 4	21 participants (Actual)	Interventional	2015-02-01	Completed
Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder [NCT00113295]	Phase 4	50 participants (Actual)	Interventional	2004-02-29	Completed
Risk and Protective Factors for SGA-induced Metabolic Syndrome in Bipolar Youth [NCT01858948]	Phase 3	19 participants (Actual)	Interventional	2013-07-31	Completed
A Randomised, Double-Blind, Parallel-Group, Flexible-Dose Study Exploring the Neurocognitive Effect of Sertindole Versus Comparator in Patients With Schizophrenia Using the MATRICS Consensus Cognitive Battery (MCCB) [NCT00654706]	Phase 3	264 participants (Actual)	Interventional	2008-03-31	Completed
A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared With Quetiapine Extended-Release in Adult and Elderly Partici [NCT04338321]	Phase 3	676 participants (Actual)	Interventional	2020-08-21	Completed
A Double-Blind, Placebo-Controlled, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults [NCT01224067]	Phase 4	40 participants (Anticipated)	Interventional	2006-03-31	Completed
A Multi-Centre, Double-Blind, Randomised, Parallel Group, Escitalopram Controlled Phase III-B Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR TM) as Monotherapy in the Treatment of Adult Patients With Agitated Major D [NCT01363310]	Phase 3	250 participants (Anticipated)	Interventional	2010-10-31	Terminated(stopped due to Termination of sponsorship)
A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate L [NCT02431702]	Phase 3	337 participants (Actual)	Interventional	2015-07-08	Completed
Quetiapine in Melancholic Depression: an fMRI Study of Treatment-induced Changes in the Neurocircuitry of the Stress Response [NCT01200901]	Phase 4	20 participants (Actual)	Interventional	2008-09-30	Completed
Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression [NCT01213121]	Phase 4	60 participants (Anticipated)	Interventional	2010-09-30	Recruiting
Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients With Schizophrenia [NCT01164059]	Phase 4	149 participants (Actual)	Interventional	2010-02-28	Completed
Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Pharmacotherapy Alone for Relapse Prevention in Major Depression. A Clinical, Controlled, Prospective and Randomized Trial [NCT01305707]	Phase 4	104 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Difficulties in recruiting)
Bioequivalence Study of Quetiapine in Healthy Volunteers, After Administering a Single Dose of the Test Extended Release Formulation, Kemoter XR With Respect to the Reference Product, Etiasel XR ® From AstraZeneca S.A. [NCT03317236]	Phase 4	24 participants (Actual)	Interventional	2017-03-13	Completed
Randomised, Double-blind, Parallel-group, Placebo-controlled, and Active Referenced Study of Lu AA34893 to Evaluate the Efficacy and Safety of Three Doses Lu AA34893 in the Treatment of Depression in Patients With Bipolar I or II Disorder [NCT00622245]	Phase 2	166 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to Human metabolite not yet covered sufficiently by nonclinical data)
A 8-week, Multi-Centre, Open-label, Non-comparative, Phase IV Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR) With Daily Dose 400mg-800mg in the Treatment of Acute Schizophrenic Patients [NCT00779506]	Phase 4	96 participants (Actual)	Interventional	2008-11-30	Completed
A 3 Weeks Open Label Study to Evaluate the Efficacy in Agitation and Safety of Quetiapine Fumarate XR in Treatment of Patients With Acute Schizophrenia [NCT00954122]	Phase 4	35 participants (Actual)	Interventional	2009-09-30	Completed
A Pilot Study of Three-Week, Randomised, Open Comparison in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose [NCT00660595]	Phase 3	29 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to To difficult to recruit patients in the acute setting)
Assessment of the Inter-patient Variability in Clinical Response and Correlated Genetic Variations in Substance Use Disorders [NCT05833399]		200 participants (Anticipated)	Observational	2022-11-28	Recruiting
An Open Label, Multicenter, Single Arm, 4-Week Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder [NCT00837343]	Phase 4	120 participants (Anticipated)	Interventional	2008-12-31	Recruiting
An 8-week, Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended-Release in Children and Adolescent Subjects With Bipolar Depression [NCT00811473]	Phase 3	193 participants (Actual)	Interventional	2009-01-31	Completed
Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up With Quetiapine XR [NCT00879307]	Phase 3	100 participants (Anticipated)	Interventional	2009-03-31	Recruiting
Effectiveness of 6 Antipsychotic Drugs in the Treatment of Acute Exacerbations of Chronic Inpatients With Schizophrenia: a Randomized Double-blind Study [NCT02192723]		550 participants (Actual)	Interventional	2012-06-30	Completed
Quetiapine Augmentation of Prolonged Exposure (PE) Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury [NCT04280965]	Early Phase 1	28 participants (Actual)	Interventional	2019-02-01	Completed
Prospective, Double-Blind, Randomized Controlled Trial of Quetiapine as a Treatment for Delirium in Critically Ill Children [NCT03572257]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2019-04-15	Withdrawn(stopped due to Closed due to inability to enroll)
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study With Approved Antipsychotics in Vivo [NCT02051387]	Phase 1	74 participants (Actual)	Interventional	2013-01-31	Completed
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone [NCT02087579]	Phase 1	305 participants (Actual)	Interventional	2014-02-28	Completed
A Double-Blind, Randomized, Multiple Dose Study of Weight Associated Parameters: SEP-363856 vs Prior Antipsychotic (PA) Standard of Care in Subjects With Schizophrenia Suffering From Metabolic Dysregulation [NCT05542264]	Phase 1	60 participants (Anticipated)	Interventional	2022-11-15	Recruiting
A Double-Blind, Placebo-Controlled Trial of Seroquel for the Treatment of Dysphoric Hypomania in Bipolar II Patients [NCT00186043]	Phase 4	55 participants (Actual)	Interventional	2008-08-31	Completed
Double-blind Placebo-controlled Trial of Quetiapine in Anorexia Nervosa [NCT00518973]		21 participants (Actual)	Interventional	2006-07-31	Completed
Interventions to Test the Alpha7 Nicotinic Receptor Model in Schizophrenia [NCT00509067]	Phase 2	43 participants (Actual)	Interventional	2007-11-30	Completed
Impact of Quetiapine Prolong and Escitalopram on the Hypothalamic-pituitary-adrenocortical (HPA)-Axis Activity in Depressed Patients [NCT00953108]	Phase 3	60 participants (Actual)	Interventional	2009-09-30	Completed
A Randomized Controlled Trial to Evaluate the Effectiveness of Clozapine Versus Olanzapine, Quetiapine or Risperidone in Treatment Resistant Bipolar Disorder [NCT02562287]	Phase 4	54 participants (Anticipated)	Interventional	2015-10-31	Recruiting
CARE II - Evaluation of Treatment Outcomes in Schizophrenic Patients Taking Part in the Integrated Care Program - a Single-country, Multi-centre Phase IV Study [NCT00681629]	Phase 4	7 participants (Actual)	Interventional	2008-07-31	Terminated(stopped due to Difficulty finding eligible sites/patients; current situation in health policy cause negative effect on existing/planned contracts for integrated care program)
Effect of Quetiapine XR on Sleep in Patients With Major Depression, as Compared With Mirtazapine [NCT00782405]	Phase 3	40 participants (Anticipated)	Interventional	2008-10-31	Completed
Quetiapine Related Neurochemical Changes as Measured by Magnetic Resonance Spectroscopy in Patients With Schizophrenia [NCT00797927]	Phase 4	30 participants (Actual)	Interventional	2007-01-31	Completed
A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects With Schizophrenia [NCT00640601]	Phase 3	331 participants (Actual)	Interventional	2008-03-31	Completed
A Multicenter, Open Label, Flexible-dose, Parallel-group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (Seroquel) and Risperidone (Risperdal) in the Long Term Treatment of Participants With Schizophrenia or Schizoaffective Disorder [NCT00206102]	Phase 4	1,098 participants (Actual)	Interventional	2003-09-30	Completed
Multimodal Neuroimaging of Treatment Effects in Adolescent Mania [NCT00893581]		169 participants (Actual)	Interventional	2009-03-31	Completed
A Phase IV, Multi-center, Double-blind, Double-dummy, Randomized, Parallel-group Study to Compare the Tolerability of Quetiapine Fumarate Immediate Release (Seroquel IR) With Quetiapine Fumarate Extended Release (Seroquel XR) During Initial Dose Escalatio [NCT00926393]	Phase 4	139 participants (Actual)	Interventional	2009-06-30	Completed
Comparative Efficacy of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment-resistant Unipolar Depression: A Randomized Controlled Trial. [NCT04936126]	Phase 4	150 participants (Anticipated)	Interventional	2021-08-07	Recruiting
A One-Year Randomized, Prospective, Parallel, Open Comparison of Subjective Well-being in Schizophrenic Out-patients Treated With Quetiapine XR (SEROQUEL XR™) or Oral Risperidone at Flexible Dose in a Naturalistic Setting [NCT00600756]	Phase 3	798 participants (Actual)	Interventional	2008-01-31	Completed
Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia:One-Year Follow up. [NCT00654576]	Phase 4	1,400 participants (Anticipated)	Interventional	2005-02-28	Completed
Determining the Efficacy and Tolerance of Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry [NCT00986167]	Phase 4	72 participants (Anticipated)	Interventional	2009-10-31	Not yet recruiting
Enhanced Identification of Very Early Response to Seroquel XR Added to an Antidepressant for the Treatment of Major Depressive Disorder With or Without Generalized Anxiety Disorder [NCT00892463]	Phase 4	26 participants (Actual)	Interventional	2009-05-31	Completed
A Randomized Open-label Active-controlled Study to Evaluate the Efficacy and Safety of Utapine Versus Seroquel in Patients With Bipolar Mania [NCT01043679]	Phase 4	40 participants (Anticipated)	Interventional	2009-07-31	Recruiting
The Efficacy and Safety of Once-daily Quetiapine Extended Release in Patients With Schizophrenia Switched From Other Antipsychotics [NCT02142556]	Phase 3	61 participants (Actual)	Interventional	2008-11-30	Completed
A Multicenter, Rand., Double-blind, Parallel-group, Pbo-controlled Study of the Efficacy and Safety of SEROQUEL® XR Compared With Pbo as an Adjunct to Treatment in Patients With Generalized Anxiety Disorder Who Demonstrate Partial or No Response to a SSRI [NCT00534599]	Phase 3	409 participants (Actual)	Interventional	2007-08-31	Completed
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication [NCT03557931]	Phase 2	233 participants (Actual)	Interventional	2018-07-13	Completed
A Multicenter, Double-Blind, Randomized, Comparison of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Agitation Associated With Dementia. [NCT00621647]	Phase 3	333 participants (Actual)	Interventional	2002-09-30	Completed
Quetiapine in the Treatment of Psychotic Depression - a Pilot Study [NCT00751504]	Phase 3	16 participants (Actual)	Interventional	2008-09-30	Completed
A Randomised, Multi-Centre Study to Compare the Efficacy and Safety of Extended Release Quetiapine Fumarate (Seroquel XR TM) Tablets as Mono-Therapy or in Combination With Lithium in the Treatment of Patients With Acute Bipolar Depression [NCT00883493]	Phase 3	421 participants (Actual)	Interventional	2009-04-30	Completed
[NCT00486798]	Phase 3	0 participants	Interventional	2007-05-31	Terminated(stopped due to study was not ethically acceptable to continue and therefore it was finally stopped)
A Randomised, 6-week, Multicentre, Open-label, Rater-blinded Parallel Group Study Comparing Quetiapine Extended Release Monotherapy and Augmentation With Lithium Augmentation in Patients With Treatment Resistant Depression [NCT00789854]	Phase 3	688 participants (Actual)	Interventional	2008-11-30	Completed
A Phase 3 Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Lurasidone in Subjects With Schizophrenia (PEARL 3 Extension Study) [NCT00789698]	Phase 3	240 participants (Actual)	Interventional	2008-12-31	Completed
An Open Label, 4-Week, Randomised, Multi-Centre, Phase IV Study to Compare the Efficacy and Safety of Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder [NCT00672490]	Phase 4	376 participants (Actual)	Interventional	2008-04-30	Completed
Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients [NCT02612948]	Phase 4	82 participants (Actual)	Interventional	2013-11-30	Completed
A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative, Phase 4 Study [NCT01254721]	Phase 4	131 participants (Actual)	Interventional	2010-12-31	Terminated(stopped due to Difficulty of recruitment.)
Effect of Quetiapine on Marijuana Withdrawal and Relapse [NCT00743366]	Phase 2	20 participants (Actual)	Interventional	2008-08-31	Completed
Atypical Antipsychotics and Hyperglycemic Emergencies: Multicentre, Retrospective Cohort Study of Administrative Data [NCT02582736]		725,489 participants (Actual)	Observational	2012-04-30	Completed
A 6-Week, Multicenter, Rater-blind, Randomized, Risperidone-controlled Study to Evaluate the Efficacy and Safety of Seroquel (Quetiapine Fumarate) in the Treatment of Chinese Han Patients With Schizophrenia [NCT00817648]	Phase 4	120 participants (Actual)	Interventional	2008-12-31	Completed
Quetiapine XR in the Treatment of Comorbid Generalized Anxiety Disorder in Bipolar Depression With or Without Substance Use Disorder [NCT00671853]	Phase 3	120 participants (Actual)	Interventional	2008-04-30	Completed
Randomized, Open-Label, Balanced, Two-treatment, Two-period, Two-sequence, Crossover, Multicentric Experimental Bioequivalence Study of Quetiapine Fumarate Film-coated Tablets 300 mg (Test)and Seroquel Film-coated Tablets 300 mg (Reference) Under Fasting [NCT01566487]	Phase 1	54 participants (Actual)	Interventional	2010-06-30	Completed
A 4-week, Multi-Centre, Open-label, Non-comparative, Phase IV Study of the Broad Clinical Benefit for Seroquel XR (Quetiapine Fumarate Extended Release) With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial [NCT01128114]	Phase 4	32 participants (Actual)	Interventional	2010-06-30	Terminated(stopped due to Poor recruitment)
Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia: a Randomized Clinical Trial [NCT06062953]	Phase 2/Phase 3	255 participants (Anticipated)	Interventional	2023-09-18	Recruiting
Anxiolytic Effects of Single-dose Quetiapine XR Administration on Clinical Symptoms and Amygdala Activation During Exposure in Patients With Simple Phobia [NCT00872716]	Phase 2	60 participants (Actual)	Interventional	2009-04-30	Completed
An Open-Label, Non-Comparative, Multi-Centre, Phase II Prospective Trial to Assess the Efficacy of Quetiapine Fumarate Augmentation of Selective Serotonin Reuptake Inhibitors (SSRIs) in SSRI-Resistant Major Depressive Disorder. [NCT00733668]	Phase 2	0 participants	Interventional	2006-03-31	Completed
A Multinational, Randomised, Double-blind, Fixed-dose, Bifeprunox Study Combining a 12-Week Placebo-controlled, Quetiapine-referenced Phase With a 12-month Quetiapine-controlled Phase in Patients With Schizophrenia [NCT00658645]	Phase 3	227 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to Interim analysis showed inadequate efficacy of bifeprunox)
Cardiovascular Biomarkers During Quetiapine Treatment of Depression [NCT00951483]	Phase 4	91 participants (Actual)	Interventional	2009-07-31	Completed
Study of Evaluating Quetiapine in Improving Sleep Quality of Schizophrenia [NCT00642369]		60 participants (Actual)	Interventional	2008-03-31	Completed
An Open Label, Randomised, Valproate-Controlled Study to Evaluate the Efficiency and Safety of Quetiapine Fumarate in the Treatment of Acute Manic Patients With Bipolar Disorder. [NCT00742638]		70 participants (Anticipated)	Interventional	2008-03-31	Recruiting
Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Comorbid Anxiety Symptoms [NCT00912535]	Phase 4	39 participants (Actual)	Interventional	2009-05-31	Completed
An Open Label, 1-sequence Cross-over, Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Receptor Occupancy of Quetiapine Fumarate Immediate Release (SEROQUEL®) With Quetiapine Fumarate Extended Release (SEROQUE [NCT00832221]	Phase 1	10 participants (Anticipated)	Interventional	2009-01-31	Completed
A Multinational, Randomised, Double-Blind, Fixed-Dose, Bifeprunox Study Combining a 12-Week Placebo-Controlled, Quetiapine-Referenced Phase With a 12-Month Quetiapine-Controlled Phase in Patients With Schizophrenia [NCT00704509]	Phase 3	346 participants (Actual)	Interventional	2008-06-30	Terminated(stopped due to Interim analysis showed inadequate efficacy of bifeprunox)
Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation [NCT04310579]	Phase 1	55 participants (Actual)	Interventional	2020-06-15	Completed
Interventional, Randomised, Double-blind, Parallel-group, Active-control, Multiple-dose Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder [NCT02901587]	Phase 1	119 participants (Actual)	Interventional	2016-09-30	Completed
Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial. [NCT00564564]	Phase 4	21 participants (Actual)	Interventional	2006-01-31	Completed
Examination of the Pharmacokinetic Properties of Three Generic Medications and Their Respective Brand Preparations in Healthy Male Volunteers [NCT01400165]	Phase 1	30 participants (Anticipated)	Interventional	2011-07-31	Recruiting
A Randomized, Pilot Clinical Trial to Assess the Comparative Efficacy and Tolerability of Quetiapine XR Versus Amitriptyline for the Treatment of Patients With Fibromyalgia [NCT00766350]	Phase 4	90 participants (Actual)	Interventional	2008-11-30	Completed
An 8-week, Randomized, Double-Blind, Placebo-Controlled Trial of Seroquel SR Co-administration for SSRI-Resistant, Comorbid Panic Disorder [NCT00619892]	Phase 4	26 participants (Actual)	Interventional	2008-02-29	Completed
[NCT00919607]	Phase 1	31 participants (Actual)	Interventional	2009-06-30	Completed
A Randomized, Double-Blind, Placebo Controlled Exploratory Study of Augmentation of Seroquel XR With Pramipexole Dihydrochloride for Bipolar Depression [NCT00893841]	Phase 2	96 participants (Actual)	Interventional	2009-02-28	Completed
Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study [NCT00983320]	Phase 4	52 participants (Actual)	Interventional	2008-04-30	Completed
Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting. [NCT00932529]	Phase 4	226 participants (Actual)	Interventional	2003-02-28	Completed
A Double-blind, Double-dummy, Randomized, Crossover Study to Compare the Tolerability of Quetiapine Fumarate Immediate Release (SEROQUEL®) With Quetiapine Fumarate Extended Release (SEROQUEL XR®) During Initial Dose Escalation in Healthy Volunteers [NCT00702676]	Phase 1	63 participants (Actual)	Interventional	2008-07-31	Completed
The Effect of the Atypical Antipsychotic Quetiapine in the Treatment of Postpartum Depressive Disorder With Psychotic Symptoms [NCT00681668]	Phase 2	5 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to Recruitment behind plan, no increase expected)
A Single-center, Randomized, Double-blind, Phase III Comparison of the Efficacy and Safety of Quetiapine Fumarate (Oral Extended Release Tablets) to Placebo in Social Phobia Patients and Changes in Their Vasodilatory Response to Methyl-Nicotinate [NCT00773162]	Phase 3	21 participants (Actual)	Interventional	2008-10-31	Completed
A 12-Month Randomized, Open-Label Study of Caregiver Psycho-education and Skills Training in Patients Recently Diagnosed With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder and Receiving Paliperidone Palmitate or Oral Antipsychotic [NCT02600741]		296 participants (Actual)	Observational	2015-07-24	Completed
Phase I Study of FK949E - Multiple Dose Study of Elderly Adult Patients With Major Depressive Disorder [NCT01903200]	Phase 1	16 participants (Actual)	Interventional	2010-02-28	Completed
[NCT00838032]	Phase 4	70 participants (Anticipated)	Interventional	2008-08-31	Recruiting
Compare Efficacy and Safety Between Quetiapine and Haloperidol in Treatment Delirium [NCT00954603]	Phase 3	52 participants (Actual)	Interventional	2009-06-30	Terminated(stopped due to few delirious patients were enrolled.)
Phase 4 Study of Efficacy and Safety of Tandospirone Combined With Atypical Antipsychotic Drugs to Improve Cognitive Function in Schizophrenia [NCT02040883]	Phase 4	100 participants (Anticipated)	Interventional	2014-02-28	Not yet recruiting
The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression [NCT00517387]	Phase 3	64 participants (Anticipated)	Interventional	2007-09-30	Completed
Treatment of Major Depressive Disorder With Psychotic Features With Quetiapine Monotherapy; Quetiapine and Citalopram; or Haloperidol and Citalopram [NCT00174603]	Phase 3	60 participants	Interventional	2005-08-31	Terminated(stopped due to Unable to recruit subjects)
Bariatric Surgery and Pharmacokinetics Quetiapine: BAR-MEDS Quetiapine [NCT03449472]		12 participants (Anticipated)	Observational	2018-01-02	Recruiting
The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Effects on Cue Reactivity in Response to Virtual Reality Public Speaking Environment [NCT00407199]	Phase 4	20 participants (Actual)	Interventional	2006-12-31	Completed
[NCT00182013]	Phase 4	106 participants (Actual)	Interventional	2001-06-30	Completed
A One-Year Multi-Centre Randomized, Double Blind, Controlled Effectiveness Study of Quetiapine and Olanzapine, Comparing Their Relative Potential in Improving Neuro-Cognitive Deficits, Functional Outcomes and Quality of Life in Schizophrenia [NCT00182442]	Phase 4	80 participants	Interventional	2003-10-31	Completed
A 26-week, Multicenter, Open-label Phase 3b Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents With Bipolar I Disorder and Adolescents With Schiz [NCT00227305]	Phase 3	381 participants (Actual)	Interventional	2004-08-31	Completed
The Effects of Quetiapine on Sleep During Alcohol Abstinence [NCT00434876]	Phase 3	22 participants (Actual)	Interventional	2007-08-31	Completed
A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) in the Treatment of Elderly Patients With Generalised Anxiety Disorder [NCT00389064]	Phase 3	450 participants (Actual)	Interventional	2006-09-30	Completed
Effects of Quetiapine XR in Schizophrenic Patients With Cannabis Abuse and/or Cannabis Induced Psychosis -Pilot Study- [NCT01071135]	Phase 3	5 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to Planned number of 30 subjects could not be recruited during recruitment phase.)
A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome [NCT00508157]	Phase 4	125 participants (Actual)	Interventional	2007-11-30	Terminated(stopped due to Slow Accrual)
A 6-week, Multicenter, Double-blind, Double-dummy, Randomized Comparison of the Efficacy & Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia [NCT00206115]	Phase 3	535 participants	Interventional	2004-11-30	Completed
A Placebo-controlled Trial of Adjunctive Quetiapine for Refractory PTSD [NCT00292370]	Phase 4	124 participants (Actual)	Interventional	2006-01-31	Completed
A Comparative Study of New Medications for Psychosis in Adolescents [NCT00222495]		30 participants	Interventional	2002-08-31	Completed
[NCT00060489]	Phase 3	0 participants	Interventional	2002-09-30	Completed
Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase [NCT01893229]	Phase 4	120 participants (Anticipated)	Interventional	2013-09-30	Recruiting
Phase I Study of FK949E - A Study of Drug-drug Interactions Between FK949E and Fluvoxamine in Healthy Male Adults [NCT01908296]	Phase 1	24 participants (Actual)	Interventional	2011-07-31	Completed
Phase I Study of FK949E - Comparison of Pharmacokinetics Between FK949E 50 mg Tablets and FK949E 150 mg Tablets in Patients With Major Depressive Disorder [NCT01919008]	Phase 1	16 participants (Actual)	Interventional	2012-03-26	Completed
An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine Versus Non-Clozapine Antipsychotics in Individuals With Treatment-resistant Schizophrenia [NCT05741502]	Phase 4	60 participants (Anticipated)	Interventional	2023-08-16	Recruiting
Algorithm Guided Treatment Strategies for Bipolar Depression [NCT01938859]	Phase 4	360 participants (Anticipated)	Interventional	2012-06-30	Active, not recruiting
A 1-year, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Phase 3 Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Sustained-release Quetiapine Fumarate (SEROQUEL) or Placebo (A [NCT00228462]	Phase 3	197 participants (Actual)	Interventional	2005-03-31	Completed
Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Lithium as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbrevia [NCT00206141]	Phase 3	672 participants	Interventional	2005-08-31	Completed
A Randomized, Placebo-Controlled Trial of Quetiapine (Seroquel) Monotherapy in the Treatment of PTSD [NCT00237393]	Phase 4	80 participants (Actual)	Interventional	2003-08-31	Completed
A Single-Blind Prospective Study of Quetiapine for the Treatment of Mood Disorders in Adolescents [NCT00221468]	Phase 3	20 participants (Actual)	Interventional	2003-06-30	Completed
A Randomized, Open-Label, Single Dose, Cross-over Study of Gastric Emptying Rate: SEP-363856 vs Prior Antipsychotic Standard of Care in Subjects With Schizophrenia [NCT05402111]	Phase 1	31 participants (Actual)	Interventional	2022-06-13	Completed
Comparison of Venlafaxine Augmentation With Quetiapine v.s. Placebo in Treatment Resistant Depression [NCT00253266]	Phase 4	126 participants (Actual)	Interventional	2008-04-30	Completed
Safety and Efficacy of Seroquel in First Episode Schizophrenia [NCT00254241]	Phase 4	80 participants	Interventional	2002-05-31	Completed
The Effect of Quetiapine on Psychotic-Like Symptoms in Borderline Personality Disordered Patients: A Randomised Placebo-Controlled Trial [NCT00254748]	Phase 2	40 participants (Anticipated)	Interventional	2004-06-30	Completed
An Open Label, Double-blind Discontinuation Study of Quetiapine (Extended Release) XR in Social Anxiety Disorder [NCT00606541]	Early Phase 1	55 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to The study was terminated by the sponsor due to budgetary issues)
Role of Quetiapine in the Prevention of ICU Delirium in Elderly Patients at a High Risk [NCT05793632]	Phase 2	90 participants (Actual)	Interventional	2023-03-01	Completed
A Phase II, 6-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial With a Quetiapine Arm to Evaluate the Efficacy, Tolerability and Safety of Oral BI 1358894 in Patients With Major Depressive Disorder With In [NCT04521478]	Phase 2	389 participants (Actual)	Interventional	2020-11-20	Active, not recruiting
Quetiapine vs. Placebo in Alcohol Relapse Prevention - a Pilot Study [NCT00561587]	Phase 2	40 participants (Anticipated)	Interventional	2007-11-30	Completed
Methamphetamine-Quetiapine Interaction in Humans: A Pilot Study [NCT00567866]	Early Phase 1	10 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to Study was terminated due to insufficient funds)
A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study [NCT00584688]	Phase 2	24 participants (Actual)	Interventional	2007-02-28	Terminated(stopped due to Lack of Enrollment)
Acute Psychotherapy for Bipolar II Depression [NCT01133821]	Phase 4	92 participants (Actual)	Interventional	2010-08-31	Completed
A Random Assignment,Parallel Group, Open Label Comparison of Clinical Outcomes and Resource Utilization Among Bipolar Disorder Patients Receiving Either Long Acting Injectable Risperidone Microspheres (Risperdal Consta® ) or Other Second Generation Oral A [NCT00177164]	Phase 3	50 participants (Actual)	Interventional	2003-11-30	Completed
A Randomized, Double-Blind, Placebo Controlled Study Of Quetiapine SR (QTP) As Adjunctive Treatment In Mixed States (MS) Of Bipolar Disorder [NCT01195363]	Phase 4	28 participants (Actual)	Interventional	2007-04-30	Completed
A Randomized, Open Label, Two-Treatment, Two-Period, Two-Sequence, Crossover, Single Dose, Bioequivalence Study of Quetiapine Fumarate Tablets 25 mg With Seroquel® 25 mg in Normal, Healthy, Adult, Human Subjects, Under Fasting Condition [NCT01603173]	Phase 1	54 participants (Actual)	Interventional	2011-04-30	Completed
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies [NCT02893371]		1,037,352 participants (Actual)	Observational	2016-09-30	Completed
Comparison of Single-Dose Plasma and Blood Concentrations of Aripiprazole, Olanzapine, Quetiapine, Paliperidone and Risperidone After Capillary and Venous Blood Sample Collection [NCT01607762]	Phase 1	31 participants (Actual)	Interventional	2012-02-29	Completed
Comparison of Quetiapine Extended-Release (Seroquel XR™) and Risperidone in the Treatment of Depressive Symptoms, in Schizophrenic or Schizoaffective Patients: A Randomized, Open Label, Flexible-dose, Parallel Group, Non Inferiority, 12-week Study [NCT00640562]	Phase 3	216 participants (Actual)	Interventional	2008-02-29	Completed
Seroquel XR for the Treatment of Peri and Postmenopausal Women With Major Depressive Disorder: Impact on Mood, Physical Symptoms, Sleep and Quality of Life [NCT00723970]	Phase 4	40 participants (Actual)	Interventional	2007-06-30	Completed
Randomized, Placebo-Controlled Effectiveness Study of Quetiapine XR in Co-Morbid Depressive and Anxiety Disorders [NCT00688818]		108 participants (Actual)	Interventional	2008-06-30	Completed
A Phase IV STudy of the Effectiveness of Quetiapine Extended Release 600mg Once a Day to Control the Symptoms of Manic Phase of Bipolar Disorder. [NCT00521365]	Phase 4	88 participants (Actual)	Interventional	2008-05-31	Completed
A 6-Week, Multi-centre, Double-blind, Double-dummy, Chlorpromazine-Controlled Randomised Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Extended-Release in the Treatment of Schizophrenic Patients With Acute Episode [NCT00882518]	Phase 3	388 participants (Actual)	Interventional	2009-04-30	Completed
Effects of Seroquel on Sleep Architecture in Patients With Bipolar Depression or Major Depressive Disorder - An Open Label Study [NCT00616889]		15 participants (Actual)	Observational	2006-05-31	Completed
A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Quetiapine Fumarate Sustained Release(Seroquel SRTM) in the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome. [NCT00675896]	Phase 4	120 participants (Anticipated)	Interventional	2007-04-30	Completed
The Interest of a Specific Combined Treatment (Psychotherapy and Pharmacotherapy) in Patients With Dissociative Disorders [NCT00630981]		30 participants (Actual)	Observational	2008-02-29	Active, not recruiting
A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated [NCT01157351]	Phase 4	450 participants (Actual)	Interventional	2010-05-31	Completed
A Study of Individualized Diagnosis and Treatment for Major Depressive Disorder With Atypical Features [NCT04209166]		780 participants (Anticipated)	Interventional	2019-08-12	Recruiting
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment [NCT02650102]	Phase 1/Phase 2	200 participants (Anticipated)	Interventional	2013-01-31	Recruiting
The Efficacy and Tolerability of Seroquel XR Combined With a Selective Serotonin Re-Uptake Inhibitor Versus Seroquel XR Monotherapy in the Acute Treatment of Major Depressive Disorder With Psychotic Features [NCT00955474]	Phase 4	32 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to AstraZeneca halted funding; patent expired for Seroquel (Quetiapine) in 2012)
Quetiapine Induced Neuroplasticity in Schizophrenic Patients: A Combined Transcranial Magnetic Stimulation (TMS) and Voxel-based Morphometry (VBM) Study [NCT00554658]	Phase 4	30 participants (Actual)	Interventional	2008-03-31	Completed
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (SEROQUEL®) Compared With Placebo in the Treatment of Generalized Anxiety Disorder [NCT00329264]	Phase 3	876 participants (Anticipated)	Interventional	2006-04-30	Completed
A 6-Week, Multicenter, Double-Blind, Double-Dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Acutely Ill Patients With Schizophrenia [NCT00085891]	Phase 3	535 participants	Interventional	2004-06-30	Completed
A 16-Week, Randomized, Controlled Trial of the Effect of Aripiprazole Versus Standard of Care on Non-HDL Cholesterol Among Patients With Schizophrenia and Bipolar I Disorder Who Have Pre-existing Metabolic Syndrome [NCT00857818]	Phase 3	64 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Slow Accrual)
Effectiveness of Quetiapine XR Versus Sertraline in Acute Depression as add-on Therapy to Previous Mood Stabilizer Treatment: a Pilot Study [NCT00857584]	Phase 3	27 participants (Actual)	Interventional	2009-05-31	Completed
Seroquel on Glucose Metabolism [NCT00214578]	Phase 4	572 participants	Interventional	2004-04-30	Completed
Clinical Trial to Investigate the Effect on Corrected QT Interval Prolongation by Psychotropic Drugs in Healthy Korean Adults After a Single Oral Administration of Escitalopram, Quetiapine, and Moxifloxacin [NCT01871701]	Phase 1	40 participants (Actual)	Interventional	2012-11-30	Completed
Phase I Study of FK949E - Multiple Dose Study of Non-Elderly Adult Patients With Major Depressive Disorder (MDD) [NCT01871974]	Phase 1	16 participants (Actual)	Interventional	2009-05-31	Completed
Pharmacokinetic Study of FK949E -A Pharmacokinetic Study in Healthy Male Volunteers to Investigate the Effect of Food on the Pharmacokinetics of FK949E [NCT01871987]	Phase 1	24 participants (Actual)	Interventional	2009-06-30	Completed
Phase 1 Study of Insulin Sensitivity, Adjusted β-Cell Function and Adiponectin Among Lean Drug-naïve Schizophrenic Subjects Treated With Atypical Antipsychotic Drugs [NCT00528359]		36 participants (Actual)	Observational	2005-10-31	Completed
Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression [NCT03207438]	Phase 4	1,790 participants (Actual)	Interventional	2006-04-30	Completed
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel SR®) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Depression [NCT00422214]	Phase 3	400 participants	Interventional	2006-12-31	Completed
A Double Dummy & Double Blind, Multicenter, Randomized Study of the Efficacy and Safety of Seroquel (Quetiapine Fumarate) and Lithium as Monotherapy in the Treatment of Acute Mania in Patients With Bipolar Disorder [NCT00448578]	Phase 3	150 participants	Interventional	2005-08-31	Completed
RAPID-An Open-Label Randomized, Multicenter Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immediate Release), Over 14 Days, in Acute Schizophrenia/Schizoaffective Disorder (Rapid Versus Conventional Titration) [NCT00457899]	Phase 3	234 participants (Anticipated)	Interventional	2007-07-31	Terminated(stopped due to Study terminated due to poor recruitment)
12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety [NCT00352469]	Phase 4	20 participants (Anticipated)	Interventional	2006-02-28	Completed
[NCT00462618]	Phase 2/Phase 3	32 participants (Actual)	Interventional	2007-04-30	Completed
Antipsychotic Polypharmacy in Schizophrenia [NCT00493233]		100 participants (Anticipated)	Interventional	2006-11-30	Completed
Double-Blind, Randomized, Parallel-Group Study With Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder Wi [NCT04513912]	Phase 3	757 participants (Actual)	Interventional	2020-09-15	Completed
Single-arm, Open-label and Multicenter Phase IV Study: Efficacy and Safety of Quetiapine in Treating Affective Symptoms of Patients With First-episode Psychosis - a Pilot Study [NCT00511277]	Phase 4	60 participants (Anticipated)	Interventional	2007-08-31	Completed
Schizophrenia Sensory Gating Deficit With Quetiapine [NCT00536783]		20 participants (Anticipated)	Observational	2004-04-30	Completed
Open-Label Pilot Study of Quetiapine Treatment for Cannabis Dependence [NCT00954681]	Phase 2	15 participants (Actual)	Interventional	2009-08-31	Completed
Quetiapine and the Dopaminergic Epigenetic Control - a Pilot Study [NCT00370500]	Phase 4	100 participants (Actual)	Interventional	2007-04-30	Completed
A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Immediate-Release Formulation of Quetiapine Fumarate as Potentiation of Selective Serotonin Reuptake Inhibitors, and Serotonin Norepinephrine Reuptake Inhibito [NCT00229645]	Phase 4	60 participants	Interventional	2003-11-30	Completed
Differences in Cognitive Function Due to Acute Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Out-Patients. [NCT00097032]	Phase 3	30 participants (Actual)	Interventional	2004-10-31	Completed
Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence [NCT00232336]	Phase 4	42 participants (Actual)	Interventional	2003-10-31	Completed
A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder [NCT00232414]	Phase 3	30 participants (Anticipated)	Interventional	2005-10-31	Completed
Quetiapine for the Treatment of Insomnia Associated With Alzheimer's Disease [NCT00232570]		18 participants (Anticipated)	Interventional	2005-11-30	Recruiting
A Multicenter, Randomized, Naturalistic, Open-Label Study Between Aripiprazole and Standard of Care in the Management of Community-Treated Schizophrenic Patients (Schizophrenia Trial of Aripiprazole - STAR) [NCT00237913]	Phase 3	700 participants	Interventional	2004-07-31	Completed
Quetiapine (Seroquel) Maintenance Treatment in Early Onset Bipolar Spectrum Disorders: An Open Prospective Longitudinal Study of the Effectiveness of Quetiapine Monotherapy in Preventing Relapse and Minimizing Neurocognitive Dysfunction Among Adolescents [NCT00252226]	Phase 3	100 participants (Anticipated)	Interventional	2004-06-30	Completed
A Multi-Centre, Double-Blind, Randomised-Withdrawal, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR™) As Monotherapy in the Maintenance Treatment of Patients With Major D [NCT00278941]	Phase 3	3,000 participants	Interventional	2005-12-31	Completed
Dopaminergic Modulation of Choroidal Blood Flow Changes During Dark/Light Transitions [NCT00280501]		21 participants (Actual)	Interventional	2005-08-31	Completed
Multicentre, Double-blind, Randomised, Parallel Group, Placebo Controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Paroxetine as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbrev [NCT00119652]	Phase 3	676 participants (Actual)	Interventional	2005-05-31	Completed
Multicenter, Randomized, Parallel-Group, Double-Blind, Phase 3 Comparison of the Efficacy & Safety of Quetiapine Fumarate to Placebo as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patient [NCT00081380]	Phase 3	710 participants	Interventional	2004-03-31	Completed
Efficacy of Quetiapine in Generalised Social Anxiety Disorder, a Double-blind, Placebo-controlled Study [NCT00302770]	Phase 3	50 participants (Anticipated)	Interventional	2006-06-30	Terminated(stopped due to This study was terminated due to poor enrollment)
Interaction Between IV Cocaine and Quetiapine [NCT00087750]	Phase 1	12 participants	Interventional	2003-10-31	Active, not recruiting
Efficacy of Quetiapine Compared to Risperidone on Negative Symptoms and Cognition With Regard to Underlying Neurobiological Mechanisms and Brain Activation. [NCT00305422]	Phase 3	45 participants (Actual)	Interventional	2001-11-30	Completed
The Comparison of Efficacy and Safety of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder [NCT00090012]	Phase 4	340 participants	Interventional	2004-07-31	Completed
Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder [NCT00122070]	Phase 3	15 participants (Actual)	Interventional	2005-05-31	Completed
A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 3b Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets Compared With Placebo in Adolescents With Schizophrenia (Abbreviate [NCT00090324]	Phase 3	249 participants (Anticipated)	Interventional	2004-09-30	Completed
Quetiapine for Primary Insomnia Patients : A Randomized Controlled Trial [NCT00328822]		16 participants (Anticipated)	Interventional	2006-12-31	Completed
A Canadian, Multicenter, Double-Blind, Randomized, Parallel-Group Study of the Safety, Tolerability, and Efficacy of Treatment With Higher Doses of Quetiapine Fumarate (Seroquel®) Greater Than 800 mg/Day in Schizophrenic or Schizoaffective Subjects. [NCT00328978]	Phase 3	330 participants	Interventional	2003-10-31	Completed
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (SEROQUEL®) Compared With Placebo in the Treatment of Generalized Anxiety Disorder [NCT00329446]	Phase 3	800 participants (Anticipated)	Interventional	2006-04-30	Completed
A Confirmatory Multicenter, Double-blind, Randomized, Placebo Controlled Study of the Use of Quetiapine Fumarate (SEROQUEL) in the Treatment of Patients With Bipolar Depression [NCT00083954]	Phase 3	530 participants	Interventional	2004-06-30	Completed
A Double-Blind Study of Quetiapine Fumarate (Seroquel) for the Treatment of Type A vs.Type B Alcoholics. [NCT00124059]	Phase 3	61 participants (Actual)	Interventional	2003-03-31	Completed
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled and Active-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (SEROQUEL®) as Monotherapy in the Treatment of Patients With MDD [NCT00321490]	Phase 3	600 participants	Interventional	2006-04-30	Completed
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Paliperidone ER Compared to Quetiapine in Subjects With an Acute Exacerbation of Schizophrenia [NCT00334126]	Phase 3	399 participants (Actual)	Interventional	2006-04-30	Completed
A 3-wk, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 3b Study of the Efficacy & Safety of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in the Treatment of Children & Adolescents With Bipolar I Mania (Abbrev [NCT00090311]	Phase 3	220 participants (Actual)	Interventional	2004-07-31	Completed
A Multicenter, Open-Label, Parallel-Group, Randomized, Flexible Dose Study To Evaluate the Safety and Tolerability of Switching From Existing Atypical Antipsychotics to Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder [NCT00347425]	Phase 3	286 participants (Actual)	Interventional	2006-12-31	Completed
A 24-Week, Multi-Centre, Open-Label, Single-Arm, Phase IV Study of the Efficacy and Safety of Seroquel (Quetiapine Fumarate) With Daily Dose 600mg-750mg as Mono-Therapy in the Treatment of Acute Schizophrenic Patients [NCT00428350]	Phase 4	120 participants (Anticipated)	Interventional	2006-12-31	Completed
Phase IV Study to Investigate if Valproate Add-on Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients [NCT00139074]	Phase 4	17 participants (Actual)	Interventional	2005-07-31	Terminated(stopped due to terminated due to very low recruitment rate (27 June 2006))
A Multi-Centre, Double-Blind, Randomised, Parallel Group, Placebo- Controlled and Active Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) as Mono- Therapy in the Treatment of Adult Patients Wit [NCT00351169]	Phase 3	450 participants (Anticipated)	Interventional	2006-05-31	Completed
A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major [NCT00351910]	Phase 3	494 participants (Actual)	Interventional	2006-05-31	Completed
A Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Versus Placebo as Adjunct Therapy With Mood Stabilizers (Lithium or Divalproex) for the Trea [NCT00114686]	Phase 3	350 participants	Interventional	2006-01-31	Completed
Randomized, Open Label, 8-Week Study of Quetiapine and Risperidone on Quality of Life in Female With Schizophrenia [NCT00498004]	Phase 4	100 participants (Anticipated)	Interventional	2007-08-31	Terminated(stopped due to difficult to recruit subject)
Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study [NCT00466609]	Phase 4	54 participants (Actual)	Interventional	2007-05-31	Completed
Quetiapine XR Monotherapy or Adjunctive Therapy to Antidepressants in the Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder [NCT00868374]	Phase 3	23 participants (Actual)	Interventional	2008-06-30	Terminated(stopped due to Study terminated due to low enrollment)
Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer And a Classic Mood Stabilizer for Bipolar Disorder [NCT01331304]	Phase 4	482 participants (Actual)	Interventional	2010-09-30	Completed
Tolerability, Safety, And Efficacy Of Ziprasidone (80 - 160 Mg/D) Versus Olanzapine (10 - 20 Mg/D), Risperidone (4 - 8 Mg/D) Or Quetiapine (300 - 750 Mg/D) In Pretreated Patients With Schizophrenia, Schizoaffective Disorder Or Schizophreniform Disorders - [NCT00159770]	Phase 3	290 participants	Interventional	2001-11-30	Completed
[NCT00161018]	Phase 3	150 participants	Interventional	2003-11-30	Completed
Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone [NCT00208143]	Phase 4	20 participants	Interventional	2003-11-30	Completed
Effectiveness of Atypical Vs Conventional Antipsychotics [NCT00237861]	Phase 4	0 participants	Interventional		Completed
Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in the Treatment of Patients With Acute Schizophrenia - a Multicentre, Double-Blind, Parallel Group, Randomized Study [NCT00254787]	Phase 2	30 participants	Interventional	2005-06-30	Completed
An International, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase IV Study of the Safety and Efficacy of Lithium Versus Placebo as an Add on to SEROQUEL XR (Quetiapine Fumarate) in Adult Patients With Acute Mania [NCT00931723]	Phase 4	356 participants (Actual)	Interventional	2009-06-30	Completed
Functional and Neurochemical Brain Changes in First-episode Bipolar Mania Following Successful Treatment With Lithium or Quetiapine [NCT00609193]		81 participants (Actual)	Observational	2008-01-31	Completed
A Phase IV Prospective, Double-blind, Double-dummy, Randomised, Crossover Study to Assess the Impact on Daily Cognitive Functioning of Quetiapine Fumarate Immediate Release (Seroquel IR®) Dosed Twice Daily and Quetiapine Fumarate Extended Release (Seroque [NCT01213836]	Phase 4	75 participants (Actual)	Interventional	2010-11-30	Completed
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression [NCT01256177]	Phase 3	361 participants (Actual)	Interventional	2010-12-31	Completed
A Naturalistic, Prospective, Single Centre, Double Blinded, Fixed Dose, Randomised, Four Week Comparison Study Investigating Efficacy, Tolerability and Safety of 200 mg Per Day Versus 400 mg Per Day Quetiapine Fumarate in 200 Drug naïve First Episode Psyc [NCT00449397]	Phase 3	150 participants	Interventional	2003-07-31	Completed
A Randomised, Controlled Trial to Investigate the Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. [NCT05973786]	Phase 4	418 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
An Open Label Dose Titration Study of Quetiapine XR in the Treatment of Postpartum Depression in Nonlactating Women Diagnosed With Bipolar Disorder (BD), Type II. [NCT01527448]		26 participants (Actual)	Interventional	2008-04-30	Completed
Effects of Quetiapine on Ultrastructural Hippocampal and Neurochemical Changes in Patients With Bipolar Disorder: Searching for Antidepressant and Mood Stabilising Neurophysiology [NCT01552837]		33 participants (Actual)	Interventional	2007-12-31	Completed
A Multicenter, Randomized, Parallel-Group, Double-Blind, Phase 3 Comparison of the Efficacy & Safety of Quetiapine Fumarate to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Valproate) in the Maintenance Treatment of Bipolar I Disorder in Ad [NCT00107731]	Phase 3	710 participants	Interventional	2004-04-30	Completed
A Randomized, Multicenter, Double-Blind, Parallel Group Study To Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients [NCT00396214]	Phase 3	83 participants (Actual)	Interventional	2007-04-30	Terminated(stopped due to This trial discontinued on 2 May 2008 due to lack of enrolment)
Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial) [NCT00014001]	Phase 4	1,600 participants	Interventional	2000-12-31	Completed
Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) [NCT00043849]	Phase 4	60 participants	Interventional	2002-07-31	Completed
Treatment and Outcome of Early Onset Bipolar Disorder [NCT00048802]	Phase 4	40 participants	Interventional	2002-08-31	Completed
Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial) [NCT00015548]		450 participants	Interventional	2001-03-31	Completed
Predicting the Optimal Pharmacotherapy for Outpatients With Schizophrenia [NCT00018642]		0 participants	Interventional	1997-04-30	Completed
[NCT00034905]	Phase 4	0 participants	Interventional	2001-07-31	Completed
Psychopharmacologic Aspects of Motor Slowing in Schizophrenia [NCT00018668]	Phase 4	0 participants	Interventional	2000-10-31	Completed
6-week Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Evaluate the Feasibility of Switching From Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate in Outpatients With Schizophrenia (Abbrevia [NCT00206128]	Phase 3	454 participants (Actual)	Interventional	2004-11-30	Completed
5-HT2A-receptor Binding: Implications for the Pathophysiology of Schizophrenia and Effects of Treatment With Antipsychotic Drugs [NCT00207064]		46 participants (Actual)	Interventional	2004-04-30	Completed
Randomized Comparison of Monotherapy (Risperidone, Quetiapine, or Olanzapine) Versus Combination Therapy (Risperidone, Quetiapine, or Olanzapine + Divalproex)in the Management of Dementia With Agitation: A Pilot Comparison of Two Standard Therapies [NCT00208819]	Phase 4	50 participants (Anticipated)	Interventional	2003-09-30	Completed
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Quetiapine in Social Anxiety Disorder [NCT00215254]	Phase 2/Phase 3	15 participants	Interventional	2004-03-31	Completed
A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence [NCT00223210]	Phase 4	100 participants (Actual)	Interventional	2005-11-30	Completed
A Randomized, Double Blind Study to Evaluate the Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder [NCT00061802]	Phase 4	225 participants (Actual)	Interventional	2003-06-30	Completed
A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Alcohol Abuse/ Dependence. [NCT00223249]	Phase 4	115 participants (Actual)	Interventional	2002-11-30	Completed
Preventing Relapse: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE) [NCT00330863]	Phase 4	357 participants (Actual)	Interventional	2006-05-31	Completed
Psychotherapy for Bipolar II Depression, Pilot Study, Phase II [NCT00411463]	Phase 2/Phase 3	25 participants (Actual)	Interventional	2006-12-31	Completed
CONSTATRE: Risperdal Consta Trial Of Relapse Prevention And Effectiveness [NCT00216476]	Phase 3	753 participants (Actual)	Interventional	2004-10-31	Completed
Glucose and Lipid Metabolism on Antipsychotic Medication [NCT00515723]		96 participants (Actual)	Interventional	2001-09-30	Completed
A Phase II Double-blind, Placebo-controlled Trial of Quetiapine for Frequent, Heavy Drinkers (Seroquel2) [NCT00674765]	Phase 2	156 participants (Actual)	Interventional	2008-01-31	Completed
Open-label Multicentre Study on Efficacy and Safety of Oral Quetiapine (Seroquel XR) in Adults With Schizophrenia [NCT00852631]	Phase 3	28 participants (Actual)	Interventional	2009-02-28	Terminated(stopped due to The study was prematurely terminated due to insufficient recruitment.)
Seroquel XR for the Management of Borderline Personality Disorder (BPD) [NCT00880919]	Phase 3	95 participants (Actual)	Interventional	2008-06-30	Completed
Neuroleptic Induced Movement Disorders in Older Patients [NCT00255879]	Phase 1	250 participants	Interventional	1999-01-31	Completed
A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder Outpatients With Current Stimulant Dependence [NCT00227123]		96 participants (Actual)	Interventional	2002-10-31	Completed
Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia [NCT00231101]		40 participants	Interventional	2004-01-31	Recruiting
A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching Any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL®) in Patients With Schizophrenia [NCT00234377]	Phase 3	550 participants	Interventional	2004-11-30	Completed
Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study [NCT00254735]	Phase 3	44 participants (Actual)	Interventional	2002-04-30	Completed
Pilot Study of the Efficacy and Safety of Quetiapine Compared With Valproate in the Treatment of Patients With Bipolar Disorder and Rapid Cycling: an Open Trial [NCT00254774]	Phase 3	44 participants (Actual)	Interventional	2002-01-31	Completed
Fast Titration Of Quetiapine Versus Currently Approved Titration: A Randomised, Multicentre, Parallel Group Open Trial In Schizophrenia And Schizoaffective Disorder [NCT00254813]	Phase 3	150 participants	Interventional	2004-10-31	Completed
An Open, Randomised, Parallel, Three Treatment Groups, Multicentre, Phase IV Study - in Real Life - to Compare the Change in Social Outcome of Quetiapine Fumarate (Seroquel®) Combined With Cognitive Remediation Therapy to Conventional Treatment in Patient [NCT00255515]	Phase 4	85 participants (Actual)	Interventional	2005-09-30	Completed
A Randomized, Open Label, Two-Treatment, Two-Period, Two-Sequence, Crossover, Single Dose, Bioequivalence Study of Quetiapine Fumarate Tablets 25 mg With Seroquel® 25 mg in Normal, Healthy, Adult, Human Subjects, Under Fed Condition [NCT01603186]	Phase 1	54 participants (Actual)	Interventional	2011-04-30	Completed
A Multicentre, Parallel Group, Randomised, Double Blind, Placebo Controlled Study of the Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder [NCT00306540]	Phase 3	90 participants (Anticipated)	Interventional	2004-12-31	Completed
Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Quetiapine Fumarate and Lithium as Monotherapy for up to 104 Weeks Maintenance Treatment of Bipolar I Disorder in Adult Patients [NCT00314184]	Phase 3	1,255 participants (Actual)	Interventional	2005-03-31	Completed
A Randomized, Double-Blind, Placebo-Controlled Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms [NCT00277667]	Phase 3	40 participants (Anticipated)	Interventional	2004-02-29	Completed
Depakote ER vs. Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia [NCT00315900]	Phase 3	20 participants (Actual)	Interventional	2006-05-01	Terminated(stopped due to Investigator closed study and left VAMC.)
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone Compared With Flexibly-Dosed Quetiapine and Placebo in the Treatment of Acute M [NCT00309699]	Phase 3	493 participants (Actual)	Interventional	2006-04-30	Completed
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (SEROQUEL®) as Monotherapy in the Treatment of Patients With MDD [NCT00320268]	Phase 3	600 participants	Interventional	2006-04-30	Completed
Fast Titration of Quetiapine Versus Conventional Titration in the Treatment of Schizophrenia/Schizoaffective Disorder: a Randomised, Parallel Group Open Trial [NCT00304473]	Phase 3	40 participants	Interventional	2004-08-31	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine o [NCT00325689]	Phase 4	323 participants (Actual)	Interventional	2006-07-31	Completed
The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients [NCT00295412]	Phase 4	0 participants	Interventional		Completed
A Randomized, Double-Blind, Parallel-Group, Fixed Dose, Clinical Trial of Quetiapine 600 mg/Day vs 1200 mg/Day for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder [NCT00297947]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2004-12-31	Completed
A Multi-center, Randomized, Open, Treatment-switching Study From Orally Administered Antipsychotic Monotherapy in the Treatment of Chronic Schizophrenic and Schizoaffective Patients [NCT00304616]	Phase 4	500 participants	Interventional	2004-10-31	Completed
Duration of Maintenance Anti-psychotic Therapy After First -Episode Schizophrenia: a Double-blind Randomized Placebo-control Relapse Prevention Study [NCT00334035]	Phase 4	169 participants (Actual)	Interventional	2003-08-31	Completed
A Multi-Centre,Double-Blind,Randomised-Withdrawal,Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine SR as Monotherapy in the Maintenance Treatment of Patients With GAD Following an Open-Label Stabilisation Period [NCT00314210]	Phase 3	575 participants	Interventional	2006-03-31	Completed
An Open-Label, Randomised, 2-Period, 2-Treatment, 2-sequence, Crossover, Steady State Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets [Test Formulation; Torrent Pharmaceuticals Ltd., India] Versus Seroquel® 300 mg Tablet [Reference Formulation; [NCT01634373]	Phase 1	0 participants	Interventional		Completed
An Open-Label, Randomised, 2-Period, 2-Treatment, 2-sequence, Crossover, Single-dose Bioequivalence Study of Quetiapine 25 mg Tablet [Test Formulation; Torrent Pharmaceuticals Ltd., India] Versus Seroquel® 25 mg Tablet [Reference Formulation; AstraZeneca, [NCT01634386]	Phase 1	0 participants	Interventional		Completed
An Open-Label, Randomised, 2-Period, 2-Treatment, 2-sequence, Crossover Single-dose Bioequivalence Study of Quetiapine 25 mg Tablet [Test Formulation; Torrent Pharmaceuticals Ltd., India] Versus Seroquel® 25 mg Tablet [Reference Formulation; AstraZeneca, [NCT01634399]	Phase 1	0 participants	Interventional		Completed
[NCT03007303]		30 participants (Anticipated)	Observational [Patient Registry]	2016-06-30	Recruiting
A Pilot Study on the Safety, Tolerability, and Effectiveness of Quetiapine in Postpartum Depression [NCT04950868]	Phase 1	30 participants (Anticipated)	Interventional	2022-03-18	Recruiting
Quetiapine as a Prophylactic Agent for Early Postoperative Delirium in High Risk Patients in Open Heart Surgeries [NCT05801289]		60 participants (Anticipated)	Interventional	2022-12-04	Recruiting
A Longitudinal Comparison of Aripiprazole vs. Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI [NCT01739127]		83 participants (Actual)	Observational	2012-11-30	Completed
Randomized Multicentric Open-label Phase III Clinical Trial to Evaluate the Efficacy of Continual Treatment Versus Discontinuation Based in the Presence of Prodromes in a First Episode of Non-affective Psychosis. [NCT01765829]	Phase 3	104 participants (Anticipated)	Interventional	2012-11-30	Recruiting
Randomized Controlled Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium : The Haloquet Trial [NCT01811459]	Phase 3	107 participants (Actual)	Interventional	2013-02-28	Completed
Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building [NCT04446234]	Phase 4	350 participants (Anticipated)	Interventional	2021-05-31	Not yet recruiting
Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction in Patients Undergoing High-dose Antipsychotic Therapy [NCT03019887]		139 participants (Actual)	Interventional	2011-04-30	Completed
A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator Controlled Trial of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial [NCT01727726]	Phase 3	2,182 participants (Actual)	Interventional	2012-12-31	Completed
Phase 2 Study of FK949E - Double-blind, Placebo-controlled, Comparative Study in Major Depressive Disorder Patients With Inadequate Response to Existing Antidepressants [NCT01725282]	Phase 2	172 participants (Actual)	Interventional	2011-12-14	Completed
Comparative Safety, Tolerability, and Effectiveness of Lithium Versus Quetiapine in Patients Across the Spectrum of Bipolar Disorder [NCT01526148]	Phase 4	42 participants (Actual)	Interventional	2012-01-31	Terminated(stopped due to Ran out of funding)
A Prospective, Sixteen-Week, Double-Blind, Placebo-Controlled, Trial of Seroquel in Combination With Treatment as Usual in Patients With GAD and Remitted Comorbid Opiate Dependence [NCT00668265]	Phase 4	14 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to The study was not completed, the funding sponsor lost interest.)
A Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia [NCT04115319]	Phase 3	475 participants (Actual)	Interventional	2019-11-15	Completed
A Randomised, Controlled Trial to Investigate the Effect of an Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. [NCT05603104]	Phase 3	1,254 participants (Anticipated)	Interventional	2023-08-01	Not yet recruiting
Brain Imaging of Quetiapine Response in Anxious Depression [NCT00982345]	Phase 4	20 participants (Actual)	Interventional	2009-03-31	Completed
Phase I Study of FK949E - Phase I Oral Multiple-dose Study in Patients With Major Depressive Disorder [NCT01924520]	Phase 1	32 participants (Actual)	Interventional	2010-11-30	Completed
Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum [NCT02978534]		4 participants (Actual)	Observational	2016-03-31	Completed
Phase IV Study of Quetiapine XR Aimed at Disability and Cognitive Impairments. [NCT00746421]	Phase 4	32 participants (Actual)	Interventional	2010-01-31	Terminated(stopped due to Sponsor withdrew funding)
Trazodone vs. Quetiapine for the Treatment of ICU Delirium: A Prospective Observational Pilot Study [NCT05307003]		60 participants (Anticipated)	Observational	2023-04-01	Recruiting
Effects of Sleep Disorders and Sedative-hypnotic Medications on Health-related Quality of Life in Chronic Kidney Disease Patients [NCT05240261]	Phase 1	60 participants (Anticipated)	Interventional	2022-05-01	Not yet recruiting
A Practical, Pilot, Randomized, Controlled Trial of Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium [NCT04513314]	Phase 4	0 participants (Actual)	Interventional	2023-03-28	Withdrawn(stopped due to coronavirus omicron variant infection typically not associated with delirium and agitation severely hampered recruitment.)
Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia [NCT00156715]	Phase 4	23 participants (Actual)	Interventional	2004-03-31	Completed
A Randomised Pragmatic Trial Comparing the Clinical and Cost Effectiveness of Lithium and Quetiapine Augmentation in Treatment Resistant Depression [NCT03004521]	Phase 4	276 participants (Anticipated)	Interventional	2016-11-30	Recruiting
Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans: an Open (e.g. Unblinded) Randomized Stay-Switch Pilot Trial [NCT01662297]	Phase 4	1 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to it became clear that recruitment was infeasible)
Quetiapine Pharmacotherapy for Cannabis Dependence [NCT01697709]	Phase 2	130 participants (Actual)	Interventional	2012-10-01	Completed
Divalproex Extended Release and Placebo, Lithium, or Quetiapine for Mania [NCT00183443]	Phase 3	75 participants (Actual)	Interventional	2005-02-28	Completed
CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin and Quetiapine for Parkinson''s Disease Psychosis (C-SAPP) [NCT04373317]	Phase 4	358 participants (Anticipated)	Interventional	2022-10-24	Recruiting
"Observational Study on the Effect of Switch to Lurasidone or Other Antipsychothics on Metabolic and Weight Changes in Subjects With Schizophrenia" [NCT04312503]		95 participants (Actual)	Observational	2020-07-13	Completed
A 6-Month, Multicenter, Double-Blind, Randomized, Flexible-Dose, Parallel-Group Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Subjects With Majo [NCT03321526]	Phase 2	107 participants (Actual)	Interventional	2017-12-12	Completed
A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Quetiapine Fumarate 25 mg Tablets Under Fed Conditions [NCT01570894]		42 participants (Actual)	Interventional	2007-07-31	Completed
A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Quetiapine Fumarate 25 mg Tablets Under Fasting Conditions [NCT01570907]		42 participants (Actual)	Interventional	2007-06-30	Completed
A Two Period, Two Treatment, Two Way, Steady State Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Fasting Conditions [NCT01570959]		56 participants (Actual)	Interventional	2007-04-30	Completed
Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents [NCT00393978]	Phase 4	75 participants (Actual)	Interventional	2006-11-30	Completed
A Single-Blind, Randomized, Naturalistic Pilot Study, Comparison of Divalproex ER and Quetiapine for Adults With Acute Mania or Mixed Episodes [NCT00397020]	Phase 4	30 participants (Actual)	Interventional	2006-12-31	Completed
Quetiapine Augmentation to SRIs for Patients With Obsessive Compulsive Disorder, a Double-blind, Placebo-controlled Study [NCT00318539]	Phase 2	90 participants	Interventional	2003-12-31	Completed
An International, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (Seroquel SR™ ) in the Treatment of Generalized Anxiety Disorder (SILV [NCT00322595]	Phase 3	800 participants (Anticipated)	Interventional	2006-05-31	Completed
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major [NCT00326105]	Phase 3	450 participants (Anticipated)	Interventional	2006-04-30	Completed
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR®) as Mono-Therapy in the Treatment of Adult Patients With Major Depressive Disorde [NCT00326144]	Phase 3	310 participants (Actual)	Interventional	2006-04-30	Completed
A Sequential and Parallel Cohort Design to Test the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry [NCT02462473]	Phase 2	9 participants (Actual)	Interventional	2015-05-31	Terminated(stopped due to Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment in Cohorts 2 and 3.)
Study of FK949E - An Open-label, Two-way Crossover Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes [NCT02362412]	Phase 3	22 participants (Actual)	Interventional	2015-02-18	Completed
Long-term Study of FK949E in Elderly Patients -Long-term Study in Elderly Bipolar Disorder Patients With Major Depressive Episodes- [NCT01737268]	Phase 3	20 participants (Actual)	Interventional	2012-10-29	Completed
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Mania [NCT00422123]	Phase 3	447 participants (Actual)	Interventional	2007-01-31	Completed
An Open-Label Study of Quetiapine Added to Oros Methylphenidate in the Treatment of ADHD and Aggressive Behavior [NCT00550147]	Phase 2	30 participants (Actual)	Interventional	2004-02-29	Completed
An Open Label, Randomized, Flexible Dose, 6-week Clinical Trial of the Safety and Efficacy of Divalproex ER vs Quetiapine in the Treatment of Behavioral Symptoms in the Elderly With Moderate to Severe Alzheimer's Dementia [NCT00375557]	Phase 4	0 participants (Actual)	Interventional	2006-10-31	Withdrawn
Efficacy of Quetiapine for Pediatric Delirium [NCT02056171]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2015-03-31	Terminated(stopped due to Unable to recruit subjects at our site within the past year.)
Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders [NCT05840861]		59 participants (Anticipated)	Observational	2020-11-05	Recruiting
A Phase 3 Randomized, Double-Blind, Active-controlled Study to Evaluate the Efficacy and Safety of Lurasidone in Acutely Psychotic Patients With Schizophrenia [NCT03465787]	Phase 3	210 participants (Actual)	Interventional	2018-04-09	Completed
Developing a Single Patient Open-label Trial Tapering Algorithm for Antipsychotics in Long-Term Care - A Pilot Study [NCT02958800]		20 participants (Anticipated)	Interventional	2016-12-31	Recruiting
A Pragmatic Randomized Trial Comparing Antipsychotics in Lewy Body Disease [NCT05590637]	Phase 4	94 participants (Anticipated)	Interventional	2022-04-22	Recruiting
Quetiapine for Bipolar Disorder and Alcohol Dependence [NCT00457197]	Phase 4	90 participants (Actual)	Interventional	2007-03-31	Completed
Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial. [NCT05737511]	Phase 4	80 participants (Anticipated)	Interventional	2023-12-30	Not yet recruiting
Open Label, Non-randomised, Single Arm, Phase IIIB Switch Study: Evaluating the Clinical Benefits of Quetiapine XR in Patients With Schizophrenia and Anxiety Disorder. [NCT01672554]	Phase 3	40 participants (Anticipated)	Interventional	2008-12-31	Active, not recruiting
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]	Phase 3	407 participants (Actual)	Interventional	2015-01-31	Terminated
An Open-Label, Sequential Study of Quetiapine Fumarate Extended Release (XR) and Mirtazapine for the Treatment of Alcohol Dependency in Very Heavy Drinkers [NCT01165541]	Phase 2	20 participants (Actual)	Interventional	2010-09-30	Completed
Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder [NCT01588457]	Phase 4	112 participants (Actual)	Interventional	2011-06-30	Completed
Drug Use-results Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder [NCT03403790]		369 participants (Actual)	Observational	2018-01-15	Completed
Quetiapine Compared With Placebo in the Management of Fibromyalgia [NCT01458964]	Phase 4	42 participants (Actual)	Interventional	2008-01-31	Completed
Comparison of Trazodone vs Quetiapine vs Placebo for the Treatment of ICU Delirium: A Randomized Controlled Trial (The TraQ Study) [NCT05085808]	Phase 4	30 participants (Anticipated)	Interventional	2024-03-01	Not yet recruiting
A Comparison Study of the Efficacy of a Rapid Titration of Quetiapine and Haloperidol in Agitated Adults in an Emergency Setting. [NCT00457366]	Phase 4	72 participants (Actual)	Interventional	2006-05-31	Completed
A Phase 2, Double-Blind, Placebo Controlled Trial to Assess the Efficacy of Quetiapine Fumarate Extended Release for the Treatment of Alcohol Dependence in Very Heavy Drinkers. [NCT00498628]	Phase 2	224 participants (Actual)	Interventional	2007-12-31	Completed
Phase II/III Study of FK949E: Placebo-controlled, Double-blind, Parallel-group Comparative Study and Open-label, Non-controlled Extension Study in Bipolar Disorder Patients With Major Depressive Episodes [NCT01725308]	Phase 2/Phase 3	431 participants (Actual)	Interventional	2012-02-07	Completed
A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder. [NCT00579280]	Phase 4	224 participants (Actual)	Interventional	2007-07-31	Completed
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3) [NCT00790192]	Phase 3	488 participants (Actual)	Interventional	2008-10-31	Completed
Double-blind, Randomized, Active Controlled Study of the Efficacy and Safety of Extended-release Quetiapine Fumarate (Seroquel XR) as Adjunctive Medication Therapy to Cognitive Behavioral Therapy in the Treat,Ent of Patients With Comorbid Major Depression [NCT01971203]		62 participants (Actual)	Interventional	2009-09-30	Completed
Mirtazapine and Quetiapine as Treatment for Postoperative Sleep Disturbance After Fast-track Knee Replacement [NCT04728581]		165 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
A Randomized Controlled Trial of Quetiapine for the Treatment of Youth With Co-occurring Substance Use Disorders and Severe Mood Dysregulation [NCT02845453]	Phase 4	24 participants (Actual)	Interventional	2017-01-20	Completed
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain [NCT01844700]	Phase 4	14 participants (Actual)	Interventional	2013-07-31	Terminated(stopped due to very slow recruitment, no sufficient results)
Clinical Management of Metabolic Problems in Patients With Schizophrenia [NCT00423878]	Phase 4	215 participants (Actual)	Interventional	2007-01-31	Completed
Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Alcohol Use in Adolescents & Young Adults [NCT00550394]	Phase 4	56 participants (Actual)	Interventional	2008-04-30	Completed
An Open Label Study of Seroquel SR® (Quetiapine) for the Treatment of Refractory and Treatment Resistant Functional Bowel Disorders [NCT00617396]		25 participants (Actual)	Interventional	2008-02-29	Completed
A Double-Blind, Placebo-Controlled Trial of the Efficacy of Quetiapine for the Reduction of Cocaine Use [NCT00631748]		60 participants (Actual)	Interventional	2008-02-29	Completed
An Open-label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines in Treatment-refractory Patients With Unipolar Depression or Generalized Anxiety Disorder and Chronic Benzodiazepine Use [NCT01244711]	Phase 4	1 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to Terminated: recruiting or enrolling participants has halted prematurely)
Improving Metabolic Parameters of Antipsychotic Child Treatment (IMPACT) [NCT00806234]	Phase 4	127 participants (Actual)	Interventional	2009-01-31	Completed
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-reference, Flexible-dose Study of Brexpiprazole in Patients With Acute Schizophrenia [NCT01810380]	Phase 3	468 participants (Actual)	Interventional	2013-03-31	Completed
Phase IV Study of the Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II) [NCT02305823]	Phase 4	203 participants (Actual)	Interventional	2005-10-31	Completed
Program to Study the Experience of Using Seroquel ® in Patients With Bipolar Disorder of the First and Second Types in Remission With Signs of Impaired Impulse Control [NCT05098353]		30 participants (Anticipated)	Interventional	2021-04-10	Recruiting
NMDA Antagonists in Bipolar Depression [NCT01833897]	Phase 4	8 participants (Actual)	Interventional	2013-03-31	Completed
Cognitive Control and Functional Connectivity During Resting State in Patients With Heightened Risk of Bipolar Disorder - a Quetiapine Challenge [NCT02451306]		54 participants (Anticipated)	Interventional	2015-06-30	Not yet recruiting
Effectiveness of Switching Antipsychotic Medications [NCT00044655]	Phase 4	219 participants (Actual)	Interventional	2001-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00044655 (1) [back to overview]	Number Who Discontinued Medication Within First 6 Study Months
NCT00113295 (5) [back to overview]	Remission (HAM-A ≤ 7)
NCT00113295 (5) [back to overview]	Response, Clinical Global Impression of Improvement (CGI-I)
NCT00113295 (5) [back to overview]	Depressive Symptoms, Montgomery-Asberg Depression Rating Scale (MADRS)
NCT00113295 (5) [back to overview]	Hamilton Anxiety Scale (HAM-A) Score at Study Endpoint.
NCT00113295 (5) [back to overview]	The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).
NCT00156715 (2) [back to overview]	Mean Number of Drinking Days Per Week
NCT00156715 (2) [back to overview]	Clinical Symptoms
NCT00177164 (4) [back to overview]	Evaluate the Number of Clinical Events (Pooled) Occurring Between 3-15 Months Following a Switch/Stabilization of the Antipsychotic Agents Among Patients Who Receive Either Risperidal Consta or One of the 4 Marketed 2nd Generation Antipsychotic Agents.
NCT00177164 (4) [back to overview]	Number of Participants With Treatment Emergent Hyperlipidemia
NCT00177164 (4) [back to overview]	Number of Participants With Treatment - Emergent Hyperglycemia
NCT00177164 (4) [back to overview]	BMI
NCT00181883 (1) [back to overview]	Change in Bipolar Symptoms as Measured by Reduction in Young-Mania Rating Scale (Y-MRS) Total Score
NCT00183443 (5) [back to overview]	Symptoms of Mania, as Measured by Young Mania Rating Scale
NCT00183443 (5) [back to overview]	Global Assessment of Functioning
NCT00183443 (5) [back to overview]	Clinical Global Impression Scale for Bipolar Disorder (CGI-BD)
NCT00183443 (5) [back to overview]	Hamilton Rating Scale for Depression (HAM-D,17)
NCT00183443 (5) [back to overview]	Social and Occupational Functioning Assessment Scale (SOFAS)
NCT00186043 (3) [back to overview]	Percentage of Participants With Clinical Global Impression for Bipolar Disorders Overall Severity Remission (Score <=2 at Week 8)
NCT00186043 (3) [back to overview]	Percentage of Participants With >=50% Improvement From Baseline in Clinical Global Impression for Bipolar Disorders Overall Severity
NCT00186043 (3) [back to overview]	Percentage of Participants With 50% Improvement From Baseline in Both Montgomery Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) Scores
NCT00206102 (15) [back to overview]	Change in Personal Evaluation of Transitions in Treatment (PETiT) Total Score
NCT00206102 (15) [back to overview]	Change in Simpson-Angus Scale (SAS) Total Score
NCT00206102 (15) [back to overview]	Presence of a Posterior Subcapsular (P) Type Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the LOCS II Grading Scale
NCT00206102 (15) [back to overview]	Change in Barnes Akathisia Rating Scale (BARS) Global Score
NCT00206102 (15) [back to overview]	Change in the PANSS Psychopathology Subscale Score
NCT00206102 (15) [back to overview]	Change in Abnormal Involuntary Movement Scale (AIMS) Total Score
NCT00206102 (15) [back to overview]	Change in Health-related Quality of Life as Measured by Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q SF) Total Score
NCT00206102 (15) [back to overview]	Change in the PANSS Negative Subscale Score
NCT00206102 (15) [back to overview]	Change in the PANSS Positive Subscale Score
NCT00206102 (15) [back to overview]	Change in the Positive and Negative Syndrome Scale (PANSS) Total Score
NCT00206102 (15) [back to overview]	Number of Participants With Potential Extrapyramidal Symptoms (EPS)
NCT00206102 (15) [back to overview]	Number of Relapses of Schizophrenia or Schizoaffective Disorder
NCT00206102 (15) [back to overview]	Change in the Clinical Global Impression - Severity of Illness (CGI-S) Score
NCT00206102 (15) [back to overview]	Presence of a Cortical (C) Type of Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the Lens Opacities Classification System II (LOCS II ) Grading Scale
NCT00206102 (15) [back to overview]	Presence of a Nuclear Opalescence (N) Type of Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the LOCS II Grading Scale
NCT00216476 (5) [back to overview]	Mean Relapse Free Period(Risperidone LAI Versus Quetiapine)
NCT00216476 (5) [back to overview]	Mean Relapse Free Period (Exploratory/Aripiprazole)
NCT00216476 (5) [back to overview]	Change From Baseline to Endpoint in Total Positive and Negative Syndrome Scale (PANSS) Score
NCT00216476 (5) [back to overview]	Change From Baseline to Endpoint in Clinical Global Impression Scale (CGI) Score
NCT00216476 (5) [back to overview]	Change From Baseline to Endpoint in Short-Form Health Survey 12 (SF-12) Scores
NCT00227305 (11) [back to overview]	Number of Patients Withdrawn Due to AEs.
NCT00227305 (11) [back to overview]	Categorical Change From OL Baseline to Week 26 in Simpson-Angus Scale (SAS)Total Score
NCT00227305 (11) [back to overview]	Categorical Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Score
NCT00227305 (11) [back to overview]	Incidence and Nature of Adverse Events (AEs)
NCT00227305 (11) [back to overview]	Changes in Tanner Stage
NCT00227305 (11) [back to overview]	Changes in Laboratory Test Results (Prolactin)
NCT00227305 (11) [back to overview]	Change From OL Baseline in Supine Systolic BP.
NCT00227305 (11) [back to overview]	Change From OL Baseline in Supine Diastolic BP.
NCT00227305 (11) [back to overview]	Change From Baseline in Weight
NCT00227305 (11) [back to overview]	Change From Baseline in Supine Pulse
NCT00227305 (11) [back to overview]	Change From Baseline in Children's Global Assessment Scale (CGAS) Score
NCT00292370 (9) [back to overview]	Change in Mean Q-LES-Q Score From Baseline to Endpoint.
NCT00292370 (9) [back to overview]	Change in Mean Sheehan Disability Scale (SDS) Scores From Baseline to Endpoint.
NCT00292370 (9) [back to overview]	Change in Mean Scores of Pittsburgh Sleep Quality Index (PSQI) From Baseline to Endpoint.
NCT00292370 (9) [back to overview]	Change in CGI-I
NCT00292370 (9) [back to overview]	Change in Clinician-Administered PTSD Scale for DSM-IV Total Score.
NCT00292370 (9) [back to overview]	Change in Arizona Sexual Experience Scale (ASEX)
NCT00292370 (9) [back to overview]	Change in Mean PANSS Total and Subscores From Baseline to Endpoint
NCT00292370 (9) [back to overview]	Change in Total Mean Hamilton Rating Scale for Depression (HAMD) Scores
NCT00292370 (9) [back to overview]	Change in Total Mean Davidson Trauma Scale (DTS)
NCT00330863 (3) [back to overview]	Substantial Clinical Deterioration Measured by Psychotic Symptoms
NCT00330863 (3) [back to overview]	Number of Patients Discontinuing From the Study
NCT00330863 (3) [back to overview]	Side Effects and Metabolic Measures
NCT00388973 (8) [back to overview]	Change From Baseline in Suicidal Thoughts as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Item 10
NCT00388973 (8) [back to overview]	Tolerability as Measured by Adverse Event Withdrawals During Treatment
NCT00388973 (8) [back to overview]	Change From Baseline in Somatic Symptoms Cluster From the Hamilton Anxiety Scale (HAM-A)
NCT00388973 (8) [back to overview]	Change From Baseline in Sleep Quality as Measured by the Pittsburgh Sleep Quality Index
NCT00388973 (8) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Week 9.
NCT00388973 (8) [back to overview]	Change From Baseline in Health-related Quality of Life, Enjoyment and Satisfaction (Q-LES-Q)
NCT00388973 (8) [back to overview]	Change From Baseline in Anxiety Symptoms Measured by Hamilton Anxiety 14 Item Scale (HAM-A)
NCT00388973 (8) [back to overview]	Change From Baseline for Satisfaction With Medication From Quality of Life, Enjoyment, Satisfaction Questionaire (Q-LES-Q)
NCT00389064 (11) [back to overview]	Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score
NCT00389064 (11) [back to overview]	Change in the Clinical Global Impression - Severity of Illness (CGI-S) Score
NCT00389064 (11) [back to overview]	Hamilton Rating Scale for Anxiety (HAM-A) Response.
NCT00389064 (11) [back to overview]	Number of Patients Reaching Hamilton Rating Scale for Anxiety (HAM-A) Remission
NCT00389064 (11) [back to overview]	Safety and Well Tolerated as Measured by Extra Pyramidal Symptoms (EPS)
NCT00389064 (11) [back to overview]	Safety and Well Tolerated as Measured in Adverse Event
NCT00389064 (11) [back to overview]	Change in Health-related Quality of Life as Measured by Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Percent Maximum Total Score
NCT00389064 (11) [back to overview]	Change in Somatic Symptoms as Measured by HAM-A Somatic Cluster Score
NCT00389064 (11) [back to overview]	Change in Psychic Anxiety Factor as Measured by HAM-A Psychic Cluster Score
NCT00389064 (11) [back to overview]	Change in Montgomery-Asberg Depression Rating Scale (MADRS)
NCT00389064 (11) [back to overview]	Change in the Visual Analogue Scale (VAS) Measuring Pain
NCT00393978 (2) [back to overview]	Change in Percent Days of Cannabis Use Per Week
NCT00393978 (2) [back to overview]	Change in Joints Per Week
NCT00397020 (1) [back to overview]	Primary Measure: Young Mania Rating Scale (YMRS) Primary Endpoint: Day 7
NCT00411463 (4) [back to overview]	Number of Participants With a Response
NCT00411463 (4) [back to overview]	Quality of Life (QOL) Collected Using the Q-LES-Q (Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form)
NCT00411463 (4) [back to overview]	Number of Participants With Greater Than or Equal to 50% Reduction in Depression Scores, With a Mania Score Less Than or Equal to 10
NCT00411463 (4) [back to overview]	Descriptive Measures of the Feasibility of IPSRT-BPII
NCT00423878 (2) [back to overview]	Efficacy Failure, Defined as Psychiatric Hospitalization, a 25 Percent Increase From Baseline on the Positive and Negative Syndrome Scale or Substantial Clinical Deterioration on the Clinical Global Impressions-Change (CGI-C)
NCT00423878 (2) [back to overview]	Change in Non-HDL Cholesterol Level for Patients Assigned to Stay and Patients Assigned to Switch Over 24 Weeks
NCT00434876 (4) [back to overview]	Insomnia Severity Index (ISI)
NCT00434876 (4) [back to overview]	Pittsburgh Sleep Quality Index (PSQI)
NCT00434876 (4) [back to overview]	Wake After Sleep Onset Time (WASO) From an In-laboratory Polysomnogram.
NCT00434876 (4) [back to overview]	Sleep Efficiency (From an In-laboratory Polysomnogram)
NCT00457197 (9) [back to overview]	The Number of Standard Drinks/Day Will Serve as the Primary Outcome Measure.
NCT00457197 (9) [back to overview]	Young Mania Rating Scale (YMRS)
NCT00457197 (9) [back to overview]	Aspartate Aminotransferase (AST)
NCT00457197 (9) [back to overview]	Alanine Aminotransferase (ALT)
NCT00457197 (9) [back to overview]	Gamma-glutamyltransferase (GGT)
NCT00457197 (9) [back to overview]	Hamilton Rating Scale for Depression (HRSD)
NCT00457197 (9) [back to overview]	Inventory of Depressive Symptomatology-Self Report (IDS-SR)
NCT00457197 (9) [back to overview]	Penn Alcohol Craving Scale (PACS)
NCT00457197 (9) [back to overview]	Percent of Heavy Drinking Days
NCT00457366 (1) [back to overview]	Change in the PANSS-EC Score Among Participants From Baseline to 2 Hours After Administration of the Medication.
NCT00498628 (14) [back to overview]	Hamilton Anxiety Scale (HAM-A)
NCT00498628 (14) [back to overview]	Drinks Per Drinking Day
NCT00498628 (14) [back to overview]	Drinks Per Day
NCT00498628 (14) [back to overview]	Drinking Consequences Score
NCT00498628 (14) [back to overview]	Percent Subjects Abstinent
NCT00498628 (14) [back to overview]	Quality of Life SF-12 - Physical Aggregate Score
NCT00498628 (14) [back to overview]	Percent Subjects With no Heavy Drinking Day
NCT00498628 (14) [back to overview]	Quality of Life SF - 12 - Mental Aggregate Score
NCT00498628 (14) [back to overview]	Percent Very Heavy Drinking Day
NCT00498628 (14) [back to overview]	Pittsburgh Sleep Quality Score
NCT00498628 (14) [back to overview]	Percent Heavy Drinking Days
NCT00498628 (14) [back to overview]	Percent Days Abstinent
NCT00498628 (14) [back to overview]	Penn Alcohol Craving Score (PACS_
NCT00498628 (14) [back to overview]	Montgomery-Asberg Depression Rating Scale (MADRS)
NCT00508157 (2) [back to overview]	Number of Participants Remaining on Metabolic Syndrome at Week 16
NCT00508157 (2) [back to overview]	Mean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (HDL) Cholesterol at Week 16
NCT00509067 (3) [back to overview]	Clinical Global Impression
NCT00509067 (3) [back to overview]	MATRICS Verbal Learning and Memory
NCT00509067 (3) [back to overview]	Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS)
NCT00515723 (2) [back to overview]	DEXA Total Fat
NCT00515723 (2) [back to overview]	Clamp Derived Insulin Sensitivity (mg/kg/Min)
NCT00518973 (5) [back to overview]	Differences in Scores on the HAM-D (Hamilton Depression Rating Scale)
NCT00518973 (5) [back to overview]	Difference in Scores on the STAI (State-Trait Anxiety Inventory)
NCT00518973 (5) [back to overview]	Differences in Scores on the PANNSS (The Positive and Negative Syndrome Scale)
NCT00518973 (5) [back to overview]	Hours Occupied by Preoccupations and Rituals Assessed by Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS)
NCT00518973 (5) [back to overview]	Difference in Scores on the EDI-2 (Eating Disorders Inventory)
NCT00521365 (14) [back to overview]	Change in the Quality of Life Questionnaire EQ5D Index From Baseline to End of the Study.
NCT00521365 (14) [back to overview]	Change in the Clinical Global Impression (CGI) Total Score From Baseline (CGI-S) to Final Visit or Last Observation Carried Forward (LOCF)(CGI-I).
NCT00521365 (14) [back to overview]	Change in the Clinical Global Impression - Improvement (CGI-I) at Final Visit or Last Observation Carried Forward (LOCF).
NCT00521365 (14) [back to overview]	Change in the Barnes Akathisia Rating Scale (BARS) Total Score From Baseline to Final Visit or Last Observation Carried Forward (LOCF).
NCT00521365 (14) [back to overview]	Change in Weight From Baseline to Final Visit or Last Observation Carried Forward (LOCF).
NCT00521365 (14) [back to overview]	Change in Waist Circumference From Baseline to Final Visit or Last Observation Carried Forward (LOCF).
NCT00521365 (14) [back to overview]	Number of Participants With Young Mania Rating Scale (YMRS) Response at Final Visit or Last Observation Carried Forward (LOCF)
NCT00521365 (14) [back to overview]	Number of Participants With Young Mania Rating Scale (YMRS) Remission at Final Visit or Last Observation Carried Forward (LOCF).
NCT00521365 (14) [back to overview]	Number of Participants With >7% Increase in Weight
NCT00521365 (14) [back to overview]	Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Visit 3
NCT00521365 (14) [back to overview]	Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Visit 2.
NCT00521365 (14) [back to overview]	Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to End of Treatment (Day 21)
NCT00521365 (14) [back to overview]	Change in the Simpson-Angus Scale (SAS) Total Score From Baseline to Final Visit or Last Observation Carried Forward (LOCF).
NCT00521365 (14) [back to overview]	Change in the Quality of Life Questionnaire EQ5D Visual Analogue Scale (VAS) From Baseline to Final Visit or Last Observation Carried Forward (LOCF).
NCT00534599 (15) [back to overview]	Least Square Mean Change From Randomization to Week 8 in Hamilton Rating Scale for Anxiety (HAM-A) Total Score
NCT00534599 (15) [back to overview]	Number of Patients With HAM-A Response (≥50% Score Reduction From Randomization) at Week 8
NCT00534599 (15) [back to overview]	Number of Patients With HAM-A Response (≥50% Score Reduction From Randomization) at Week 1
NCT00534599 (15) [back to overview]	Number of Patients With HAM-A Remission (Total Score ≤7) at Week 8
NCT00534599 (15) [back to overview]	"Number of Patients With Clinical Global Impression-Global Improvement (CGI-I) Score of Much/Very Much Improved at Week 8"
NCT00534599 (15) [back to overview]	Least Square Mean Change From Randomization to Week 1 in CGI-S Score
NCT00534599 (15) [back to overview]	Least Square Mean Change From Randomization to Week 1 in HAM-A Psychic Anxiety Subscale Score
NCT00534599 (15) [back to overview]	Mean Change From Randomization to Week 8 in Q-LES-Q Item 15 (Satisfaction With Medication) Score
NCT00534599 (15) [back to overview]	Least Square Mean Change From Randomization to Week 1 in HAM-A Somatic Anxiety Subscale Score
NCT00534599 (15) [back to overview]	Least Square Mean Change From Randomization to Week 8 in Clinical Global Impression-Severity of Illness (CGI-S) Score
NCT00534599 (15) [back to overview]	Least Square Mean Change From Randomization to Week 8 in HAM-A Psychic Anxiety Subscale Score
NCT00534599 (15) [back to overview]	Least Square Mean Change From Randomization to Week 8 in Quality of Life Enjoyment and Satisfaction Questionaire (Q-LES-Q) Percent Maximum Total Score
NCT00534599 (15) [back to overview]	Least Square Mean Change From Randomization to Week 8 in HAM-A Somatic Anxiety Subscale Score
NCT00534599 (15) [back to overview]	Least Square Mean Change From Randomization to Week 1 in HAM-A Total Score
NCT00534599 (15) [back to overview]	Mean Change From Randomization to Week 8 in Q-LES-Q Item 16 (Overall Quality of Life) Score
NCT00550147 (5) [back to overview]	Swanson, Nolan and Pelham IV (SNAP-IV) Oppositional-Defiant Disorder Subscale
NCT00550147 (5) [back to overview]	CGI-S: Clinical Global Improvement Scale
NCT00550147 (5) [back to overview]	RAAPP: Rating of Aggression Against People and/or Property Scale
NCT00550147 (5) [back to overview]	Attention Deficit/Hyperactivity Disorder Rating Scale -IV- Parent Version (ADHDRS-IV-Parent Version)
NCT00550147 (5) [back to overview]	Modified Overt Aggression Scale (MOAS)
NCT00550394 (4) [back to overview]	Drinks Per Day
NCT00550394 (4) [back to overview]	Drinks Per Drinking Day
NCT00550394 (4) [back to overview]	Percent Heavy Drinking Days
NCT00550394 (4) [back to overview]	Percentage of Days Abstinent
NCT00579280 (11) [back to overview]	Change From Baseline on Sheehan- Suicidality Tracking Scale S-STS (2008 Version With 8 Items)
NCT00579280 (11) [back to overview]	Change From Baseline in Hamilton Anxiety Scale (HAM-A) Scores
NCT00579280 (11) [back to overview]	Change From Baseline on Patient Global Improvement Scale (PGI-21) for Anxiety Symptoms
NCT00579280 (11) [back to overview]	Change From Baseline on Montgomery Asberg Depression Rating Scale (MADRS)
NCT00579280 (11) [back to overview]	Change From Baseline on Sheehan Disability Scale (SDS) - Total
NCT00579280 (11) [back to overview]	Change From Baseline on Clinician Global Impression Scale for Bipolar Disorder (CGI-BP) (Overall Severity)
NCT00579280 (11) [back to overview]	Change From Baseline on Rapid Ideas Scale (RISc)
NCT00579280 (11) [back to overview]	Change From Baseline in Young Mania Rating Scale (YMRS)
NCT00579280 (11) [back to overview]	Change From Baseline in the CGI-21 Anxiety
NCT00579280 (11) [back to overview]	Change From Baseline in Sheehan Panic Disorder Scale (SPS)
NCT00579280 (11) [back to overview]	Change From Baseline in Sheehan Irritability Scale (SIS)
NCT00600756 (31) [back to overview]	The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Extra-pyramidal Events at Month 12 in the Safety Population
NCT00600756 (31) [back to overview]	The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants at Month 12 in the Safety Population With Individual Symptoms Assessed by the Modified UKU: Hyperprolactinaemia in Women
NCT00600756 (31) [back to overview]	The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants at Month 12 in the Safety Population With Individual Symptoms Assessed by the Modified UKU: Sexual Dysfunction in Men
NCT00600756 (31) [back to overview]	The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants Who Discontinued the Study Because of an TEAE at Month 12 in the Safety Population
NCT00600756 (31) [back to overview]	The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants Who Had at Least 1 Cardiac TEAE at Month 12 in the Safety Population
NCT00600756 (31) [back to overview]	The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants Who Had at Least 1 Extra-pyramidal TEAE at Month 12 in the Safety Population
NCT00600756 (31) [back to overview]	The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants With a Treatment-emergent Adverse Event (TEAEs) at Month 12 in the Safety Population
NCT00600756 (31) [back to overview]	The Safety and Tolerability of Quetiapine XR vs Risperidone by Evaluating the Number of Participants at Month 12 in Safety Population With Individual Symptoms Assessed by the Modified Udvalg for Kliniske Undersogelser, Side Effect Rating Scale: Neurologic
NCT00600756 (31) [back to overview]	To Evaluate the Effect of Quetiapine XR Versus Risperidone at Month 12 in the ITT Population Regarding Health Economics Outcomes by Evaluating the Functional Improvement Rate of the Modified Vocational Status Index/ Location Code Index: Stable State
NCT00600756 (31) [back to overview]	Change From Baseline in Mean Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-K) Total Score at Month 12 in the Intent-to-Treat (ITT) Population
NCT00600756 (31) [back to overview]	Change From Baseline in Mean Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-K) Total Score at Month 12 in the Per Protocol Population
NCT00600756 (31) [back to overview]	Change From Baseline in the Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-K) Subscale Score: Emotional Regulation at Month 12 in the ITT Population.
NCT00600756 (31) [back to overview]	Change From Baseline in the Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-K) Subscale Score: Mental Functioning at Month 12 in the ITT Population.
NCT00600756 (31) [back to overview]	Change From Baseline in the Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-K) Subscale Score: Physical Functioning at Month 12 in the ITT Population.
NCT00600756 (31) [back to overview]	Change From Baseline in the Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-K) Subscale Score: Self-control at Month 12 in the ITT Population.
NCT00600756 (31) [back to overview]	Change From Baseline in the Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-K) Subscale Score: Social Integration at Month 12 in the ITT Population.
NCT00600756 (31) [back to overview]	Evaluation of Effect of Quetiapine XR Versus Risperidone on the Health-related Quality of Life of Patients With Schizophrenia by Evaluating the Change From Baseline in EQ-5D(Euro Quality of Life-5 Dimension) Index Score at Month 12 in the ITT Population.
NCT00600756 (31) [back to overview]	Number of Participants Using Antidepressants at Month 12 in the ITT Population
NCT00600756 (31) [back to overview]	Number of Subjects Who Had an Unscheduled Visits Due to Worsening of Schizophrenia, Dose Change, or Adverse Event at Month 12 in the ITT Population
NCT00600756 (31) [back to overview]	Responder Rate at Month 6 in the Per Protocol Population Using the Subjective Well-being Under Neuroleptics Scale, Short Version (SWN-K) Total Score
NCT00600756 (31) [back to overview]	The Compliance of Patients Taking Quetiapine XR Versus Risperidone at Month 12 by Evaluating the Number of Participants Who Returned Study Drug at Month 12 in the ITT Population
NCT00600756 (31) [back to overview]	The Effect of Quetiapine XR Versus Risperidone at Month 12 in the ITT Population on Core Schizophrenic and Depressive Symptoms by Evaluating the Change From Baseline in CGI-SCH Overall Severity Score
NCT00600756 (31) [back to overview]	The Effect of Quetiapine XR Versus Risperidone at Month 12 in the ITT Population on Core Schizophrenic and Depressive Symptoms by Evaluating the Change From Baseline in CGI-SCH Overall Severity Score (Improved).
NCT00600756 (31) [back to overview]	The Effect of Quetiapine XR Versus Risperidone at Month 12 in the ITT Population on Core Schizophrenic and Depressive Symptoms by Evaluating the Change From Baseline in the Calgary Depression Scale for Schizophrenia (CDSS) Total Score
NCT00600756 (31) [back to overview]	The Effect of Quetiapine XR Versus Risperidone by Evaluating the Relapse Rate at Month 12 in the ITT Population
NCT00600756 (31) [back to overview]	The Effect of Quetiapine XR Versus Risperidone Regarding Health Economics Outcomes by Evaluating the Mean Number of Lost School/Work Days at Month 12 in the ITT Population
NCT00600756 (31) [back to overview]	The Effect of Quetiapine XR Versus Risperidone Regarding Health Economics Outcomes by Evaluating the Number of Participants Using Other Psychotropic Medications at Month 12 in the ITT Population
NCT00600756 (31) [back to overview]	The Effect of Quetiapine XR Versus Risperidone Regarding Health Economics Outcomes by Evaluating the Participants With at Least 1 Hospitalization Due to Psychiatric Disorders at Month 12 in the ITT Population
NCT00600756 (31) [back to overview]	The Effect of Quetiapine XR Versus Risperidone Regarding Health Economics Outcomes by Evaluating the Time Between First Study Drug Intake and First Hospitalization for Patients With 1 Hospitalization in the ITT Population
NCT00600756 (31) [back to overview]	The Remission Rate in Both the Quetiapine XR Group and the Risperidone Group at Month 12 in the ITT Population
NCT00600756 (31) [back to overview]	The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Mean Change From Baseline to Month 12 in Prolactin Levels in the Safety Population
NCT00617396 (1) [back to overview]	Adequate Relief in Pain Score During Treatment
NCT00619892 (2) [back to overview]	Change in Scores in Measurements of Depressive Symptoms (Hamilton Depression Rating Scale, HAM-D), Generalized Anxiety Symptoms (Hamilton Anxiety Rating Scale, HAM-A) and the Sleep Quality Item of the Pittsburgh Sleep Quality Index (PSQI).
NCT00619892 (2) [back to overview]	Change in Mean Total Panic Disorder Severity Scale (PDSS) Scores
NCT00631748 (2) [back to overview]	Percentage of Participants Attaining Abstinence for Three Weeks
NCT00631748 (2) [back to overview]	Timeline Followback Interview (TLFB)
NCT00640562 (11) [back to overview]	Change From Baseline to Week 12 of PANSS Score
NCT00640562 (11) [back to overview]	Change From Screening Visit to Week 12 of Prolactin Live
NCT00640562 (11) [back to overview]	Concomitant Use of Antidepressive Drugs From Baseline to Week 12
NCT00640562 (11) [back to overview]	Concomitant Use of Antidepressive Drugs From Baseline to Week 12
NCT00640562 (11) [back to overview]	Change From Baseline to Week 12 of HAM-D Score
NCT00640562 (11) [back to overview]	- Change From Baseline to Week 12 of Clinical Global Impression (CGI- Severity of Illness) Score
NCT00640562 (11) [back to overview]	Body Mass Index (BMI) at Week 12
NCT00640562 (11) [back to overview]	CGI- Global Improvement Mean Score at Week 12
NCT00640562 (11) [back to overview]	Change From Baseline in the Simpson Angus Scale (SAS) Total Score to Week 12 as an Indication of Neurological Side Effects Section
NCT00640562 (11) [back to overview]	Change From Baseline to Week 12 of Calgary Depression Scale for Schizophrenia (CDSS) Score.
NCT00640562 (11) [back to overview]	Change From Baseline to Week 12 of Drug Attitude Inventory 10 Item Scale (DAI 10) Score
NCT00640601 (11) [back to overview]	Change in Social and Occupational Functioning Assessment Scale (SOFAS)
NCT00640601 (11) [back to overview]	Change in Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Negative Scale Score
NCT00640601 (11) [back to overview]	Change in Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Positive Scale Score
NCT00640601 (11) [back to overview]	Change in Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Total Score
NCT00640601 (11) [back to overview]	Change in Clinical Global Impression-Improvement (CGI-I) Scale
NCT00640601 (11) [back to overview]	Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study
NCT00640601 (11) [back to overview]	Change in Barnes Akathisia Rating Scale (BARS)
NCT00640601 (11) [back to overview]	Change in Safety Measure: Simpson-Angus Scale (SAS)
NCT00640601 (11) [back to overview]	Change in Global Assessment Scale (GAS)
NCT00640601 (11) [back to overview]	Change in Clinical Global Impression-Severity (CGI-S) Scale
NCT00640601 (11) [back to overview]	Change in Clinical Global Impression-Clinical Benefit (CGI-CB) Score
NCT00642369 (2) [back to overview]	Percentage of Slow Wave Sleep
NCT00642369 (2) [back to overview]	Percentage of Rapid Eye Movement Sleep
NCT00671853 (6) [back to overview]	Change in Clinical Global Impressions of Improvement or Severity (CGI-I or S) Score
NCT00671853 (6) [back to overview]	Change in Hamilton Rating Scale for Anxiety (HAM-A)
NCT00671853 (6) [back to overview]	Change in the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Score
NCT00671853 (6) [back to overview]	Change in the 17 Item Hamilton Rating Scale for Depression (HAM-D-17) Score
NCT00671853 (6) [back to overview]	Response Rate (≥ 50% Improvement) on Hamilton Rating Scale for Depression (HAM-D-17)
NCT00671853 (6) [back to overview]	Remission Rate (≤ 7) on Hamilton Rating Scale for Depression (HAM-D-17)
NCT00672490 (9) [back to overview]	Change From Baseline in the Young Mania Rating Scale (YMRS) Item 4 Score to Each Assessment
NCT00672490 (9) [back to overview]	Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 28)
NCT00672490 (9) [back to overview]	Remission Rate (Number of Patients With Clinically Significant Remission)
NCT00672490 (9) [back to overview]	Response Rate (Number of Patients With Clinically Response)
NCT00672490 (9) [back to overview]	Change From Baseline in the Clinical Global Impressions for Bipolar Disorder Severity of Illness (CGI-BP-S) Score to Each Assessment (Day 28)
NCT00672490 (9) [back to overview]	Treatment of Agitation (Change From Baseline in the PANSS Activation Subscale Score to Day 28)
NCT00672490 (9) [back to overview]	Treatment of Aggression Risk (Change From Baseline in the PANSS Supplement Aggression Risk Subscale Score to Day 28)
NCT00672490 (9) [back to overview]	Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score to Each Assessment(Day 28)
NCT00672490 (9) [back to overview]	Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score to Each Assessment (Day 28)
NCT00674765 (1) [back to overview]	TimeLine Follow Back (TLFB) to Measure Percent Heavy Drinking Days During the Medication/Placebo Phase
NCT00681668 (1) [back to overview]	The Change in the Hamilton Rating Scale for Depression (HAM-D)
NCT00743366 (1) [back to overview]	Measure of Relapse: Change in Puffs Chosen Between Baseline and Relapse Phase
NCT00746421 (2) [back to overview]	Brief Assessment of Cognition for Affective Disorders (BAC-A)
NCT00746421 (2) [back to overview]	The Continuous Performance Test-Identical Pairs Version
NCT00779506 (7) [back to overview]	The Change in Positive and Negative Syndrome Scale(PANSS)Total Score
NCT00779506 (7) [back to overview]	Positive and Negative Syndrome Scale (PANSS) Positive Score
NCT00779506 (7) [back to overview]	Positive and Negative Syndrome Scale (PANSS) Negative Score
NCT00779506 (7) [back to overview]	Positive and Negative Syndrome Scale (PANSS) General Psychopathology Score
NCT00779506 (7) [back to overview]	Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT00779506 (7) [back to overview]	Global Assessment of Functioning (GAF) Score
NCT00779506 (7) [back to overview]	Clinical Global Impression (CGI) Score
NCT00789698 (4) [back to overview]	Change From the Acute Phase Baseline to the End (Month 12) of the Double-blind Treatment in the Positive and Negative Syndrome Scale (PANSS)
NCT00789698 (4) [back to overview]	Change From the Acute Phase Baseline to Month 6 of the Double-blind Treatment in the CogState Computerized Cognitive Scores.
NCT00789698 (4) [back to overview]	Change From the Acute Phase Baseline to the End (Month 12) of the Double-blind Treatment in the Clinical Global Impression Severity Scale (CGI-S) Scores
NCT00789698 (4) [back to overview]	Relapse of Psychotic Symptoms
NCT00789854 (30) [back to overview]	Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, All Patients
NCT00789854 (30) [back to overview]	Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With One Previous Treatment Failure
NCT00789854 (30) [back to overview]	Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With Two Previous Treatment Failure
NCT00789854 (30) [back to overview]	Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, All Patients
NCT00789854 (30) [back to overview]	Change in Anxiety Measured by STAI, Trait Anxiety Inventory
NCT00789854 (30) [back to overview]	Change in Anxiety Measured by State-Trait Anxiety Inventory (STAI), State Anxiety Inventory
NCT00789854 (30) [back to overview]	Change in Anxiety Measured by Visual Analog Scale (VAS)
NCT00789854 (30) [back to overview]	Change in Beck Depression Inventory (BDI)
NCT00789854 (30) [back to overview]	Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With One Previous Treatment Failure
NCT00789854 (30) [back to overview]	Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With Two Previous Treatment Failures
NCT00789854 (30) [back to overview]	Change in Clinical Global Impression Scale (CGI-S), All Patients
NCT00789854 (30) [back to overview]	Change in Clinical Global Impression Scale (CGI-S), Patients With One Previous Treatment Failure
NCT00789854 (30) [back to overview]	Change in Clinical Global Impression Scale (CGI-S), Patients With Two Previous Treatment Failure
NCT00789854 (30) [back to overview]	Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Modified Intention to Treat Analysis Set)
NCT00789854 (30) [back to overview]	Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis Set)
NCT00789854 (30) [back to overview]	Change in Pain, Measured by Visual Analog Scale (VAS)
NCT00789854 (30) [back to overview]	Change in Quality of Life Measured by Health Questionnaire EQ-5D as Utility
NCT00789854 (30) [back to overview]	Change in Quality of Life Measured by Short-form Health Survey (SF-36), Mental Component
NCT00789854 (30) [back to overview]	Change in Quality of Life Measured by Short-form Health Survey (SF-36), Physical Component
NCT00789854 (30) [back to overview]	Change in Sleep Quality Measured by Montgomery Asberg Depression Rating Scale (MADRS), Item 4
NCT00789854 (30) [back to overview]	Change in Sleep Quality Measured by Pittsburgh Sleep Quality Index (PSQI)
NCT00789854 (30) [back to overview]	Change in Work Productivity and Activity Impairment: General Health (WPAI:GH)
NCT00789854 (30) [back to overview]	Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With One Previous Treatment Failure
NCT00789854 (30) [back to overview]	Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With Two Previous Treatment Failure
NCT00789854 (30) [back to overview]	Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤12
NCT00789854 (30) [back to overview]	Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤8
NCT00789854 (30) [back to overview]	Depression Remission; Montgomery-Asberg Depression Rating Scale MADRS ≤10, All Patients
NCT00789854 (30) [back to overview]	Responder: Clinical Global Impression Improvement (CGI-I) Item 2, All Patients
NCT00789854 (30) [back to overview]	Responder: Clinical Global Impression Improvement (CGI-I) Item 2, Patients With Two Previous Treatment Failure
NCT00789854 (30) [back to overview]	Responder: Clinical Global Impression Improvement (CGI)-I Item 2, Patients With One Previous Treatment Failure
NCT00790192 (2) [back to overview]	Secondary Outcome: CGI-S From Baseline to the End of the Double-blind Treatment
NCT00790192 (2) [back to overview]	Primary Efficacy Endpoint: Mean Change in Total PANSS Score From Baseline to the End of the Double Blind Phase
NCT00806234 (4) [back to overview]	Triglyceride Levels
NCT00806234 (4) [back to overview]	Body Mass Index (BMI) Z-score Change
NCT00806234 (4) [back to overview]	Change in Low Density Lipoprotein (LDL) Cholesterol Level
NCT00806234 (4) [back to overview]	Change in Whole Body Insulin Sensitivity Index
NCT00811473 (6) [back to overview]	The Number of Patients With the Response, Where Response is Defined as ≥50% Reduction From Baseline to Final Assessment (Day 57) in CDRS-R Total Score
NCT00811473 (6) [back to overview]	The Proportion of Patients at Final Assessment (Day 57) With Improvement of Overall Bipolar Illness
NCT00811473 (6) [back to overview]	Change From Baseline to Final Assessment (Day 57) in the CGI-BP-S
NCT00811473 (6) [back to overview]	Number of Patients Reaching Remission Where Remission is Defined as CDRS-R Total Score ≤28 at Final Assessment (Day 57).
NCT00811473 (6) [back to overview]	Change in the Children Depression Rating Scale, Revised (CDRS-R) Total Score From Baseline to Final Assessment (Day 57)
NCT00811473 (6) [back to overview]	CGI-BP-C Score at Final Assessment (Day 57)
NCT00852631 (3) [back to overview]	Clinical Global Impression - Severity of Illness (CGI-S) Score
NCT00852631 (3) [back to overview]	Change in Clinical Global Impression - Severity of Illness (CGI-S) Score
NCT00852631 (3) [back to overview]	Change in Positive and Negative Syndrome Scale (PANSS) Total Score
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 8 in the Hamilton Anxiety Rating Scale (HARS) Total Score
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 8 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score
NCT00857584 (18) [back to overview]	Number of Patients Response at Week 1
NCT00857584 (18) [back to overview]	Number of Patients With Remission at Week 1.
NCT00857584 (18) [back to overview]	Number of Patients With Remission at Week 2.
NCT00857584 (18) [back to overview]	Number of Patients With Remission at Week 4.
NCT00857584 (18) [back to overview]	Number of Patients With Remission at Week 8.
NCT00857584 (18) [back to overview]	Number of Patients With Response at Week 2
NCT00857584 (18) [back to overview]	Number of Patients With Response at Week 4.
NCT00857584 (18) [back to overview]	Number of Patients With Response at Week 8.
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 1 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 2 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 1 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 2 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 4 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 4 in the Hamilton Anxiety Rating Scale (HARS) Total Score
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 4 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score
NCT00857584 (18) [back to overview]	The Mean Change From Baseline to Week 8 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score
NCT00857818 (3) [back to overview]	Mean Baseline Fasting Non-HDL Levels
NCT00857818 (3) [back to overview]	Mean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (Non-HDL) Cholesterol Levels
NCT00857818 (3) [back to overview]	Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and 1 or More AEs
NCT00868374 (1) [back to overview]	Change in 17 Item Hamilton Rating Scale for Depression (HAM-D-17)
NCT00880919 (9) [back to overview]	Global Assessment of Functioning Scale (GAF)
NCT00880919 (9) [back to overview]	Montgomery-Åsberg Depression Rating Scale (MADRS)
NCT00880919 (9) [back to overview]	Sheehan Disability Scale (SDS)
NCT00880919 (9) [back to overview]	Symptom Checklist -90-Revised (SCL-90-R)
NCT00880919 (9) [back to overview]	Young Mania Rating Scale (YMS)
NCT00880919 (9) [back to overview]	Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD)
NCT00880919 (9) [back to overview]	Overt Aggression Scale - Modified (OAS-M)
NCT00880919 (9) [back to overview]	Barratt Impulsiveness Scale (BIS)
NCT00880919 (9) [back to overview]	Borderline Evaluation of Severity Over Time (BEST)
NCT00882518 (9) [back to overview]	Change From Baseline in PANSS Aggression, Hostility Clusters Score at the End of Treatment at Day 42
NCT00882518 (9) [back to overview]	Change From Baseline in PANSS Depression Clusters Score at the End of Treatment at Day 42
NCT00882518 (9) [back to overview]	Percentage of Patients With Clinical Global Impression (CGI) Global Improvement Rating Less Than or Equal to 3 at the End of Treatment at Day 42
NCT00882518 (9) [back to overview]	Number of Patients Achieving a Reduction of at Least 30% From Baseline PANSS Total Score at the End of Treatment at Day 42
NCT00882518 (9) [back to overview]	Change in the CGI Severity of Illness Score From Baseline at the End of Treatment at Day 42
NCT00882518 (9) [back to overview]	Change From Baseline of the Positive and Negative Syndrome Scale (PANSS) Total Score at the End of Treatment at Day 42
NCT00882518 (9) [back to overview]	Change From Baseline in PANSS Positive Subscale Score at the End of Treatment at Day 42
NCT00882518 (9) [back to overview]	Change From Baseline in PANSS General Psychopathological Subscale Score at the End of Treatment at Day 42
NCT00882518 (9) [back to overview]	Change From Baseline in PANSS Negative Subscale Score at the End of Treatment at Day 42
NCT00883493 (10) [back to overview]	Change in Young Mania Rating Scale (YMRS) Total Score.
NCT00883493 (10) [back to overview]	Change in the Pittsburgh Sleep Quality Index (PSQI)Total Score.
NCT00883493 (10) [back to overview]	Change in the Clinical Global Impression Severity (CGI-S) Score.
NCT00883493 (10) [back to overview]	Response Rate for MADRS.
NCT00883493 (10) [back to overview]	Treatment Satisfaction Questionnaire (TSQ) Scores.
NCT00883493 (10) [back to overview]	Change in Hamilton Rating Scale for Anxiety (HAM-A) Total Score
NCT00883493 (10) [back to overview]	Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score.
NCT00883493 (10) [back to overview]	Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Score.
NCT00883493 (10) [back to overview]	Hamilton Rating Scale for Depression (HAM-D) Total Score.
NCT00883493 (10) [back to overview]	Change in the Sheehan Disability Scale (SDS) Total Score.
NCT00926393 (13) [back to overview]	Area Under the Modified Bond-Lader Visual Analog Scale-time Curve
NCT00926393 (13) [back to overview]	Change in Abnormal Involuntary Movement Scale (AIMS) Total Score
NCT00926393 (13) [back to overview]	Change in Barnes Akathisia Rating Scale (BARS) Global Score
NCT00926393 (13) [back to overview]	Change in Simpson-Angus Scale (SAS) Total Score
NCT00926393 (13) [back to overview]	Maximum Intensity Modified Bond-Lader Visual Analog Scale Score
NCT00926393 (13) [back to overview]	Modified Bond-Lader Visual Analog Scale Score After 100-mg Dose (Day 3)
NCT00926393 (13) [back to overview]	Modified Bond-Lader Visual Analog Scale Score After 200-mg Dose (Day 4)
NCT00926393 (13) [back to overview]	Modified Bond-Lader Visual Analog Scale Score After 300-mg Dose (Day 5)
NCT00926393 (13) [back to overview]	Modified Bond-Lader Visual Analog Scale Score After 300-mg Dose (Day 6)
NCT00926393 (13) [back to overview]	Modified Bond-Lader Visual Analog Scale Score After 50-mg Dose (Day 2)
NCT00926393 (13) [back to overview]	Number of Patients With Potential Extrapyramidal Symptoms (EPS)
NCT00926393 (13) [back to overview]	Number of Patients With Potential Somnolence
NCT00926393 (13) [back to overview]	Time to Maximum Intensity Modified Bond-Lader Visual Analog Scale Score
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in Each YMRS Item Score No. 9
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in PANSS Activation Subscale Score
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in PANSS Positive Subscale Score
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in Positive and Negative Syndrome Scale (PANSS) Total Score
NCT00931723 (21) [back to overview]	Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 43)
NCT00931723 (21) [back to overview]	Improvement of Overall Bipolar Illness
NCT00931723 (21) [back to overview]	Remission
NCT00931723 (21) [back to overview]	The Number of Patients With Clinically Significant Response.
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in Each YMRS Item Score No. 5
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in CGI-BP-C (Clinical Global Impressions for Bipolar Disorder-Change From Preceding Phase)
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in CGI-BP-S (Clinical Global Impressions for Bipolar Disorder-Severity of Illness)
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in Each YMRS Item Score No. 1
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in Each YMRS Item Score No. 10
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in Each YMRS Item Score No. 11
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in Each YMRS Item Score No. 2
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in Each YMRS Item Score No. 3
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in Each YMRS Item Score No. 4
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in Each YMRS Item Score No. 6
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in Each YMRS Item Score No. 7
NCT00931723 (21) [back to overview]	Change From Baseline to Day 43 in Each YMRS Item Score No. 8
NCT00951483 (7) [back to overview]	Change in Hamilton Rating Scale for Anxiety (HAM-A)
NCT00951483 (7) [back to overview]	Change in Hamilton Rating Scale for Depression With 21 Items (HAMD-21)
NCT00951483 (7) [back to overview]	Change in Hamilton Rating Scale for Depression With Seven Items (HAM-D-7)
NCT00951483 (7) [back to overview]	Change in Hamilton Rating Scale for Depression With 17 Items (HAM-D-17)
NCT00951483 (7) [back to overview]	Change in Beck Depression Inventory (BDI)
NCT00951483 (7) [back to overview]	Change in 14-item Perceived Stress Scale (PSS-14)
NCT00951483 (7) [back to overview]	C-Reactive Protein at 12 Weeks
NCT00954122 (7) [back to overview]	Change From Baseline to Final Visit at Day 21 in PANSS Negative, General Psychopathological Scores
NCT00954122 (7) [back to overview]	Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S)
NCT00954122 (7) [back to overview]	Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score
NCT00954122 (7) [back to overview]	Change From Baseline in Absolute Clinical Global Impression-Improvement (CGI-I) Scale
NCT00954122 (7) [back to overview]	Change of the Positive and Negative Syndrome Scale Excited Component (PANSS-EC) Score Compared From Baseline to Day 21.
NCT00954122 (7) [back to overview]	Change From Baseline to Final Visit at Day 21 in PANSS Positive, General Psychopathological Scores.
NCT00954122 (7) [back to overview]	Change From Baseline in Positive and Negative Syndrome Scale Excited Component (PANSS-EC) Score
NCT00954681 (1) [back to overview]	Maximum Tolerated Dose of Quetiapine
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Attention Sub-scale Scores at Baseline and Week 8.
NCT00955474 (15) [back to overview]	Psychosis
NCT00955474 (15) [back to overview]	LDL Blood Levels at Baseline and Week 8.
NCT00955474 (15) [back to overview]	HDL Blood Levels at Baseline and Week 8.
NCT00955474 (15) [back to overview]	Blood Level of Triglycerides at Baseline and Week 8.
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Language Sub-scale Score.
NCT00955474 (15) [back to overview]	Fasting Blood Glucose
NCT00955474 (15) [back to overview]	Depression
NCT00955474 (15) [back to overview]	CPFQ (Cognitive and Psychological Functioning Questionnaire)
NCT00955474 (15) [back to overview]	Blood Level of Total Cholesterol Levels Were Collected at Baseline and Week 8.
NCT00955474 (15) [back to overview]	Blood Hemoglobin A1C at Baseline and Week 8.
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Immediate Memory Sub-scale Score
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Total Score
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Visuospatial/Constructional Sub-scale.
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Delayed Memory Subscale Scores at Baseline and Week 8.
NCT00982345 (1) [back to overview]	17-item Hamilton Depression Rating Scale (HDRS)
NCT01066143 (1) [back to overview]	Change From Baseline in GAD Symptomatology at the Week 12 Timepoint.
NCT01066156 (1) [back to overview]	Change From Baseline in PTSD Symptomatology at the Week 8 Timepoint.
NCT01133821 (2) [back to overview]	Remission
NCT01133821 (2) [back to overview]	Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ)-Short Form
NCT01157351 (6) [back to overview]	Time to First Psychiatric Hospitalization
NCT01157351 (6) [back to overview]	Change From Baseline in Personal and Social Performance (PSP) Total Score During Overall Treatment Duration
NCT01157351 (6) [back to overview]	Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score During Overall Treatment Duration
NCT01157351 (6) [back to overview]	Percentage of Participants in Each Event Category of First Treatment Failure
NCT01157351 (6) [back to overview]	Time to First Psychiatric Hospitalization or Arrest/Incarceration
NCT01157351 (6) [back to overview]	Time to First Treatment Failure
NCT01165541 (1) [back to overview]	Number of Very Heavy Drinking Days Per Week
NCT01195363 (1) [back to overview]	Number of Patients Whose Mood Improved According to MADRS and YMRS Scale Scores.
NCT01213836 (7) [back to overview]	Mean Treatment Satisfaction for Treatment Satisfaction Questionnaire of Medication (TSQM)
NCT01213836 (7) [back to overview]	Number of Dropouts.
NCT01213836 (7) [back to overview]	Mean for Attentional Standardised Composite Score Based on Performance Scores From the CogState Test Battery Domains Detection (Speed of Processing)and Identification (Attention/Vigilance)
NCT01213836 (7) [back to overview]	Mean Overall Sedation as Measured by the Modified Bond-Lader Visual Analogue Scale (VAS) When Administered According to Label
NCT01213836 (7) [back to overview]	Mean Overall Sedation as Measured by the Stanford Sleepiness Scale When Administered According to Label
NCT01213836 (7) [back to overview]	Mean Ratio of Morning Plasma Concentration of Quetiapine and Nor-quetiapine for Quetiapine IR and Quetiapine XR, at Steady-state Conditions in the End of Each Treatment Period 1 and 2.
NCT01213836 (7) [back to overview]	Mean Daytime Cognitive Performance Using CogState: - Working Memory - Verbal Learning) -Reasoning and Problem Solving
NCT01244711 (1) [back to overview]	Montgomery Asberg Depression Rating Scale (MADRS)
NCT01254721 (2) [back to overview]	The Changes From Baseline in Young Mania Rating Scale (YMRS) Total Score to Day 29
NCT01254721 (2) [back to overview]	The Change From Baseline up to Day 29 and Final Assessment in the Clinical Global Impression-Severity of Illness Scale (CGI-S)
NCT01256177 (9) [back to overview]	"The Proportion of Patients at Week 8 With a Clinical Global Impression - Bipolar - Change (CGI-BP-C) of Much or Very Much Improved"
NCT01256177 (9) [back to overview]	Incidence of Treatment-emergent Mania (AE of Mania or Hypomania, Defined as Young Mania Rating Scale [YMRS] Score ≥16 on 2 Consecutive Assessments or Final Assessment)
NCT01256177 (9) [back to overview]	Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Remission (the Proportion of Subjects With a MADRS Total Score ≤ 12 at Week 8 Assessment)
NCT01256177 (9) [back to overview]	Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Response (Subjects With ≥50% Reduction From Baseline to Week 8 in MADRS Total Score)
NCT01256177 (9) [back to overview]	Change From Baseline (Visit 2) to End of Study (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT01256177 (9) [back to overview]	Change From Baseline to Week 8 Assessment in the Clinical Global Impression Bipolar - Severity (CGI-BP-S)
NCT01256177 (9) [back to overview]	Change From Baseline to Week 8 in HAM-D Total Scores
NCT01256177 (9) [back to overview]	Change From Baseline to Week 8 in Item 10 of Montgomery-Asberg Depression Rating Scale (MADRS) for Suicidal Ideation
NCT01256177 (9) [back to overview]	Change From Baseline to Each Assessment in MADRS Total Score
NCT01331304 (4) [back to overview]	Necessary Clinical Adjustments
NCT01331304 (4) [back to overview]	Longitudinal Interval Follow up Evaluation Range of Impaired Functioning Tool (LIFE-RIFT)
NCT01331304 (4) [back to overview]	Clinical Global Impression-Efficacy Index (CGI-EI)
NCT01331304 (4) [back to overview]	Risk of Cardiovascular Disease - Framingham Risk Score
NCT01526148 (2) [back to overview]	Time to Study Discontinuation
NCT01526148 (2) [back to overview]	Lithium vs. Quetiapine Effects on General Cardiovascular Disease Risk as Measured by Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
NCT01588457 (4) [back to overview]	Demographic in Randomization 1 Group
NCT01588457 (4) [back to overview]	Baseline Randomization Percentage of Bipolar Types
NCT01588457 (4) [back to overview]	Bipolar Inventory of Symptoms Scale (BISS)
NCT01588457 (4) [back to overview]	Global Assessment of Functioning
NCT01662297 (9) [back to overview]	Change in Insomnia Severity Index (ISI) Scores
NCT01662297 (9) [back to overview]	Change in RAND Short Form 36 Item Health Survey (RAND-SF36) General Health Subscale Over Time
NCT01662297 (9) [back to overview]	Medical Outcomes Study Sleep Scale- Sleep Index (Short)
NCT01662297 (9) [back to overview]	Percentage of Heavy Drinking Days
NCT01662297 (9) [back to overview]	Percentage of Negative Urine Drug Screens
NCT01662297 (9) [back to overview]	Change in Alcohol Urge Questionnaire (AUQ)Scores Over Time
NCT01662297 (9) [back to overview]	Change in Average Pittsburgh Sleep Quality Inventory (PSQI)Score
NCT01662297 (9) [back to overview]	Change in Brief Symptom Inventory (BSI) Over Time
NCT01662297 (9) [back to overview]	Change in Epworth Sleepiness Scale (ESS) Over Time
NCT01697709 (2) [back to overview]	Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study
NCT01697709 (2) [back to overview]	Number of Participants Stratified by Marijuana Abstinence Days Per Week
NCT01725282 (6) [back to overview]	Change From Baseline in Pittsburgh Sleep Quality Index (PSQI)
NCT01725282 (6) [back to overview]	Percentage of Participants With Improvement in Clinical Global Impressions-Improvement (CGI-I)
NCT01725282 (6) [back to overview]	Change From Baseline in Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36)
NCT01725282 (6) [back to overview]	Safety Assessed by the Incidence of Adverse Events (AE), Vital Signs, Electrocardiogram (ECG) and Laboratory Tests
NCT01725282 (6) [back to overview]	Change From Baseline in Hamilton Rating Score for Depression (HAM-D17)
NCT01725282 (6) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Wish to be Dead (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline in Young Mania Rating Scale (YMRS) (Treatment Period I)
NCT01725308 (74) [back to overview]	Change From Baseline in YMRS (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline in YMRS (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline in MADRS Total Score (Treatment Period I)
NCT01725308 (74) [back to overview]	Change From Baseline in MADRS Total Score (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline in MADRS Total Score (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Clinical Global Impression-Bipolar Disorder-Change (CGI-BP-C): Mania (Treatment Period I)
NCT01725308 (74) [back to overview]	Change From Baseline in Hamilton Depression Rating Scale (HAM-D17) Total Score (Treatment Period I)
NCT01725308 (74) [back to overview]	Change From Baseline in HAM-D17 (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline in HAM-D17 (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline in Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS): Total Score (Treatment Period I)
NCT01725308 (74) [back to overview]	Change From Baseline in DIEPSS: Total Score (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline in DIEPSS: Total Score (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline in DIEPSS: Parkinsonism (Treatment Period I)
NCT01725308 (74) [back to overview]	Change From Baseline in DIEPSS: Parkinsonism (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline in DIEPSS: Parkinsonism (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline in Clinical Global Impression-Bipolar Disorder-Severity (CGI-BP-S): Mania (Treatment Period I)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Preliminary Act to Suicide (Combined Treatment Period I and II
NCT01725308 (74) [back to overview]	Change From Baseline in CGI-BP-S: Overall Bipolar Illness (Treatment Period I)
NCT01725308 (74) [back to overview]	Change From Baseline in CGI-BP-S: Overall Bipolar Illness (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline in CGI-BP-S: Overall Bipolar Illness (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline in CGI-BP-S: Mania (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline in CGI-BP-S: Mania (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With MADRS Response (Treatment Period I)
NCT01725308 (74) [back to overview]	Number of Participants With MADRS Response (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With MADRS Response (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With MADRS Remission (Treatment Period I)
NCT01725308 (74) [back to overview]	Number of Participants With MADRS Remission (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With MADRS Remission (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With HAM-D17 Response (Treatment Period I)
NCT01725308 (74) [back to overview]	Number of Participants With HAM-D17 Response (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With HAM-D17 Response (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to Columbia Suicide Severity Rating Scale (C-SSRS): Suicidal Ideation (Treatment Period I)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Wish to be Dead (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline to End of Treatment Period I in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT01725308 (74) [back to overview]	Change From Baseline in CGI-BP-S: Depression (Treatment Period I)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Thoughts With Method (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Thoughts With Method (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Thoughts With Method (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Thoughts (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Thoughts (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Intent Without a Plan (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Intent Without a Plan (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Intent Without a Plan (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline in CGI-BP-S: Depression (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Change From Baseline in CGI-BP-S: Depression (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	CGI-BP-C: Overall Bipolar Illness (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	CGI-BP-C: Overall Bipolar Illness (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	CGI-BP-C: Mania (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	CGI-BP-C: Mania (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	CGI-BP-C: Depression (Treatment Period I)
NCT01725308 (74) [back to overview]	CGI-BP-C: Depression (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	CGI-BP-C: Depression (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Intent With a Plan (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Intent With a Plan (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Intent With a Plan (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors (Treatment Period I)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Suicide Attempt (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Suicide Attempt (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Suicidal Behavior (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Suicidal Behavior (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Self-injury Behavior Without Intent (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Self-injury Behavior Without Intent (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Preliminary Act to Suicide (Combined Treatment Period I and II
NCT01725308 (74) [back to overview]	CGI-BP-C: Overall Bipolar Illness (Treatment Period I)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Interrupted Attempt (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Interrupted Attempt (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Discontinued Attempt (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Discontinued Attempt (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Completed Suicide (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Completed Suicide (Combined Treatment Period I and II)
NCT01725308 (74) [back to overview]	Number of Participants With Adverse Events (Treatment Period I)
NCT01725308 (74) [back to overview]	Number of Participants With Adverse Events (Combined Treatment Period I and II)
NCT01727726 (9) [back to overview]	CGI-I Response Rate
NCT01727726 (9) [back to overview]	MADRS Response at Week 6
NCT01727726 (9) [back to overview]	Montgomery Asberg Depression Rating Scale (MADRS)
NCT01727726 (9) [back to overview]	Number of Participants With MADRS
NCT01727726 (9) [back to overview]	Sheehan Disability Scale (SDS)
NCT01727726 (9) [back to overview]	Change From End of Phase A in MADRS Total Score for Trial Week 2 and Week 4.
NCT01727726 (9) [back to overview]	Clinical Global Impression Score
NCT01727726 (9) [back to overview]	Number of Participants With Adverse Events
NCT01727726 (9) [back to overview]	Sheehan Disability Scale (SDS) Individual Item Scores.
NCT01737268 (9) [back to overview]	Change From Baseline to Last Assessment in Treatment Period in Clinical Global Impression-Bipolar-Severity of Illness (CGI-BP-S): Overall Bipolar Illness
NCT01737268 (9) [back to overview]	Change From Baseline to Last Assessment in Treatment Period in CGI-BP-S: Mania
NCT01737268 (9) [back to overview]	Change From Baseline to Last Assessment in Treatment Period in CGI-BP-S: Depression
NCT01737268 (9) [back to overview]	CGI-BP-C: Mania
NCT01737268 (9) [back to overview]	CGI-BP-C: Depression
NCT01737268 (9) [back to overview]	Change From Baseline to Last Assessment in Treatment Period in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT01737268 (9) [back to overview]	Number of Participants With Adverse Events
NCT01737268 (9) [back to overview]	Clinical Global Impression-Bipolar-Change (CGI-BP-C): Overall Bipolar Illness
NCT01737268 (9) [back to overview]	Change From Baseline to Last Assessment in Treatment Period in Hamilton Depression Scale (HAM-D17)
NCT01810380 (18) [back to overview]	Change From Baseline to Week 6 in PANSS Positive Subscale Score
NCT01810380 (18) [back to overview]	Change From Baseline to Week 6 in PANSS Negative Subscale Score
NCT01810380 (18) [back to overview]	Change From Baseline to Week 6 in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement
NCT01810380 (18) [back to overview]	Change From Baseline to Week 6 in PANSS Marder Factor Scores: Positive Symptoms
NCT01810380 (18) [back to overview]	Change From Baseline to Week 6 in PANSS Marder Factor Scores: Negative Symptoms
NCT01810380 (18) [back to overview]	Change From Baseline to Week 6 in PANSS Marder Factor Scores: Disorganized Thoughts
NCT01810380 (18) [back to overview]	Change From Baseline to Week 6 in PANSS Marder Factor Scores: Anxiety/Depression
NCT01810380 (18) [back to overview]	Change From Baseline to Week 6 in PANSS General Psychopathology Subscale Score
NCT01810380 (18) [back to overview]	Change From Baseline to Week 6 in CGI-S Score
NCT01810380 (18) [back to overview]	CGI-I Score at Week 6
NCT01810380 (18) [back to overview]	Discontinuation Due to Lack of Efficacy During the Study
NCT01810380 (18) [back to overview]	PSP Functional Remission Rate at Week 6
NCT01810380 (18) [back to overview]	PSP Functional Response Rate at Week 6
NCT01810380 (18) [back to overview]	Response Rate at Week 6
NCT01810380 (18) [back to overview]	Change From Baseline to Week 6 in PANSS Excited Component Score
NCT01810380 (18) [back to overview]	Change From Baseline to Week 6 in PANSS Total Score
NCT01810380 (18) [back to overview]	PSP Domain D: Disturbing and Aggressive Behaviours at Week 6
NCT01810380 (18) [back to overview]	Change From Baseline to Week 6 in PSP Total Score
NCT01833897 (5) [back to overview]	Loss of Motivated Behavior HAM-D Factor
NCT01833897 (5) [back to overview]	Beck's Depression Inventory
NCT01833897 (5) [back to overview]	HAM-D Suicide Item
NCT01833897 (5) [back to overview]	Hamilton Anxiety Scale
NCT01833897 (5) [back to overview]	Hamilton Depression Rating Scale (HAM-D)
NCT01844700 (4) [back to overview]	Weight Change
NCT01844700 (4) [back to overview]	BMI Percentile
NCT01844700 (4) [back to overview]	BMI Z-scores
NCT01844700 (4) [back to overview]	Percent Weight Change Compared to Baseline Weight
NCT01858948 (3) [back to overview]	Body Mass Index (BMI)
NCT01858948 (3) [back to overview]	Fasting Blood Triglycerides Levels
NCT01858948 (3) [back to overview]	Manic Symptom Severity
NCT01971203 (4) [back to overview]	Changes in Sexual Functioning Questionnaire (CSFQ)
NCT01971203 (4) [back to overview]	Clinical Global Impression Scales for Severity and Improvement
NCT01971203 (4) [back to overview]	HAM-A
NCT01971203 (4) [back to overview]	MADRS
NCT02056171 (3) [back to overview]	Change in Delirium Severity
NCT02056171 (3) [back to overview]	Time to First Resolution of Delirium
NCT02056171 (3) [back to overview]	Total ICU Days With Delirium
NCT02362412 (9) [back to overview]	Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT02362412 (9) [back to overview]	Clinical Global Impression-Bipolar-Change (CGI-BP-C):Mania
NCT02362412 (9) [back to overview]	Clinical Global Impression-Bipolar-Change (CGI-BP-C):Depression
NCT02362412 (9) [back to overview]	Number of Participants With Adverse Events
NCT02362412 (9) [back to overview]	Clinical Global Impression-Bipolar-Severity of Illness (CGI-BP-S): Mania
NCT02362412 (9) [back to overview]	Clinical Global Impression-Bipolar-Severity of Illness (CGI-BP-S):Depression
NCT02362412 (9) [back to overview]	Hamilton Depression Scale (HAM-D17)
NCT02362412 (9) [back to overview]	Clinical Global Impression-Bipolar-Change (CGI-BP-C):Overall Bipolar Illness
NCT02362412 (9) [back to overview]	Clinical Global Impression-Bipolar-Severity of Illness (CGI-BP-S): Overall Bipolar Illness
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Reasoning and Problem Solving: MCCB Domain
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Medication Satisfaction Questionnaire (MSQ) Score
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Functioning as Measured by the Personal and Social Performance (PSP) Total Score
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Clinical Global Impression Severity (CGI-S) Score
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Attention/Vigilance Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Adjusted Intracortical Myelin Fraction Score as Measured by Inversion Recovery (IR) and Spin Echo Magnetic Resonance Imaging (MRI)
NCT02431702 (31) [back to overview]	Part 3 (Disease Modification): Personal and Social Performance (PSP) Total Observed Score
NCT02431702 (31) [back to overview]	Part 3 (Disease Modification): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Working Memory Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Visual Learning Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Speed of Processing Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Social Cognition Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Reasoning and Problem Solving: MCCB Domain
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Medication Satisfaction Questionnaire (MSQ) Total Score
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Functioning as Measured by the Personal and Social Performance (PSP) Total Score
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Clinical Global Impression Severity (CGI-S) Score
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Attention/Vigilance Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Adjusted Intracortical Myelin (ICM) Fraction Score as Measured by Inversion Recovery (IR) and Spin Echo Magnetic Resonance Imaging (MRI)
NCT02431702 (31) [back to overview]	Part 3 (EDP): Time to First Treatment Failure
NCT02431702 (31) [back to overview]	Part 3 (EDP): Number of Participants With Change From Baseline in Severity of Psychotic Symptoms, as Measured by CRDPSS
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Number of Participants With Change From Baseline in Severity of Psychotic Symptoms, as Measured by Clinician-Rated Dimensions of Psychosis Symptom Severity Scale (CRDPSS)
NCT02431702 (31) [back to overview]	Part-2 (Disease Progression): Time to First Treatment Failure
NCT02431702 (31) [back to overview]	Part 3 (Extended Disease Progression [EDP]): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score
NCT02431702 (31) [back to overview]	Part 2 (Disease Progression): Change From Baseline in Verbal Learning Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Working Memory Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Visual Learning Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Verbal Learning Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Speed of Processing Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 3 (EDP): Change From Baseline in Social Cognition Score: MCCB Domain
NCT02431702 (31) [back to overview]	Part 3 (Disease Modification): Change From Baseline in Adjusted Intracortical Myelin Fraction Score as Measured by Inversion Recovery (IR) and Spin Echo Magnetic Resonance Imaging (SE MRI)
NCT02462473 (8) [back to overview]	Adherence to Antipsychotic Medication as Assessed by Brief Adherence Rating Scale (BARS) at Week 0 and 12
NCT02462473 (8) [back to overview]	Number of Participants With Medication Treatment Modifications (MTM)
NCT02462473 (8) [back to overview]	Clinician's Rating Scale of Adherence (CRS) Score at Week 0 and 12
NCT02462473 (8) [back to overview]	Dimensions of Psychosis Symptom Severity Scale (DPSS) Total Score at Week 0 and 12
NCT02462473 (8) [back to overview]	Number of Participants With Factors Considered in Clinical Decision as Assessed by Clinical Assessment of the Schizophrenia Patient (CASP)
NCT02462473 (8) [back to overview]	Patient Satisfaction Survey (PSS) Total Score at Week 0 and 12
NCT02462473 (8) [back to overview]	Antipsychotic Medication Plasma Levels (AMPL) During the Active Assessment Phase at Week 12
NCT02462473 (8) [back to overview]	Clinical Global Impression-Severity (CGI-S) Score at Week 0 and 12
NCT02720198 (11) [back to overview]	Changes of Quality of Life in Scores on Sheehan Disability Scale (SDS) Total
NCT02720198 (11) [back to overview]	Number of Subjects With General Improvement in Scores on Clinical Global Impression Scale- Improvement (CGI-I)
NCT02720198 (11) [back to overview]	Number of Subjects With Global Improvement in Scores on Clinical Global Impression Scale- Severity (CGI-S)
NCT02720198 (11) [back to overview]	Remission Rate
NCT02720198 (11) [back to overview]	Response Rate
NCT02720198 (11) [back to overview]	Changes in Neurocognition by Changes in Scores on Reyes Verbal Learning Test
NCT02720198 (11) [back to overview]	Changes in Neurocognition by Changes in Scores on Scores on Digit Symbol Substitution Test (DSST)
NCT02720198 (11) [back to overview]	Changes in Scores on Apathy Evaluation Scale (AES).
NCT02720198 (11) [back to overview]	Changes in Sexual Dysfunction by Changes in Scores on Arizona Sexual Experience Scale (ASEX)
NCT02720198 (11) [back to overview]	Changes of Anxiety Symptoms in Scores on Hamilton Anxiety Rating Scale (HAM-A)
NCT02720198 (11) [back to overview]	Changes of Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
NCT02845453 (5) [back to overview]	Change in Timeline Followback of Substance Use (TLFB)
NCT02845453 (5) [back to overview]	Change in the Number of Negative Urine Toxicology Specimens
NCT02845453 (5) [back to overview]	Change in Symptoms of Mania
NCT02845453 (5) [back to overview]	Change in Symptoms of Depression
NCT02845453 (5) [back to overview]	Change in Craving for the Substance That the Participant Identifies as Most Problematic
NCT03019887 (1) [back to overview]	Number of Participants With Relapse
NCT03207438 (4) [back to overview]	MADRS Response Rates
NCT03207438 (4) [back to overview]	Number of Participants With 50 Percent Or Greater Reduction in the MADRS Score Over Time for the Quetiapine XR 150-300mg and Placebo 2 Arms/Groups Stratified by Depression Type (Melancholic vs. Nonmelancholic)
NCT03207438 (4) [back to overview]	Modified MADRS Response Rates
NCT03207438 (4) [back to overview]	Modified MADRS Response Rate
NCT03321526 (38) [back to overview]	Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score
NCT03321526 (38) [back to overview]	Percentage of Participants With Shifts in Triglycerides From High to Very High
NCT03321526 (38) [back to overview]	Percentage of Participants With Shifts in Triglycerides From Borderline to Very High
NCT03321526 (38) [back to overview]	Percentage of Participants With Shifts in Triglycerides From Borderline to High
NCT03321526 (38) [back to overview]	Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to Borderline
NCT03321526 (38) [back to overview]	Percentage of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Total Score
NCT03321526 (38) [back to overview]	Percentage of Participants With Clinically Relevant Changes in Extrapyramidal Symptoms Assessed by the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Score
NCT03321526 (38) [back to overview]	Percentage of Participants With Abnormalities in Electrocardiogram (ECG) Parameters
NCT03321526 (38) [back to overview]	Percentage of Participants With Abnormalities in Clinical Laboratory Parameters
NCT03321526 (38) [back to overview]	Percentage of Participants With Shifts in Fasting Blood Glucose From Borderline to High
NCT03321526 (38) [back to overview]	Percentage of Participants With Shifts in Triglycerides From Normal to Very High
NCT03321526 (38) [back to overview]	Percentage of Participants With Sustained Remission up to Week 24
NCT03321526 (38) [back to overview]	Percentage of Participants With Sustained Response up to Week 24
NCT03321526 (38) [back to overview]	Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability
NCT03321526 (38) [back to overview]	Percentage of Participants With Weight Gain of >=7% of Baseline Body Weight at Week 24
NCT03321526 (38) [back to overview]	Time to All-Cause Discontinuation of Study Drug
NCT03321526 (38) [back to overview]	Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24
NCT03321526 (38) [back to overview]	Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline Insomnia Severity Index [ISI] Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score Less Than [<] 15) at Week 12
NCT03321526 (38) [back to overview]	Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISI Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score <15) at Week 18
NCT03321526 (38) [back to overview]	Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISIscore >=15) Versus Those Without Significant Insomnia (Baseline ISI Score 15) at Week 24
NCT03321526 (38) [back to overview]	Change From Baseline in MADRS Total Score Over Time
NCT03321526 (38) [back to overview]	Percentage of Participants With Abnormalities in Vital Sign Parameters
NCT03321526 (38) [back to overview]	Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to High
NCT03321526 (38) [back to overview]	Change From Baseline in MADRS Total Score Over Time, by Mode Dose
NCT03321526 (38) [back to overview]	Change From Baseline in MADRS-6 Score Over Time
NCT03321526 (38) [back to overview]	Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a at Weeks 12 and 24
NCT03321526 (38) [back to overview]	Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI) Short Form 8a at Weeks 12 and 24
NCT03321526 (38) [back to overview]	Change From Baseline in Quality of Life in Depression Scale (QLDS) Score at Weeks 12 and 24
NCT03321526 (38) [back to overview]	Change From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and During the Evening at Weeks 6 and 24
NCT03321526 (38) [back to overview]	Change From Baseline in Symbol Digit Modalities Test (SDMT) at Weeks 6, 12, and 24
NCT03321526 (38) [back to overview]	Change From Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Score at Weeks 12 and 24
NCT03321526 (38) [back to overview]	Percentage of Participants With Shifts in Triglycerides From Normal to High
NCT03321526 (38) [back to overview]	Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Scale Score at Weeks 12 and 24
NCT03321526 (38) [back to overview]	Change From Baseline in the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Weeks 12, 18, and 24
NCT03321526 (38) [back to overview]	Change From Baseline in the Patient Global Impression Severity (PGI-S) Scale Score at Weeks 12 and 24
NCT03321526 (38) [back to overview]	Change From Baseline in Trail Making Test - Part B (TMT-Part B) at Weeks 6, 12, and 24
NCT03321526 (38) [back to overview]	Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC)
NCT03321526 (38) [back to overview]	Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Events of Special Interest
NCT03557931 (8) [back to overview]	Number of Participants With Clinically Significant Differences in Simpson Angus Scale (SAS) Values
NCT03557931 (8) [back to overview]	Number of Participants With Clinically Significant Differences in Barnes Akathisia Rating Scale (BARS) Values
NCT03557931 (8) [back to overview]	Change From Baseline to Week 12/End of Treatment (EoT) in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) Neurocognitive Composite Score
NCT03557931 (8) [back to overview]	Number of Participants With Clinically Significant Differences in Columbia-Suicide Severity Rating Scale (C-SSRS) Values
NCT03557931 (8) [back to overview]	Number of Participants With Clinically Significant Differences in Abnormal Involuntary Movement Scale (AIMS) Values
NCT03557931 (8) [back to overview]	Number of Participants With Adverse Event (AE)
NCT03557931 (8) [back to overview]	Concentration at Trough Level (Ctrough) for ASP4345
NCT03557931 (8) [back to overview]	Change From Baseline to Week 12/EoT in University of California San Diego Performance-based Skills Assessment-2 Extended Range (UPSA-2-ER) Total Score
NCT03568500 (2) [back to overview]	Percentage Of Days With Good Patch Coverage
NCT03568500 (2) [back to overview]	Participant Adherence
NCT04164758 (1) [back to overview]	Treatment-emergent Adverse Events (TEAEs)
NCT04338321 (25) [back to overview]	Change From Baseline in Participant-reported Health-related Quality of Life (HRQoL) and Health Status as Assessed by 36-item Short-Form Health Survey (SF-36) Scale Score
NCT04338321 (25) [back to overview]	Change From Baseline in Participant-reported Health-related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score: Health Status Index
NCT04338321 (25) [back to overview]	Change From Baseline in Participant-reported Health-related Quality of Life Group, as Assessed by EQ-5D-5L Score: Health Status Index at LOCF
NCT04338321 (25) [back to overview]	Change From Baseline in Participant-reported HRQoL and Health Status as Assessed by SF-36 Scale Score at LOCF
NCT04338321 (25) [back to overview]	Change From Baseline in Participant-reported Quality of Life as Assessed by QLDS Total Score at LOCF
NCT04338321 (25) [back to overview]	Change From Baseline in Participant-reported Quality of Life as Assessed by Quality of Life in Depression Scale (QLDS) Total Score
NCT04338321 (25) [back to overview]	Change From Baseline in Participant-reported Work Productivity as Assessed by WPAI: Depression Questionnaire at LOCF
NCT04338321 (25) [back to overview]	Clinician-rated Overall Severity of Depressive Illness as Assessed by Clinical Global Impression - Change (CGI-C) Scale Score
NCT04338321 (25) [back to overview]	Number of Participants With Clinician-rated Overall Severity of Depressive Illness as Assessed by CGI-C Scale Score at LOCF
NCT04338321 (25) [back to overview]	Change From Baseline in Clinician-rated Overall MADRS Score at Last Observation Carried Forward (LOCF)
NCT04338321 (25) [back to overview]	Change From Baseline in Clinician-rated Overall MADRS Score
NCT04338321 (25) [back to overview]	Change From Baseline in Participant-reported Depressive Symptoms as Assessed by PHQ 9-item Total Score at LOCF
NCT04338321 (25) [back to overview]	Change From Baseline in Participant-reported Depressive Symptoms as Assessed by Patient Health Questionnaire (PHQ) 9-item Total Score
NCT04338321 (25) [back to overview]	Number of Participants With TEAEs of Special Interest
NCT04338321 (25) [back to overview]	Change From Baseline in Clinician-rated Overall Severity of Depressive Illness as Assessed by Clinical Global Impression - Severity (CGI-S) Scale Score
NCT04338321 (25) [back to overview]	Change From Baseline in Participant-reported Functional Impairment and Associated Disability as Assessed by SDS Total Score at LOCF
NCT04338321 (25) [back to overview]	Change From Baseline in Participant-reported Functional Impairment and Associated Disability as Assessed by Sheehan Disability Scale (SDS) Total Score
NCT04338321 (25) [back to overview]	Change From Baseline in Participant-reported Health Status as Assessed by EQ-5D-5L Score: VAS
NCT04338321 (25) [back to overview]	Change From Baseline in Participant-reported Work Productivity as Assessed by Work Productivity and Activity Impairment (WPAI): Depression Questionnaire
NCT04338321 (25) [back to overview]	Change From Baseline in Participant-reported Health Status as Assessed by EQ-5D-5L Score: VAS at LOCF
NCT04338321 (25) [back to overview]	Percentage of Participants With Remission as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS) Score at Week 8
NCT04338321 (25) [back to overview]	Percentage of Participants With Both Remission at Week 8 and Relapse-free Until Week 32
NCT04338321 (25) [back to overview]	Change From Baseline in Clinician-rated Overall Severity of Depressive Illness as Assessed by CGI-S Scale Score at LOCF
NCT04338321 (25) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT04338321 (25) [back to overview]	Number of Participants With Suicidal Ideation or Behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) Score

Number Who Discontinued Medication Within First 6 Study Months

(NCT00044655)
Timeframe: Measured at Six Months

Intervention	participants (Number)
Stay	11
Switch	23

Intervention	participants (Number)
Quetiapine, 25-400mg/Day Augmentation of Continued Paroxetine	4
Placebo Augmentation of Continued Paroxetine	2

Intervention	units on a scale (Mean)
	Baseline (Week 10)	Endpoint (Week 18)
Placebo Augmentation of Continued Paroxetine	12.36	11.64
Quetiapine, 25-400mg/Day Augmentation of Continued Paroxetine	11.45	10.27

Intervention	units on a scale (Mean)
	Baseline	Week 18	Change
Placebo Augmentation of Continued Paroxetine	15.82	15.55	-0.3
Quetiapine, 25-400mg/Day Augmentation of Continued Paroxetine	16.27	13.64	-2.6

Intervention	units on a scale (Mean)
	PCS score	MCS score
Aripiprazole	2.4	4.9
Quetiapine	1.0	2.7
Risperidone LAI	2.1	3.2

Intervention	units on a scale (Mean)
	Baseline Q-LES-Q	Endpoint Q-LES-Q
Arm 2 OL Paroxetine + DB Placebo	37.85	38.22
Arm 3: OL Paroxetine + DB Quetiapine	40.44	41.06

Intervention	units on a scale (Mean)
	Baseline SDS-WS	Endpoint SDS-WS	Baseline SDS-SL	Endpoint SDS-SL	Baseline SDS-FL	Endpoint SDS-FL
Arm 2 OL Paroxetine + DB Placebo	5.07	4.58	6.67	5.92	5.85	5.39
Arm 3: OL Paroxetine + DB Quetiapine	4.44	4.66	5.64	4.95	4.72	4.61

Intervention	units on a scale (Mean)
	Baseline PSQI	Endpoint PSQI
Arm 2 OL Paroxetine + DB Placebo	11.60	8.70
Arm 3: OL Paroxetine + DB Quetiapine	12.69	13.19

Intervention	units on a scale (Mean)
	Baseline CGI-I	Endpoint CGI-I
Arm 2 OL Paroxetine + DB Placebo	3.56	2.61
Arm 3: OL Paroxetine + DB Quetiapine	3.36	2.22

Intervention	units on a scale (Mean)
	CAPS Total Baseline	CAPS Total Endpoint
Arm 2 OL Paroxetine + DB Placebo	72.15	67.90
Arm 3: OL Paroxetine + DB Quetiapine	68.78	51.52

Intervention	units on a scale (Mean)
	Baseline ASEX	Endpoint ASEX
Arm 2 OL Paroxetine + DB Placebo	22.00	21.93
Arm 3: OL Paroxetine + DB Quetiapine	17.88	16.94

Intervention	units on a scale (Mean)
	Baseline Total PANSS	Endpoint Total PANSS
Arm 2 OL Paroxetine + DB Placebo	46.63	43.92
Arm 3: OL Paroxetine + DB Quetiapine	47.76	42.24

Intervention	units on a scale (Mean)
	Baseline HAMD	Endpoint HAMD
Arm 2 OL Paroxetine + DB Placebo	14.60	12.29
Arm 3: OL Paroxetine + DB Quetiapine	13.84	9.29

Intervention	units on a scale (Mean)
	Baseline DTS	Endpoint DTS
Arm 2 OL Paroxetine + DB Placebo	82.19	84.06
Arm 3: OL Paroxetine + DB Quetiapine	77.25	61.50

Intervention	units on a scale (Mean)
	Bruising easily	Rash	Urticaria (hives, itching)	Blurred vision	sedation/drowsiness	Restlessness	Insomnia	Malaise (weakness, fatigue)	Stiffness	Tremor	Dizziness	Headache	Fever	Sore Throat	Dry Mouth	Hypersalivation	Enuresis	Constipation	Diarrhea	Anorexia (loss of appetite)	Nausea	Vomiting	Menstrual Irregularity	Breast tenderness/galactorrhea
Injectable	1.43	1.53	1.60	1.76	2.34	2.48	2.38	2.22	2.01	1.77	1.82	1.99	1.27	1.64	2.36	1.76	1.63	1.75	1.65	1.89	1.78	1.48	1.62	1.39
Oral	1.48	1.44	1.71	1.91	2.53	2.43	2.36	2.14	1.97	1.75	1.78	1.89	1.24	1.57	2.25	1.84	1.56	1.64	1.68	1.69	1.72	1.51	1.55	1.32

Intervention	scores on Q-LES-Q scale (Least Squares Mean)
	Baseline	Post-Intervention
Medication	40.0	48.7
Psychotherapy	34.6	37.0

Intervention	participants (Number)
	50% reduction in HRSD 25 score and YMRS <= 10	Non-responder
Medication	3	8
Psychotherapy	4	10

Intervention	units on a scale (Mean)
	ISI (baseline)	ISI (week 7)
Placebo	14.80	6.70
Quetiapine XR	17.00	5.40

Intervention	units on a scale (Mean)
	PSQI (baseline)	PSQI (week 4)	PSQI (week 9)
Placebo	14.60	13.80	13.80
Quetiapine XR	14.70	13.20	14.50

Intervention	minutes (Mean)
	WASO (baseline)	WASO (week 8)
Placebo	61.17	66.99
Quetiapine XR	101.87	60.71

Intervention	percentage (Mean)
	Sleep Efficiency (baseline)	Sleep Efficiency (after 8 weeks of treatment)
Placebo	78.63	82.80
Quetiapine XR	70.70	79.45

quetiapine fumarate

Description

Cross-References

Synonyms (4)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Research

Studies (2,925)

Study Types

Clinical Trials (371)

Trial Overview

Trial Outcomes

Number Who Discontinued Medication Within First 6 Study Months

Remission (HAM-A ≤ 7)

Response, Clinical Global Impression of Improvement (CGI-I)

Depressive Symptoms, Montgomery-Asberg Depression Rating Scale (MADRS)

Hamilton Anxiety Scale (HAM-A) Score at Study Endpoint.

The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).

Mean Number of Drinking Days Per Week

Clinical Symptoms

Evaluate the Number of Clinical Events (Pooled) Occurring Between 3-15 Months Following a Switch/Stabilization of the Antipsychotic Agents Among Patients Who Receive Either Risperidal Consta or One of the 4 Marketed 2nd Generation Antipsychotic Agents.

Number of Participants With Treatment Emergent Hyperlipidemia

Number of Participants With Treatment - Emergent Hyperglycemia

BMI

Change in Bipolar Symptoms as Measured by Reduction in Young-Mania Rating Scale (Y-MRS) Total Score

Symptoms of Mania, as Measured by Young Mania Rating Scale

Global Assessment of Functioning

Clinical Global Impression Scale for Bipolar Disorder (CGI-BD)

Hamilton Rating Scale for Depression (HAM-D,17)

Social and Occupational Functioning Assessment Scale (SOFAS)

Percentage of Participants With Clinical Global Impression for Bipolar Disorders Overall Severity Remission (Score <=2 at Week 8)

Percentage of Participants With >=50% Improvement From Baseline in Clinical Global Impression for Bipolar Disorders Overall Severity

Percentage of Participants With 50% Improvement From Baseline in Both Montgomery Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) Scores

Change in Personal Evaluation of Transitions in Treatment (PETiT) Total Score

Change in Simpson-Angus Scale (SAS) Total Score

Presence of a Posterior Subcapsular (P) Type Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the LOCS II Grading Scale

Change in Barnes Akathisia Rating Scale (BARS) Global Score

Change in the PANSS Psychopathology Subscale Score

Change in Abnormal Involuntary Movement Scale (AIMS) Total Score

Change in Health-related Quality of Life as Measured by Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q SF) Total Score

Change in the PANSS Negative Subscale Score

Change in the PANSS Positive Subscale Score

Change in the Positive and Negative Syndrome Scale (PANSS) Total Score

Number of Participants With Potential Extrapyramidal Symptoms (EPS)

Number of Relapses of Schizophrenia or Schizoaffective Disorder

Change in the Clinical Global Impression - Severity of Illness (CGI-S) Score

Presence of a Cortical (C) Type of Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the Lens Opacities Classification System II (LOCS II ) Grading Scale

Presence of a Nuclear Opalescence (N) Type of Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the LOCS II Grading Scale

Mean Relapse Free Period(Risperidone LAI Versus Quetiapine)

Mean Relapse Free Period (Exploratory/Aripiprazole)

Change From Baseline to Endpoint in Total Positive and Negative Syndrome Scale (PANSS) Score

Change From Baseline to Endpoint in Clinical Global Impression Scale (CGI) Score

Change From Baseline to Endpoint in Short-Form Health Survey 12 (SF-12) Scores

Number of Patients Withdrawn Due to AEs.

Categorical Change From OL Baseline to Week 26 in Simpson-Angus Scale (SAS)Total Score

Categorical Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Score

Incidence and Nature of Adverse Events (AEs)

Changes in Tanner Stage

Changes in Laboratory Test Results (Prolactin)

Change From OL Baseline in Supine Systolic BP.

Change From OL Baseline in Supine Diastolic BP.

Change From Baseline in Weight

Change From Baseline in Supine Pulse

Change From Baseline in Children's Global Assessment Scale (CGAS) Score

Change in Mean Q-LES-Q Score From Baseline to Endpoint.

Change in Mean Sheehan Disability Scale (SDS) Scores From Baseline to Endpoint.

Change in Mean Scores of Pittsburgh Sleep Quality Index (PSQI) From Baseline to Endpoint.

Change in CGI-I

Change in Clinician-Administered PTSD Scale for DSM-IV Total Score.

Change in Arizona Sexual Experience Scale (ASEX)

Change in Mean PANSS Total and Subscores From Baseline to Endpoint

Change in Total Mean Hamilton Rating Scale for Depression (HAMD) Scores

Change in Total Mean Davidson Trauma Scale (DTS)

Substantial Clinical Deterioration Measured by Psychotic Symptoms

Number of Patients Discontinuing From the Study

Intervention	score on a scale (Least Squares Mean)
Quetiapine Fumerate Plus Medical Management	2.4
Sugar Pill Plus Medical Management	3.0

Intervention	score on a scale (Least Squares Mean)
Quetiapine Fumerate Plus Medical Management	18.5
Sugar Pill Plus Medical Management	22.5

Intervention	score on a scale (Least Squares Mean)
Quetiapine Fumerate Plus Medical Management	51.5
Sugar Pill Plus Medical Management	50.7

Intervention	percentage heavy drinking days (Least Squares Mean)
Quetiapine Fumerate Plus Medical Management	16.5
Sugar Pill Plus Medical Management	18.8

Intervention	percentage of heavy drinking days (Least Squares Mean)
Quetiapine Fumerate Plus Medical Management	37.1
Sugar Pill Plus Medical Management	37.9

Intervention	percentage of days abstinent (Least Squares Mean)
Quetiapine Fumerate Plus Medical Management	49.5
Sugar Pill Plus Medical Management	47.1

Intervention	score on a scale (Mean)
Quetiapine Fumerate Plus Medical Management	12.1
Sugar Pill Plus Medical Management	12.8

Intervention	units on a scale (Mean)
	Baseline	Week 4	Week 8	Week 12	Week 16
Galantamine and CDP-choline Group	4.32	4	3.67	3.87	3.8
Placebo Group	4.38	3.92	4.04	4	3.68

Intervention	kilograms of body fat (Mean)
	Baseline	6 Weeks	12 Weeks
Olanzapine	32.24	34.38	35.45
Quetiapine	28.83	29.60	30.10
Risperidone	27.66	28.29	29.23
Total	30.25	31.05	31.52
Ziprasidone	31.60	31.18	30.66

Intervention	Units on the scale (Mean)
	Positive Scale	Negative Scale	General Scale
Placebo	NA	NA	NA
Quetiapine	NA	NA	NA